gabapentin and Ache
gabapentin has been researched along with Ache in 418 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The addition of gabapentin to moderate sedation during D&E did not result in lower maximum recalled procedural pain." | 9.69 | Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial. ( Brant, AR; Floyd, S; Lotke, PS; Reeves, MF; Scott, RK; Tefera, E; Ye, PP, 2023) |
| "The addition of venlafaxine to prophylactic gabapentin did not result in improvements in pain control and quality of life among patients with head and neck cancer." | 9.69 | Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial. ( Attwood, K; Farrugia, M; Hermann, G; Iovoli, AJ; Ma, SJ; Neimanis, D; Singh, AK; Smith, KA; Wang, K, 2023) |
| "The purpose of this paper is to determine whether prophylactic gabapentin usage in patients undergoing definitive concurrent chemotherapy and radiation therapy (chemoRT) for oropharyngeal cancer (OPC) improves treatment-related oral mucositis pain, opioid use, and feeding tube (FT) placement." | 9.51 | Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. ( Ali, H; Chang, S; Cook, A; Fakhoury, L; Ghanem, T; Han, X; Modh, A; Momin, S; Money, S; Movsas, B; Sheqwara, J; Siddiqui, F; Tam, S; Wu, V, 2022) |
| "Use of the gabapentinoids for pain continues to increase." | 9.41 | Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval. ( Al-Jammali, Z; Herink, MC; Williams, CD, 2023) |
| "This study aims to evaluate the efficacy of gabapentin treatment in dry eye disease (DED) and neuropathic ocular pain." | 9.41 | Is gabapentin effective in dry eye disease and neuropathic ocular pain? ( Ongun, GT; Ongun, N, 2021) |
| " At interim analysis, gabapentin use resulted in a decrease in pain (P = ." | 9.34 | Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation. ( Cmelak, A; Ghiam, M; Gibson, MK; Gilbert, J; Hawkins, D; Lou, D; Murphy, BA; Niermann, K; Smith, DK, 2020) |
| " Both gabapentin and duloxetine groups had significantly more reduction in pain VAS and WOMAC and its subscales compared to acetaminophen group, with no significant difference between groups." | 9.30 | Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis. ( Azami, A; Enteshari-Moghaddam, A; Habibzadeh, A; Isazadehfar, K; Jahanpanah, P; Mohebbi, H, 2019) |
| " Nonetheless, pain intensity reduction is achieved with 50% of the minimum required gabapentin dose alone (800 to 1600 mg/d) in classic NDD trials." | 9.22 | Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. ( Aguilar Navarro, S; Mimenza Alvarado, A, 2016) |
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 9.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Pregabalin has been used for the treatment of pain." | 9.22 | A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain. ( Kawakami, J; Naito, T; Yagi, T; Yoshikawa, N, 2016) |
| "Based on the obtained data, prophylactic lornoxicam controlled postendodontic treatment pain more effectively than did the placebo drugs, and gabapentin was more effective in controlling the pain than either lornoxicam or the placebo." | 9.19 | Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain. ( Aktuna, S; Işik, B; Turan, A; Yaman, S, 2014) |
| "Gabapentin is increasingly being used for the treatment of postoperative pain and a variety of psychiatric diseases, including chronic anxiety disorders." | 9.17 | Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. ( Clarke, H; Katz, J; Katznelson, R; Kirkham, KR; Ko, R; Ma, M; Mitsakakis, N; Orser, BA; Snyman, A, 2013) |
| "Gabapentin has demonstrated efficacy in clinical trials as a pre-emptive analgesic and in acute postoperative pain management." | 9.15 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 9.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study." | 9.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "This study compared the efficacy and safety of tramadol/acetaminophen (T/A) and gabapentin in the management of painful diabetic neuropathy." | 9.14 | Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010) |
| " The risk of phantom pain (gabapentin vs." | 9.12 | A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006) |
| "Gabapentin, an oral non-opioid analgesic, has been used to decrease pain after a variety of surgical procedures." | 9.12 | Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia. ( Karamanlioglu, B; Pamukçu, Z; Turan, A; White, PF, 2007) |
| "To assess the efficacy and safety of gabapentin in patients with fibromyalgia." | 9.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "To estimate the cost-effectiveness of branded pregabalin (PGB) versus generic gabapentin (GBP) in patients with neuropathic pain (NeP) due to painful diabetic polyneuropathy (DPN) or post-herpetic neuralgia (PHN) in Spain." | 9.12 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "To test the hypotheses that both amitriptyline and gabapentin are more effective in relieving neuropathic pain than an active placebo, diphenhydramine." | 9.12 | Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007) |
| "To determine the analgesic effect of the addition of gabapentin to opioids in the management of neuropathic cancer pain." | 9.11 | Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. ( Arcuri, E; Barbieri, M; Bonezzi, C; Caraceni, A; De Conno, F; Gorni, G; Maltoni, M; Martini, C; Tirelli, W; Visentin, M; Yaya Tur, R; Zecca, E, 2004) |
| "Patients reported significant pain relief in favor of gabapentin in the first period." | 9.11 | Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004) |
| "We evaluated the effects of gabapentin and carbamazepine for pain relief in 36 Guillain-Barré syndrome patients." | 9.11 | The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. ( Kumar, A; Navkar, DV; Pandey, CK; Raza, M; Singh, UK; Tripathi, M, 2005) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "A double-blind, randomised, placebo-controlled 8-week study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain, using doses up to 2400 mg/day." | 9.10 | Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002) |
| "To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS)." | 9.10 | Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. ( de la Llave, Y; Garcia-Borreguero, D; Hernandez, G; Larrosa, O; Masramon, X; Verger, K, 2002) |
| "Gabapentin, an antiepileptic drug, has been used effectively for different types of pain management." | 9.10 | Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study. ( Agarwal, A; Baronia, A; Bose, N; Garg, G; Pandey, CK; Singh, N; Singh, PK; Singh, U, 2002) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "The aim of our study was to explore a potential analgesic effect of gabapentin in patients with neuropathic pain caused by anticancer treatment." | 9.10 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| "Reports of gabapentin use in diabetic peripheral neuropathy pain stimulate a need for controlled trials to determine its comparative efficacy to the therapeutic standard of amitriptyline hydrochloride." | 9.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in painful diabetic neuropathy." | 9.09 | Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000) |
| "Twenty-one patients referred with refractory genitourinary pain were treated with oral gabapentin." | 9.09 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "To evaluate the effects of gabapentin on pain scores and opiate use." | 9.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)." | 9.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "To evaluate the effect of gabapentin monotherapy on pain associated with diabetic peripheral neuropathy." | 9.08 | Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. ( Backonja, M; Beydoun, A; Edwards, KR; Fonseca, V; Garofalo, E; Hes, M; LaMoreaux, L; Schwartz, SL, 1998) |
| "Gabapentinoids are frequently used in the management of cancer pain." | 8.98 | A critical appraisal of gabapentinoids for pain in cancer patients. ( Bennett, MI; Jordan, RI; Mulvey, MR, 2018) |
| "This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 8.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain." | 8.90 | Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. ( Butler, PM; Kurowski, D; Perloff, MD; Yan, PZ, 2014) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain." | 8.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| "Gabapentin is a drug that has been widely used in the treatment of chronic pain states." | 8.83 | alpha2delta and the mechanism of action of gabapentin in the treatment of pain. ( Lee, K; Luo, ZD; Maneuf, YP, 2006) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 8.82 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain." | 8.82 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| " The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain." | 8.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 8.81 | [Gabapentin therapy for pain]. ( Block, F, 2001) |
| "Although its exact mode of action is not known, gabapentin appears to have a unique effect on voltage-dependent calcium ion channels at the postsynaptic dorsal horns and may, therefore, interrupt the series of events that possibly leads to the experience of a neuropathic pain sensation." | 8.81 | Gabapentin: pharmacology and its use in pain management. ( Kam, PC; Rose, MA, 2002) |
| "There have been many proposed uses for gabapentin, including midscapular pain secondary to radiation myelopathy, RSD, neuropathic pain, postherpetic neuralgia, and migraine prophylaxis." | 8.79 | Use of gabapentin in pain management. ( Connelly, JF; Wetzel, CH, 1997) |
| "To observe the therapeutic effect of metformin on pathological pain in mice with radiation dermatitis and explore the underlying mechanism." | 8.31 | [Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway]. ( An, Q; Cao, J; Han, F; Liu, H, 2023) |
| "Gabapentin is often used to manage pain in children with dystonic cerebral palsy, however the evidence for its effectiveness in this population is limited." | 8.02 | A pilot feasibility study of gabapentin for managing pain in children with dystonic cerebral palsy. ( Antolovich, G; Baker, F; Chalkiadis, G; Copeland, L; Harvey, A; McKinnon, C; Orsini, F; Rice, J; Scheinberg, A; Stewart, K; Thorley, M; Waugh, MC, 2021) |
| "We aimed to report our institution's experience with gabapentin therapy to manage agitation and pain in the neonatal intensive care unit (NICU) setting." | 7.96 | Gabapentin for pain, movement disorders, and irritability in neonates and infants. ( Burnsed, JC; Heinan, K; Letzkus, L; Zanelli, S, 2020) |
| "We assessed the efficacy and safety of extended-release gabapentin in a 15-week, open-label, single-arm, single-center study in patients with fibromyalgia (FM)." | 7.83 | The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study. ( Hong, KS; North, JM; Rauck, RL, 2016) |
| "The study objective was to describe presenting pain behaviors, daily dose, and response to gabapentin for the management of frequent recurrent pain in this population." | 7.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "We report two cases of infants with NI, identified to have significant improvement in apnea following empiric treatment with gabapentin for presumed central pain and/or visceral hyperalgesia." | 7.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 7.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "The frequency of PHN after untreated zoster varies widely." | 7.79 | Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999) |
| "To characterize and compare healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy (pDPN) newly prescribed pregabalin or gabapentin in a real-world clinical setting." | 7.78 | Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. ( Harnett, J; Mardekian, J; Udall, M, 2012) |
| "This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors." | 7.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "The aim of this study was to assess the role of adding gabapentin (Neurontin) to the prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI)." | 7.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "To determine the utility of substitution of pregabalin (PGB) for gabapentin (GBP) therapy in the relief of neuropathic pain (NeP) in patients with peripheral neuropathy (PN)." | 7.76 | Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. ( Toth, C, 2010) |
| "Gabapentin, an anticonvulsant, is widely accepted as an alternative therapeutic agent for neuropathic pain and has proved to produce analgesic effects in a mouse model of visceral pain." | 7.76 | Analgesic effects of gabapentin on mechanical hypersensitivity in a rat model of chronic pancreatitis. ( Chen, H; Liao, XZ; Mao, YF; Sun, JH; Xiong, YC; Xu, H; Zhou, MT, 2010) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 7.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "This retrospective study evaluated the efficacy of gabapentin for the treatment of pain syndromes related to radiation-induced mucositis in patients with head and neck cancers treated with concurrent chemoradiation." | 7.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain." | 7.75 | Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009) |
| " Using pharmacological and transgenic approaches in mice, we evaluated adrenergic receptor (AR) implication in the action of the tricyclic antidepressant desipramine, the noradrenaline and serotonin reuptake inhibitor venlafaxine, and the noradrenaline reuptake inhibitor reboxetine." | 7.75 | Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. ( Barrot, M; Doridot, S; Freund-Mercier, MJ; Hein, L; Petit-Demoulière, N; Tessier, LH; Yalcin, I, 2009) |
| "In order to detect an anti-nociceptive interaction between morphine and gabapentin, the anti-allodynic and anti-hyperalgesic effects of these drugs, administered either separately or in combination, were determined using the von Frey and acetone tests in a rat model of neuropathic pain (Bennett model)." | 7.75 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Gabapentin is a gamma-aminobutyric acid analog used for numerous neurologic conditions, including neuropathic pain and epilepsy." | 7.75 | Gabapentin therapy for pain and irritability in a neurologically impaired infant. ( Cox, TH; Garner, SS; Haney, AL, 2009) |
| "During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls." | 7.74 | Effects of gabapentin on morphine consumption and pain in severely burned patients. ( Cuignet, O; Pirson, J; Soudon, O; Zizi, M, 2007) |
| "The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain." | 7.74 | A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007) |
| "Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed." | 7.74 | Pregabalin and duloxetine for the treatment of neuropathic pain disorders. ( Terneus, W, 2007) |
| "Although gabapentin may relieve neuropathic pain by actions at many sites, these results suggest that its actions in the brain to cause spinal cholinergic activation predominate after oral administration." | 7.74 | Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. ( Eisenach, JC; Hayashida, K; Parker, R, 2007) |
| "These data demonstrated the comparable efficacy of gabapentin with morphine in visceral pain." | 7.74 | Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice. ( Meymandi, MS; Sepehri, G, 2008) |
| "To use gabapentin to relieve discomfort in a painful, blind glaucomatous eye of a patient unwilling to undergo further invasive treatment." | 7.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "A rat model of cancer-induced bone pain using the MRMT-1 cell line injected into the tibia was established to investigate the efficacy of acute (10, 30, 100 mg/kg) and chronic (30 mg/kg) systemic gabapentin on electrophysiological superficial dorsal horn neuronal responses to natural and noxious electrical stimuli, as well as on pain-related behavior." | 7.73 | Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. ( Dickenson, AH; Donovan-Rodriguez, T; Urch, CE, 2005) |
| "The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear." | 7.73 | Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. ( Aiyar, J; Anker, N; Belley, M; Bristow, L; Campbell, B; Cohen, C; Park, KT; Ren, K; Stearns, B; Urban, MO, 2005) |
| "Here, we have examined the effect of the novel antinociceptive agent CHF3381 on the development of nocifensive behaviour as well as secondary mechanical allodynia and hyperalgesia induced by intraplantar injection of capsaicin in rats." | 7.73 | CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. ( Bassani, F; Bergamaschi, M; Tonino Bolzoni, P; Villetti, G, 2005) |
| "Not all neuropathic pain patients gain relief from current therapies that include the anticonvulsant, gabapentin, thought to modulate calcium channel function." | 7.73 | Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. ( Dickenson, AH; Hunt, SP; Rahman, W; Rygh, LJ; Suzuki, R; Webber, M, 2005) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 7.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| " In this study the co-administration of gabapentin with morphine is evaluated in acute model of pain." | 7.73 | Gabapentin enhances the analgesic response to morphine in acute model of pain in male rats. ( Meymandi, MS; Mobasher, M; Sepehri, G, 2006) |
| " In order to avoid drug interactions as well as adverse effects of carbamazepine in myasthenia gravis, gabapentin was chosen for the treatment of neuropathic pain." | 7.72 | Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. ( Beuche, W; Scheschonka, A, 2003) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 7.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | 7.72 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "We report and discuss a case of severe neuropathic orbital pain refractory to standard analgesics that responded well to treatment with the anticonvulsant gabapentin." | 7.72 | Treatment of neuropathic orbital pain with gabapentin. ( Kancharla, A; Sloan, PA, 2003) |
| "The antiepileptic drug, gabapentin, and another structurally related compound, pregabalin, are increasingly employed in the pharmacotherapy of chronic pain states, although their primary mechanism of action remains a topic of active study." | 7.72 | Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. ( Chesler, EJ; Kokayeff, A; Lariviere, WR; Mogil, JS; Ritchie, J; Wilson, SG, 2003) |
| "Combined spinal administration of gabapentin and low doses of morphine significantly reduces pain-related behaviors in this acute rat pancreatitis model, whereas these agents were ineffective when used alone in this dose range." | 7.72 | Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. ( Lu, Y; Smiley, MM; Vera-Portocarrero, LP; Westlund, KN; Zidan, A, 2004) |
| "We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain." | 7.72 | Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004) |
| "Although gabapentin was originally developed for treating partial seizures, it has been used mainly to treat various peripheral neuropathic pain conditions; however, there is very limited experience with gabapentin for the treatment of pain conditions of the central nervous system like central post-stroke pain syndrome." | 7.71 | Central post-stroke pain syndrome: yet another use for gabapentin? ( Chen, B; DeLisa, JA; Foye, PM; Nadler, SF; Stitik, TP, 2002) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 7.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain." | 7.71 | Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection. ( Andoh, T; Kuraishi, Y; Nojima, H; Shiraki, K; Takasaki, I, 2001) |
| "The objective of this study was to assess the efficacy and safety of Gabapentin as the sole analgesic in patients with HIV-related painful neuropathy." | 7.71 | Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. ( Bottura, P; La Spina, I; Maggiolo, F; Porazzi, D; Suter, F, 2001) |
| "A patient with mycosis fungoides illustrates the problem of pain management during wound care and suggests the utility of a novel treatment, gabapentin." | 7.71 | Gabapentin for pain control in cancer patients' wound dressing care. ( Devulder, J; Lambert, J; Naeyaert, JM, 2001) |
| "To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| ") gabapentin, administered before and after the injection of formalin into the rat hindpaw, on pain behavior and hemodynamics." | 7.70 | The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat. ( Yaksh, TL; Yoon, MH, 1999) |
| "Neuropathic pain is a syndrome that affects around 1% of population." | 6.71 | Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. preliminary results. ( Espinoza-Raya, J; Granados-Soto, V; Medina-Santillán, R; Morales-Franco, G; Reyes-García, G, 2004) |
| "Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy." | 6.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "His pain was scored as a five on a six-point visual analog scale, and it persisted despite routine supportive therapy." | 6.50 | [A case of Guillain-Barré syndrome with severe pain successfully controlled with acetaminophen, gabapentin, and parenterally infused fentanyl]. ( Anzai, S; Hashimoto, Y; Nagasawa, K; Suzuki, T, 2014) |
| "Gabapentin has become popular as a first-line treatment for neuropathic pain because of its efficacy as an antineuropathic agent and relatively benign side-effect profile." | 6.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Gabapentin is a novel anticonvulsant that may have a unique effect on voltage-dependent Ca2+ channel currents at postsynaptic dorsal horn neurons." | 6.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| " However, studies of real-world gabapentinoid dosing demonstrate that the recommended dose targets are frequently not met and do not consider renal insufficiency." | 5.91 | Characterization of Outpatient Gabapentinoid Prescribing for Pain. ( A Bowman, L; Banks, C; Merrey, J; Waldfogel, JM, 2023) |
| "The addition of gabapentin to moderate sedation during D&E did not result in lower maximum recalled procedural pain." | 5.69 | Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial. ( Brant, AR; Floyd, S; Lotke, PS; Reeves, MF; Scott, RK; Tefera, E; Ye, PP, 2023) |
| "The addition of venlafaxine to prophylactic gabapentin did not result in improvements in pain control and quality of life among patients with head and neck cancer." | 5.69 | Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial. ( Attwood, K; Farrugia, M; Hermann, G; Iovoli, AJ; Ma, SJ; Neimanis, D; Singh, AK; Smith, KA; Wang, K, 2023) |
| "The purpose of this paper is to determine whether prophylactic gabapentin usage in patients undergoing definitive concurrent chemotherapy and radiation therapy (chemoRT) for oropharyngeal cancer (OPC) improves treatment-related oral mucositis pain, opioid use, and feeding tube (FT) placement." | 5.51 | Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. ( Ali, H; Chang, S; Cook, A; Fakhoury, L; Ghanem, T; Han, X; Modh, A; Momin, S; Money, S; Movsas, B; Sheqwara, J; Siddiqui, F; Tam, S; Wu, V, 2022) |
| "Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population." | 5.46 | sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. ( Bialer, M; Brennan, KC; Devor, M; Kaufmann, D; Smith, MD; West, PJ; White, HS; Yagen, B, 2017) |
| "Use of the gabapentinoids for pain continues to increase." | 5.41 | Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval. ( Al-Jammali, Z; Herink, MC; Williams, CD, 2023) |
| "Prophylactic gabapentin appears to be a promising treatment option for preventing pain, reducing opioids, and reducing weight loss in patients undergoing head and neck cancer therapy." | 5.41 | Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis. ( Murphy, BA; Smith, DK; Smith, LE, 2023) |
| "This study aims to evaluate the efficacy of gabapentin treatment in dry eye disease (DED) and neuropathic ocular pain." | 5.41 | Is gabapentin effective in dry eye disease and neuropathic ocular pain? ( Ongun, GT; Ongun, N, 2021) |
| "Gabapentin was found to reversibly decrease, but not suppress the flinching frequency of the second response peak only." | 5.40 | Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain. ( Danhof, M; Della Pasqua, O; Taneja, A; Troconiz, IF, 2014) |
| "6 h, oral bioavailability of 37% and 90%) with anti-inflammatory activity (ED 50 = 37 micromol/kg, mouse) and efficacy in pain models (thermal hyperalgesia, ED 50 = 72 micromol/kg, rat)." | 5.35 | Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. ( Adair, RM; Altenbach, RJ; Bettencourt, BM; Brioni, JD; Cowart, MD; Drizin, I; Esbenshade, TA; Fix-Stenzel, SR; Honore, P; Hsieh, GC; Liu, H; Marsh, KC; McPherson, MJ; Milicic, I; Miller, TR; Sullivan, JP; Wetter, JM; Wishart, N; Witte, DG, 2008) |
| "Here, we tested the effect of FK1706 on painful diabetic neuropathy in rat model of diabetes induced by streptozotocin (STZ)." | 5.35 | FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. ( Matsuoka, N; Murai, N; Mutoh, S; Price, RD; Yamaji, T; Yamamoto, H; Yamazaki, S, 2008) |
| "Pain is the result of an emotional and sensory experience and preclinical models of OA can thus be useful to better understand the underlying mechanisms of the disease and test new therapeutic options." | 5.35 | Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. ( Dickenson, AH; Ghandehari, J; Vonsy, JL, 2009) |
| "Primary erythermalgia (erythromelalgia) is a rare autosomal dominant condition characterized by intermittent attacks of erythema, increased skin temperature and severe burning pain in the extremities, in a bilateral symmetrical distribution." | 5.35 | Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. ( Atherton, D; Elmslie, F; Mansour, S; Mortimer, P; Natkunarajah, J, 2009) |
| "Gabapentin has established efficacy in the reduction of burn-induced hyperalgesia and allodynia in animal and human experimental burn models." | 5.35 | Successful use of gabapentin in acute pain management following burn injury: a case series. ( Cramond, T; Gray, P; Williams, B, 2008) |
| " At interim analysis, gabapentin use resulted in a decrease in pain (P = ." | 5.34 | Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation. ( Cmelak, A; Ghiam, M; Gibson, MK; Gilbert, J; Hawkins, D; Lou, D; Murphy, BA; Niermann, K; Smith, DK, 2020) |
| "Chronic muscle pain is a problem with high prevalence in clinical practice and its pharmacological treatment is difficult." | 5.34 | Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. ( Beyreuther, BK; Geis, C; Sommer, C; Stöhr, T, 2007) |
| "Ambroxol's effects were compared with those of gabapentin." | 5.33 | Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. ( Arndt, K; Gaida, W; Klinder, K; Weiser, T, 2005) |
| " This dosage produced a substantial but non-significant decrease in the incidence of postherpetic pain-related responses." | 5.32 | Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. ( Kuraishi, Y; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2004) |
| "Gabapentin (GBP) is a new antiepileptic agent with an original spectrum of activity." | 5.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)." | 5.31 | Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000) |
| " Both gabapentin and duloxetine groups had significantly more reduction in pain VAS and WOMAC and its subscales compared to acetaminophen group, with no significant difference between groups." | 5.30 | Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis. ( Azami, A; Enteshari-Moghaddam, A; Habibzadeh, A; Isazadehfar, K; Jahanpanah, P; Mohebbi, H, 2019) |
| "A variety of treatments for the pain were ineffective." | 5.30 | Gabapentin for treatment of neuropathic pain in a 12-year-old girl. ( McGraw, T; Stacey, BR, 1998) |
| "In this cohort, extended-release gabapentin, as compared with a placebo, did not reduce tampon test pain." | 5.27 | Gabapentin for the Treatment of Vulvodynia: A Randomized Controlled Trial. ( Bachmann, GA; Brown, CS; Foster, DC; Wan, J, 2018) |
| " Nonetheless, pain intensity reduction is achieved with 50% of the minimum required gabapentin dose alone (800 to 1600 mg/d) in classic NDD trials." | 5.22 | Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. ( Aguilar Navarro, S; Mimenza Alvarado, A, 2016) |
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 5.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Pregabalin has been used for the treatment of pain." | 5.22 | A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain. ( Kawakami, J; Naito, T; Yagi, T; Yoshikawa, N, 2016) |
| "Based on the obtained data, prophylactic lornoxicam controlled postendodontic treatment pain more effectively than did the placebo drugs, and gabapentin was more effective in controlling the pain than either lornoxicam or the placebo." | 5.19 | Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain. ( Aktuna, S; Işik, B; Turan, A; Yaman, S, 2014) |
| "Gabapentin is increasingly being used for the treatment of postoperative pain and a variety of psychiatric diseases, including chronic anxiety disorders." | 5.17 | Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. ( Clarke, H; Katz, J; Katznelson, R; Kirkham, KR; Ko, R; Ma, M; Mitsakakis, N; Orser, BA; Snyman, A, 2013) |
| "Gabapentin has demonstrated efficacy in clinical trials as a pre-emptive analgesic and in acute postoperative pain management." | 5.15 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 5.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| " Up to estimated 336 patients (interim analyses) with acute herpes zoster pain (VAS > 30 mm) will be randomised to one of three groups (a) semi-standardised acupuncture (168 patients); (b) gabapentine with individualised dosage between 900-3600 mg/d (84 patients); (c) sham laser acupuncture." | 5.14 | Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. ( Fleckenstein, J; Hoffrogge, P; Irnich, D; Kramer, S; Lang, PM; Lehmeyer, L; Mansmann, U; Pfab, F; Ring, J; Schober, GM; Schotten, KJ; Thoma, S; Weisenseel, P, 2009) |
| "The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study." | 5.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "This study compared the efficacy and safety of tramadol/acetaminophen (T/A) and gabapentin in the management of painful diabetic neuropathy." | 5.14 | Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010) |
| "Topical gabapentin seems to be well-tolerated and associated with significant pain relief in women with vulvodynia." | 5.13 | Topical gabapentin in the treatment of localized and generalized vulvodynia. ( Blais, LR; Boardman, LA; Cooper, AS; Raker, CA, 2008) |
| " The analgesic activity of CHF3381 was investigated in the heat-capsaicin human pain model and compared with those of gabapentin." | 5.12 | CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model. ( Dahl, JB; Fabbri, L; Hilsted, KL; Imbimbo, BP; Mathiesen, O, 2006) |
| " The risk of phantom pain (gabapentin vs." | 5.12 | A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006) |
| "Gabapentin, an oral non-opioid analgesic, has been used to decrease pain after a variety of surgical procedures." | 5.12 | Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia. ( Karamanlioglu, B; Pamukçu, Z; Turan, A; White, PF, 2007) |
| "To assess the efficacy and safety of gabapentin in patients with fibromyalgia." | 5.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "To estimate the cost-effectiveness of branded pregabalin (PGB) versus generic gabapentin (GBP) in patients with neuropathic pain (NeP) due to painful diabetic polyneuropathy (DPN) or post-herpetic neuralgia (PHN) in Spain." | 5.12 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "To test the hypotheses that both amitriptyline and gabapentin are more effective in relieving neuropathic pain than an active placebo, diphenhydramine." | 5.12 | Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007) |
| "To determine the analgesic effect of the addition of gabapentin to opioids in the management of neuropathic cancer pain." | 5.11 | Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. ( Arcuri, E; Barbieri, M; Bonezzi, C; Caraceni, A; De Conno, F; Gorni, G; Maltoni, M; Martini, C; Tirelli, W; Visentin, M; Yaya Tur, R; Zecca, E, 2004) |
| "Patients reported significant pain relief in favor of gabapentin in the first period." | 5.11 | Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004) |
| "We evaluated the effects of gabapentin and carbamazepine for pain relief in 36 Guillain-Barré syndrome patients." | 5.11 | The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. ( Kumar, A; Navkar, DV; Pandey, CK; Raza, M; Singh, UK; Tripathi, M, 2005) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "A double-blind, randomised, placebo-controlled 8-week study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain, using doses up to 2400 mg/day." | 5.10 | Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002) |
| "To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS)." | 5.10 | Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. ( de la Llave, Y; Garcia-Borreguero, D; Hernandez, G; Larrosa, O; Masramon, X; Verger, K, 2002) |
| "Gabapentin, an antiepileptic drug, has been used effectively for different types of pain management." | 5.10 | Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study. ( Agarwal, A; Baronia, A; Bose, N; Garg, G; Pandey, CK; Singh, N; Singh, PK; Singh, U, 2002) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "The aim of our study was to explore a potential analgesic effect of gabapentin in patients with neuropathic pain caused by anticancer treatment." | 5.10 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| "Reports of gabapentin use in diabetic peripheral neuropathy pain stimulate a need for controlled trials to determine its comparative efficacy to the therapeutic standard of amitriptyline hydrochloride." | 5.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in painful diabetic neuropathy." | 5.09 | Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000) |
| "Twenty-one patients referred with refractory genitourinary pain were treated with oral gabapentin." | 5.09 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "To evaluate the effects of gabapentin on pain scores and opiate use." | 5.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)." | 5.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "To evaluate the effect of gabapentin monotherapy on pain associated with diabetic peripheral neuropathy." | 5.08 | Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. ( Backonja, M; Beydoun, A; Edwards, KR; Fonseca, V; Garofalo, E; Hes, M; LaMoreaux, L; Schwartz, SL, 1998) |
| "The gabapentinoid drugs gabapentin and pregabalin were originally developed as antiseizure drugs but now are prescribed mainly for treatment of pain." | 5.01 | A Clinical Overview of Off-label Use of Gabapentinoid Drugs. ( Brett, AS; Goodman, CW, 2019) |
| "Gabapentinoids are frequently used in the management of cancer pain." | 4.98 | A critical appraisal of gabapentinoids for pain in cancer patients. ( Bennett, MI; Jordan, RI; Mulvey, MR, 2018) |
| " Overall, there was a low quality of evidence that gabapentin, pregabalin, amitriptyline, and venlafaxine were effective in reducing pain intensity in patients with cancer pain." | 4.95 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 4.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain." | 4.90 | Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. ( Butler, PM; Kurowski, D; Perloff, MD; Yan, PZ, 2014) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Depomed is developing an extended-release (ER) oral formulation of gabapentin, a GABA receptor agonist commonly used for the treatment of epilepsy and seizures, neuropathic pain and hot flushes." | 4.84 | Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention, Gabapentin GR. ( , 2007) |
| "Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain." | 4.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| "Gabapentin, a gamma-aminobutyric acid (GABA) analogue anticonvulsant, is also an effective analgesic agent in neuropathic and inflammatory, but not acute, pain systemically and intrathecally." | 4.83 | Mechanisms of the antinociceptive action of gabapentin. ( Cheng, JK; Chiou, LC, 2006) |
| "Gabapentin is a drug that has been widely used in the treatment of chronic pain states." | 4.83 | alpha2delta and the mechanism of action of gabapentin in the treatment of pain. ( Lee, K; Luo, ZD; Maneuf, YP, 2006) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 4.82 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain." | 4.82 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| " The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain." | 4.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 4.81 | [Gabapentin therapy for pain]. ( Block, F, 2001) |
| "Although its exact mode of action is not known, gabapentin appears to have a unique effect on voltage-dependent calcium ion channels at the postsynaptic dorsal horns and may, therefore, interrupt the series of events that possibly leads to the experience of a neuropathic pain sensation." | 4.81 | Gabapentin: pharmacology and its use in pain management. ( Kam, PC; Rose, MA, 2002) |
| "Gabapentin has been approved for the treatment of neuropathic pain in six European countries, New Zealand and Australia, and numerous countries in Latin America." | 4.81 | Gabapentin. Pfizer. ( Wheeler, G, 2002) |
| "Gabapentin, an antiepileptic agent, is a safe and versatile medication also used in the adjunctive treatment of painful disorders." | 4.80 | Interstitial cystitis and the potential role of gabapentin. ( Hansen, HC, 2000) |
| "There have been many proposed uses for gabapentin, including midscapular pain secondary to radiation myelopathy, RSD, neuropathic pain, postherpetic neuralgia, and migraine prophylaxis." | 4.79 | Use of gabapentin in pain management. ( Connelly, JF; Wetzel, CH, 1997) |
| " Examining antiepileptic prescribing to residents with ADRD who had disruptive behaviors and/or reported pain suggests that two of the most common antiepileptics, valproic acid and gabapentin, are being used in clinically distinct ways." | 4.31 | Antiepileptic prescribing to persons living with dementia residing in nursing homes: A tale of two indications. ( Candon, M; Gerlach, LB; Maust, DT; Strominger, J, 2023) |
| "To observe the therapeutic effect of metformin on pathological pain in mice with radiation dermatitis and explore the underlying mechanism." | 4.31 | [Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway]. ( An, Q; Cao, J; Han, F; Liu, H, 2023) |
| " Because there was no difference in pain, analgesic usage, or time to discharge between groups, investigation regarding gabapentin use for outpatient urogynecologic surgery is needed." | 4.12 | Effects of Preoperative Gabapentin on Clinical Outcomes After Outpatient Midurethral Sling Placement. ( Dengler, KL; DiCarlo-Meacham, AM; Olsen, C; Stone, GW; Von Pechmann, W; Welch, EK; Wheat, JE, 2022) |
| "In patients with diabetic neuropathy who were prescribed gabapentin and pregabalin, there is an increased risk for heart failure, myocardial infarction, peripheral vascular disease, stroke, deep venous thrombosis, and pulmonary embolism with long-term use." | 4.12 | Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy. ( Blankfield, RP; Davis, PB; Kaebler, DC; Pan, Y; Xu, R, 2022) |
| " Acute morphine or gabapentin treatment partly attenuated allodynia in males, but not females." | 4.12 | Persistent sensory changes and sex differences in transgenic mice conditionally expressing HIV-1 Tat regulatory protein. ( Bagdas, D; Bigbee, J; Caillaud, M; Damaj, MI; Hauser, KF; Knapp, PE; McKiver, B; Nass, SR; Ondo, O; Paris, JJ; Toma, W; Warncke, UO, 2022) |
| "Gabapentinoid drugs (gabapentin and pregabalin) are increasingly used for pain as both patients and physicians seek opioid-sparing or opioid-reducing strategies." | 4.12 | Gabapentinoid Dosing and Associated Toxicities in Patients With or Without Concomitant Opioids During Hospitalization. ( Atayee, R; Lee, K; Sadeghi, S; Tu, TG, 2022) |
| "Little is known about relationships between opioid- and gabapentinoid-use patterns and healthcare expenditures that may be affected by pain management and risk of adverse outcomes." | 4.02 | Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries. ( Bhattacharjee, S; Kwoh, CK; Lo-Ciganic, WH; Malone, DC; Reisfield, GM; Slack, M; Tighe, PJ; Wilson, DL; Zhou, L, 2021) |
| "To evaluate if gabapentin permeates feline skin in vitro and in vivo and to determine if pain scores improve after administration." | 4.02 | A pilot study of transdermal gabapentin in cats. ( Costa, AP; Slovak, JE, 2021) |
| "Gabapentin is often used to manage pain in children with dystonic cerebral palsy, however the evidence for its effectiveness in this population is limited." | 4.02 | A pilot feasibility study of gabapentin for managing pain in children with dystonic cerebral palsy. ( Antolovich, G; Baker, F; Chalkiadis, G; Copeland, L; Harvey, A; McKinnon, C; Orsini, F; Rice, J; Scheinberg, A; Stewart, K; Thorley, M; Waugh, MC, 2021) |
| "We aimed to report our institution's experience with gabapentin therapy to manage agitation and pain in the neonatal intensive care unit (NICU) setting." | 3.96 | Gabapentin for pain, movement disorders, and irritability in neonates and infants. ( Burnsed, JC; Heinan, K; Letzkus, L; Zanelli, S, 2020) |
| "Gabapentin, a prescription medication approved for the treatment of seizures and neuralgia, is often prescribed off-label for substance use treatment, mental health problems, and pain." | 3.91 | Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers. ( Buttram, ME; Cicero, TJ; Ellis, MS; Kurtz, SP, 2019) |
| "Multiple approaches are needed to mitigate gabapentin misuse, including limiting availability in institutional settings and informal channels as well as addressing the needs of drug users who experience physical pain and withdrawal symptoms." | 3.91 | An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user. ( Buttram, ME; Cicero, TJ; Havens, JR; Kurtz, SP, 2019) |
| " She was diagnosed with shingles, started on valacyclovir and gabapentin, and eventually went on to deliver a healthy infant." | 3.88 | Shingles in Pregnancy: An Elusive Case of Left Upper Quadrant Abdominal Pain. ( Chin, JM; Schlueter, RJ; Wong, JW, 2018) |
| "Prior work applied hierarchical clustering, coarsened exact matching (CEM), time series regressions with lagged variables as inputs, and microsimulation to data from three randomized clinical trials (RCTs) and a large German observational study (OS) to predict pregabalin pain reduction outcomes for patients with painful diabetic peripheral neuropathy." | 3.88 | Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy. ( Alexander, J; Bonfanti, G; Brodsky, M; Edwards, RA; Emir, B; Grugni, R; Manca, L; Parsons, B; Savoldelli, A; Watt, S; Whalen, E, 2018) |
| " Daily gabapentin treatment attenuated mechanical allodynia and reduced face-grooming episodes in dIoN-CCI rats." | 3.85 | An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017) |
| "Gabapentinoids are effective adjunct drugs for reducing postoperative pain." | 3.83 | Comparison of the effects of gabapentin and pregabalin on wound healing in rats. ( Korkmaz, M; Sarıtaş, TB; Sarıtaş, ZK; Sevimli, A, 2016) |
| "We assessed the efficacy and safety of extended-release gabapentin in a 15-week, open-label, single-arm, single-center study in patients with fibromyalgia (FM)." | 3.83 | The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study. ( Hong, KS; North, JM; Rauck, RL, 2016) |
| " Mechanical allodynia elicited by burn injury was partially reversed by meloxicam (5 mg/kg), gabapentin (100 mg/kg) and oxycodone (3 and 10 mg/kg), while thermal allodynia and gait abnormalities were only significantly improved by amitriptyline (3 mg/kg) and oxycodone (10 mg/kg)." | 3.83 | Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target. ( Deuis, JR; Lewis, RJ; Vetter, I; Yin, K, 2016) |
| " In particular, 14 and 15 were found to be more potent than morphine for both acute and inflammatory pain models and 100-fold more potent than gabapentin in a diabetic neuropathic pain model." | 3.81 | Antinociceptive Grayanoids from the Roots of Rhododendron molle. ( Li, Y; Liu, Y; Liu, YB; Lv, HN; Ma, SG; Qu, J; Yu, SS; Zhang, JJ, 2015) |
| " Data pertaining to demographics, diagnosis, oral morphine dose equivalent of the opioid at the time of discharge, adjuvant analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and pain scores as reported by nurses and physicians were collected." | 3.81 | Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements? ( Davis, MP; Gordon, P; Gross, J; Sharma, P; Shinde, S, 2015) |
| " Sleep disruption-induced hypersensitivity was pharmacologically characterized with drugs relevant for pain treatment, including gabapentin (30 mg/kg and 50 mg/kg), Ica-6p (Kv7." | 3.81 | Development and pharmacological characterization of a model of sleep disruption-induced hypersensitivity in the rat. ( Gilmour, G; Kennedy, JD; Schuh-Hofer, S; Treede, RD; Wafford, KA; Wodarski, R; Yurek, DA, 2015) |
| "The study objective was to describe presenting pain behaviors, daily dose, and response to gabapentin for the management of frequent recurrent pain in this population." | 3.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Synthetic approaches to gabapentin bioconjugates that overcome the tendency of gabapentin to cyclize into its γ-lactam are studied." | 3.80 | Gabapentin hybrid peptides and bioconjugates. ( Alamry, KA; Goncalves, K; Ibrahim, MA; Katritzky, AR; Lebedyeva, IO; Neubert, J; Ostrov, DA; Patel, K; Sileno, SM; Steel, PJ, 2014) |
| "We report two cases of infants with NI, identified to have significant improvement in apnea following empiric treatment with gabapentin for presumed central pain and/or visceral hyperalgesia." | 3.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 3.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "The frequency of PHN after untreated zoster varies widely." | 3.79 | Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999) |
| "To characterize and compare healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy (pDPN) newly prescribed pregabalin or gabapentin in a real-world clinical setting." | 3.78 | Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. ( Harnett, J; Mardekian, J; Udall, M, 2012) |
| "Prescription opioids and anticonvulsants such as gabapentin are often used as combination therapeutics for chronic as well as acute post-operative pain conditions although the effectiveness of such combinations may be dependent on the intensity of the pain state." | 3.78 | Temperature-dependent enhancement of the antinociceptive effects of opioids in combination with gabapentin in mice. ( Neelakantan, H; Walker, EA, 2012) |
| " A recent study from our laboratory revealed that gabapentin, a recommended first-line treatment for multiple neuropathic conditions, could also efficiently antagonize thermal hyperalgesia evoked by complete Freund's adjuvant (CFA)-induced monoarthritis (MA)." | 3.78 | Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats. ( Deng, XM; Li, SS; Xu, B; Xu, H; Yang, JL; Zhang, WS; Zhang, YQ, 2012) |
| "This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors." | 3.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "The aim of this study was to assess the role of adding gabapentin (Neurontin) to the prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI)." | 3.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "To determine the utility of substitution of pregabalin (PGB) for gabapentin (GBP) therapy in the relief of neuropathic pain (NeP) in patients with peripheral neuropathy (PN)." | 3.76 | Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. ( Toth, C, 2010) |
| "Gabapentin, an anticonvulsant, is widely accepted as an alternative therapeutic agent for neuropathic pain and has proved to produce analgesic effects in a mouse model of visceral pain." | 3.76 | Analgesic effects of gabapentin on mechanical hypersensitivity in a rat model of chronic pancreatitis. ( Chen, H; Liao, XZ; Mao, YF; Sun, JH; Xiong, YC; Xu, H; Zhou, MT, 2010) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 3.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "This retrospective study evaluated the efficacy of gabapentin for the treatment of pain syndromes related to radiation-induced mucositis in patients with head and neck cancers treated with concurrent chemoradiation." | 3.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain." | 3.75 | Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009) |
| "Gabapentin is widely used in the management of pain." | 3.75 | Gabapentin toxicity in renal failure: the importance of dose adjustment. ( Miller, A; Price, G, 2009) |
| "Gabapentin is used in analgesic treatment of neuropathic pain, and large interindividual variation has been observed in the pharmacokinetics (PK) of the drug." | 3.75 | A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. ( Carlsson, KC; Eriksen, HO; Hoem, NO; Karlsson, MO; Moberg, ER; van de Schootbrugge, M, 2009) |
| " Using pharmacological and transgenic approaches in mice, we evaluated adrenergic receptor (AR) implication in the action of the tricyclic antidepressant desipramine, the noradrenaline and serotonin reuptake inhibitor venlafaxine, and the noradrenaline reuptake inhibitor reboxetine." | 3.75 | Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. ( Barrot, M; Doridot, S; Freund-Mercier, MJ; Hein, L; Petit-Demoulière, N; Tessier, LH; Yalcin, I, 2009) |
| "Our data suggest that activation of spinal or dorsal root ganglion HCN channels or both is not involved in formalin-induced pain, and intrathecal gabapentin does not act as an HCN channel activator to achieve its antinociceptive effect in the formalin test." | 3.75 | Intrathecal gabapentin does not act as a hyperpolarization-activated cyclic nucleotide-gated channel activator in the rat formalin test. ( Chen, CC; Cheng, JK; Huang, YJ; Lin, CF; Lin, CS; Tsaur, ML, 2009) |
| "We compared the inhibitory action of gabapentin, which is used to treat neuropathic pain, on mechanical allodynia induced by chemotherapeutic agents, paclitaxel, oxaliplatin, and vincristine, in mice." | 3.75 | Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. ( Andoh, T; Fujita, M; Gauchan, P; Ikeda, K; Kato, A; Kuraishi, Y; Sasaki, A, 2009) |
| "In order to detect an anti-nociceptive interaction between morphine and gabapentin, the anti-allodynic and anti-hyperalgesic effects of these drugs, administered either separately or in combination, were determined using the von Frey and acetone tests in a rat model of neuropathic pain (Bennett model)." | 3.75 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Gabapentin is a gamma-aminobutyric acid analog used for numerous neurologic conditions, including neuropathic pain and epilepsy." | 3.75 | Gabapentin therapy for pain and irritability in a neurologically impaired infant. ( Cox, TH; Garner, SS; Haney, AL, 2009) |
| "We examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (hereafter referred to as Pfizer and Parke-Davis) for off-label indications (prophylaxis against migraine and treatment of bipolar disorders, neuropathic pain, and nociceptive pain), comparing internal company documents with published reports." | 3.75 | Outcome reporting in industry-sponsored trials of gabapentin for off-label use. ( Bero, L; Dickersin, K; Scherer, RW; Vedula, SS, 2009) |
| "During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls." | 3.74 | Effects of gabapentin on morphine consumption and pain in severely burned patients. ( Cuignet, O; Pirson, J; Soudon, O; Zizi, M, 2007) |
| " To further establish the neurochemical basis for its supraspinally mediated analgesic action, concentrations of spinal noradrenaline, 4-hydroxy-3-methoxyphenylglycol (MHPG), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA) and dopamine were measured using high-performance liquid chromatography in a murine neuropathic pain model that was prepared by partial ligation of the sciatic nerve (the Seltzer model)." | 3.74 | Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury. ( Honda, M; Ono, H; Takasu, K; Takeuchi, Y; Tanabe, M, 2007) |
| "The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain." | 3.74 | A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007) |
| "Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed." | 3.74 | Pregabalin and duloxetine for the treatment of neuropathic pain disorders. ( Terneus, W, 2007) |
| "Although gabapentin may relieve neuropathic pain by actions at many sites, these results suggest that its actions in the brain to cause spinal cholinergic activation predominate after oral administration." | 3.74 | Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. ( Eisenach, JC; Hayashida, K; Parker, R, 2007) |
| "Although this is a small study, it appears that gabapentin and nortriptyline are effective in the treatment of idiopathic chronic orchialgia but not post-vasectomy pain." | 3.74 | Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery. ( Lee, LK; Miller, B; Sinclair, AM, 2007) |
| "These data demonstrated the comparable efficacy of gabapentin with morphine in visceral pain." | 3.74 | Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice. ( Meymandi, MS; Sepehri, G, 2008) |
| " The three models were benchmarked using compounds known to be active in neuropathic pain patients and nerve injury animal models, including gabapentin, amitriptyline and clonidine." | 3.74 | Transient allodynia pain models in mice for early assessment of analgesic activity. ( Cheevers, CV; Donello, JE; Gil, DW, 2008) |
| "We have previously demonstrated that gabapentin supraspinally activates the descending noradrenergic system to ameliorate pain hypersensitivity in mice with partial nerve ligation." | 3.74 | Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice. ( Ono, H; Takasu, K; Tanabe, M, 2008) |
| "Gabapentin (GBP; 1-(aminomethyl)cyclohexane acetic acid) is used clinically in the treatment of pain." | 3.74 | Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study. ( Chapman, V; Governo, RJ; Marsden, CA; Morris, PG, 2008) |
| "Data were obtained from a cohort of 603 patients with neuropathic pain undergoing analgesic treatment with gabapentin who completed four health scales: Medical Outcomes Study Sleep Scale, Sheehan Disability Scale, Covi Anxiety Scale, and Raskin Depression scale." | 3.74 | Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patient-reported outcomes measures. ( Pardo, A; Rejas, J; Ruiz, MA, 2008) |
| "To use gabapentin to relieve discomfort in a painful, blind glaucomatous eye of a patient unwilling to undergo further invasive treatment." | 3.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "There is evidence supporting the antinociceptive effects of carbamazepine, oxcarbazepine, gabapentin, and topiramate in various models of neuropathic pain as well as inflammatory somatic pain." | 3.74 | The antinociceptive effects of anticonvulsants in a mouse visceral pain model. ( Boskovic, B; Milovanovic, S; Paranos, S; Prostran, MS; Stepanovic-Petrovic, RM; Tomic, MA; Ugresic, ND; Vuckovic, SM, 2008) |
| "Duloxetine, a selective but balanced serotonergic and noradrenergic reuptake inhibitor, was evaluated in the acute nociceptive pain models of tail flick and hot plate in mice and in the persistent and/or inflammatory pain models of acetic acid-induced writhing in mice, carrageenan-induced thermal hyperalgesia and mechanical allodynia in rats, and capsaicin-induced mechanical allodynia in rats." | 3.73 | Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. ( Jones, CK; Peters, SC; Shannon, HE, 2005) |
| "A rat model of cancer-induced bone pain using the MRMT-1 cell line injected into the tibia was established to investigate the efficacy of acute (10, 30, 100 mg/kg) and chronic (30 mg/kg) systemic gabapentin on electrophysiological superficial dorsal horn neuronal responses to natural and noxious electrical stimuli, as well as on pain-related behavior." | 3.73 | Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. ( Dickenson, AH; Donovan-Rodriguez, T; Urch, CE, 2005) |
| "The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear." | 3.73 | Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. ( Aiyar, J; Anker, N; Belley, M; Bristow, L; Campbell, B; Cohen, C; Park, KT; Ren, K; Stearns, B; Urban, MO, 2005) |
| " In the current study, we evaluated the behavioral effects of two standard drugs used clinically for neuropathic pain, the anticonvulsant gabapentin and antidepressant imipramine, in rats at different times after peripheral nerve injury." | 3.73 | The effect of antinociceptive drugs tested at different times after nerve injury in rats. ( Borsook, D; Hama, AT, 2005) |
| "Here, we have examined the effect of the novel antinociceptive agent CHF3381 on the development of nocifensive behaviour as well as secondary mechanical allodynia and hyperalgesia induced by intraplantar injection of capsaicin in rats." | 3.73 | CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. ( Bassani, F; Bergamaschi, M; Tonino Bolzoni, P; Villetti, G, 2005) |
| "The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested after intraperitoneal administration in rat models of acute, persistent and neuropathic pain." | 3.73 | Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. ( Blackburn-Munro, G; Nielsen, AN; Pedersen, LH, 2005) |
| "Not all neuropathic pain patients gain relief from current therapies that include the anticonvulsant, gabapentin, thought to modulate calcium channel function." | 3.73 | Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. ( Dickenson, AH; Hunt, SP; Rahman, W; Rygh, LJ; Suzuki, R; Webber, M, 2005) |
| " The effects of diacerhein were compared with those of gabapentin, a drug used clinically for the management of neuropathic pain." | 3.73 | The effects of diacerhein on mechanical allodynia in inflammatory and neuropathic models of nociception in mice. ( Calixto, JB; Campos, MM; Medeiros, R; Quintão, NLM; Santos, ARS, 2005) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 3.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| " In this study the co-administration of gabapentin with morphine is evaluated in acute model of pain." | 3.73 | Gabapentin enhances the analgesic response to morphine in acute model of pain in male rats. ( Meymandi, MS; Mobasher, M; Sepehri, G, 2006) |
| "A series of mutual prodrugs derived from gabapentin, pregabalin, memantine, venlafaxine were synthesized and their pharmacological properties to treat neuropathic pain were investigated in a rat model of chronic sciatic nerve constriction injury (CCI)." | 3.72 | Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury. ( Bo-Hua, Z; He, L; Hong-Ju, Y; Jun-Wei, W; Nan, Z; Wei-Guo, S; Wei-Xiu, Y; Zhe-Hui, G; Zheng-Hua, G; Zhi-Pu, L; Zhong-Wei, J, 2004) |
| "Gabapentin has recently been used clinically as an antihyperalgesic agent to treat certain neuropathic pain states." | 3.72 | Gabapentin markedly reduces acetic acid-induced visceral nociception. ( Cui, M; Feng, Y; Willis, WD, 2003) |
| "Case report on a patient with SUNCT-syndrome (short lasting, unilateral neuralgiform headache attacks with conjunctival injection, sweating, and rhinorrhoea) who was successfully treated with gabapentin." | 3.72 | [Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003) |
| " In order to avoid drug interactions as well as adverse effects of carbamazepine in myasthenia gravis, gabapentin was chosen for the treatment of neuropathic pain." | 3.72 | Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. ( Beuche, W; Scheschonka, A, 2003) |
| "To test whether gabapentin, an anticonvulsant, is able to inhibit responses to peritoneal irritation-induced visceral pain and to examine the effect of gabapentin on spinal cord amino acid release." | 3.72 | [Effect of anticonvulsant gabapentin on visceral nociception and its relationship with amino acid neurotransmitters released from spinal cord]. ( Cui, M; Feng, Y; Willis, WD, 2003) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 3.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | 3.72 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "Little is known about current practice in using the anticonvulsant gabapentin in the management of cancer-related neuropathic pain." | 3.72 | The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003) |
| "We report and discuss a case of severe neuropathic orbital pain refractory to standard analgesics that responded well to treatment with the anticonvulsant gabapentin." | 3.72 | Treatment of neuropathic orbital pain with gabapentin. ( Kancharla, A; Sloan, PA, 2003) |
| "The antiepileptic drug, gabapentin, and another structurally related compound, pregabalin, are increasingly employed in the pharmacotherapy of chronic pain states, although their primary mechanism of action remains a topic of active study." | 3.72 | Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. ( Chesler, EJ; Kokayeff, A; Lariviere, WR; Mogil, JS; Ritchie, J; Wilson, SG, 2003) |
| "A pharmacokinetic-pharmacodynamic (PK/PD) model relating pain relief to gabapentin plasma concentrations was derived from a phase 3 study." | 3.72 | The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain. ( Cook, JA; Ewy, WE; Lockwood, PA; Mandema, JW, 2003) |
| "Combined spinal administration of gabapentin and low doses of morphine significantly reduces pain-related behaviors in this acute rat pancreatitis model, whereas these agents were ineffective when used alone in this dose range." | 3.72 | Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. ( Lu, Y; Smiley, MM; Vera-Portocarrero, LP; Westlund, KN; Zidan, A, 2004) |
| "We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain." | 3.72 | Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004) |
| "To clarify molecular substrates involved in the development of radicular pain, and to investigate the responsiveness of radicular pain to gabapentin." | 3.71 | Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain. ( Abe, M; Han, W; Kurihara, T; Shinomiya, K; Tanabe, T, 2002) |
| "Although gabapentin was originally developed for treating partial seizures, it has been used mainly to treat various peripheral neuropathic pain conditions; however, there is very limited experience with gabapentin for the treatment of pain conditions of the central nervous system like central post-stroke pain syndrome." | 3.71 | Central post-stroke pain syndrome: yet another use for gabapentin? ( Chen, B; DeLisa, JA; Foye, PM; Nadler, SF; Stitik, TP, 2002) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 3.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain." | 3.71 | Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection. ( Andoh, T; Kuraishi, Y; Nojima, H; Shiraki, K; Takasaki, I, 2001) |
| "The objective of this study was to assess the efficacy and safety of Gabapentin as the sole analgesic in patients with HIV-related painful neuropathy." | 3.71 | Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. ( Bottura, P; La Spina, I; Maggiolo, F; Porazzi, D; Suter, F, 2001) |
| "A patient with mycosis fungoides illustrates the problem of pain management during wound care and suggests the utility of a novel treatment, gabapentin." | 3.71 | Gabapentin for pain control in cancer patients' wound dressing care. ( Devulder, J; Lambert, J; Naeyaert, JM, 2001) |
| "By use of the rat formalin test, a model of persistent pain, we examined the effect of a combination of amitriptyline and gabapentin, which are used to treat chronic pain in humans." | 3.71 | The interaction between gabapentin and amitriptyline in the rat formalin test after systemic administration. ( Heughan, CE; Sawynok, J, 2002) |
| " To resolve this issue, we combined immunocytochemical and patch recording techniques to study the actions of GBP on NMDA receptors in dorsal horn cells isolated from rats with inflammation and to determine the gamma-aminobutyric acid (GABA) content in the recorded cells." | 3.71 | Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. ( Gu, Y; Huang, LY, 2002) |
| "To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Gabapentin is an effective option for the treatment of neuropathic pain syndromes because of its efficacy and favorable side-effect profile." | 3.70 | Gabapentin induced polyneuropathy. ( Gould, HJ, 1998) |
| ") gabapentin, administered before and after the injection of formalin into the rat hindpaw, on pain behavior and hemodynamics." | 3.70 | The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat. ( Yaksh, TL; Yoon, MH, 1999) |
| "The anticonvulsant gabapentin is effective against neuropathic pain, but the primary site(s) and mechanism(s) of action are unknown." | 3.70 | Antinociceptive effect of systemic gabapentin in mononeuropathic rats, depends on stimulus characteristics and level of test integration. ( Christensen, D; Kayser, V, 2000) |
| "Gabapentin is a novel anticonvulsant that may be of value for the relief of clinical pain." | 3.69 | Spinal gabapentin is antinociceptive in the rat formalin test. ( Davis, AM; Elliott, KJ; Inturrisi, CE; Shimoyama, M; Shimoyama, N, 1997) |
| "The novel anti-epileptic drugs lamotrigine, felbamate and gabapentin were compared in rat experimental models of acute (tail flick) and chronic pain: the chronic constriction injury and spinal nerve ligation models." | 3.69 | The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. ( Fontana, DJ; Gogas, KR; Hedley, LR; Hunter, JC; Jacobson, LO; Kassotakis, L; Thompson, J, 1997) |
| "Pain was not found to be different between the treatment arms." | 2.94 | A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer. ( Attwood, K; Bourgeois, DJ; Hermann, GM; Iovoli, AJ; Miller, A; Platek, AJ; Singh, AK; Wang, C, 2020) |
| "This severe pain is mostly refractory to palliative analgesic treatment, and the latter was only detected by specific and sensitive outcomes." | 2.87 | Pain characterization and response to palliative care in dogs with naturally-occurring appendicular osteosarcoma: An open label clinical trial. ( Beauchamp, G; Blair, J; de Lorimier, LP; Lussier, B; Monteiro, BP; Moreau, M; Pelletier, JP; Troncy, E, 2018) |
| "Patients with diabetic polyneuropathy were examined to study their biological age, rate of aging and pain syndrome." | 2.76 | [Biological age and the pain syndrome at diabetic polyneuropathy]. ( Emel'ianov, VV; Galkin, VV; Nesterova, MV, 2011) |
| "Gabapentin is an important adjuvant to the management of opiate dependence both in acute detoxification as well as stabilisation phase." | 2.71 | Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. ( Jain, MK; Kumar, P, 2003) |
| "Gabapentin 2400 mg/day was given in case of treatment failure or if imipramine treatment was not possible." | 2.71 | Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion. ( Bach, FW; Jensen, TS; Rasmussen, PV; Sindrup, SH, 2004) |
| "Neuropathic pain is a syndrome that affects around 1% of population." | 2.71 | Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. preliminary results. ( Espinoza-Raya, J; Granados-Soto, V; Medina-Santillán, R; Morales-Franco, G; Reyes-García, G, 2004) |
| "Oxcarbazepine appears to be a promising alternative monotherapeutic approach for patients affected by PHN." | 2.71 | Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. ( Auletta, C; Brogi, A; Brogi, F; Criscuolo, S; Lippi, S, 2005) |
| "Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain." | 2.71 | Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. ( Buchanan, TJ; Huggins, JP; Iannetti, GD; Smart, TS; Tracey, I; Vennart, W; Wise, RG; Zambreanu, L, 2005) |
| "Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy." | 2.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "Mechanistic approaches and multimodal analgesic techniques have been clearly demonstrated to be the most effective pain management strategy to improve outcomes." | 2.55 | Analgesia in the surgical intensive care unit. ( Brudney, CS; Ehieli, E; Pyati, S; Yalamuri, S, 2017) |
| " Rodent models of CIPN have been developed using a range of dosing regimens to reproduce pain-like behaviours akin to patient-reported symptoms." | 2.53 | Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics. ( Duggett, NA; Flatters, SJL; Hopkins, HL, 2016) |
| "Pain was rated on a scale from 0 (no pain) to 10 (maximum pain)." | 2.52 | Pharmacological treatment for pain in Guillain-Barré syndrome. ( Liu, J; McNicol, ED; Wang, LN, 2015) |
| "Gabapentin is a reasonable first-line choice, and opioid medications can be added for more severe pain but there are few clinical trials to inform specific recommendations." | 2.52 | Headache and Pain in Guillain-Barré Syndrome. ( Farmakidis, C; Herskovitz, S; Inan, S; Milstein, M, 2015) |
| "His pain was scored as a five on a six-point visual analog scale, and it persisted despite routine supportive therapy." | 2.50 | [A case of Guillain-Barré syndrome with severe pain successfully controlled with acetaminophen, gabapentin, and parenterally infused fentanyl]. ( Anzai, S; Hashimoto, Y; Nagasawa, K; Suzuki, T, 2014) |
| "Pain was rated on a scale from 0 (no pain) to 10 (maximum pain)." | 2.49 | Pharmacological treatment for pain in Guillain-Barré syndrome. ( Liu, J; McNicol, ED; Wang, LN, 2013) |
| "Once established, postherpetic neuralgia is particularly difficult to treat, and is often resistant to conventional analgesics." | 2.47 | [Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia]. ( Takasaki, I, 2011) |
| "Chronic pain is now viewed as a biopsychosocial phenomenon, in which biological, psychological, and social factors are at work." | 2.44 | Practical management strategies for the chronic pain patient. ( Forde, G; Stanos, S, 2007) |
| "neuropathic pain) is not very satisfactorily managed." | 2.44 | [Central and peripheral mechanisms in antinociception: current and future perspectives]. ( Fürst, Z, 2008) |
| "Migraine and headache studies are excluded in this revision." | 2.43 | Anticonvulsant drugs for acute and chronic pain. ( Carroll, D; Collins, S; Jadad, A; McQuay, H; Moore, A; Wiffen, P, 2005) |
| "Gabapentin has become popular as a first-line treatment for neuropathic pain because of its efficacy as an antineuropathic agent and relatively benign side-effect profile." | 2.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Gabapentin was originally designed as an anti-convulsant gamma-aminobutyric acid (GABA) mimetic capable of crossing the blood-brain barrier." | 2.42 | Cellular and molecular action of the putative GABA-mimetic, gabapentin. ( Chung, FZ; Gonzalez, MI; Lee, K; Maneuf, YP; Pinnock, RD; Sutton, KS, 2003) |
| "The most common risk factor for shingles and its potential sequela, PHN, is advanced age." | 2.42 | Post-herpetic neuralgia case study: optimizing pain control. ( Baron, R, 2004) |
| "Gabapentin has demonstrated efficacy, specifically in painful diabetic neuropathy and postherpetic neuralgia." | 2.41 | Use of anticonvulsants for treatment of neuropathic pain. ( Backonja, MM, 2002) |
| "Gabapentin is a novel anticonvulsant that may have a unique effect on voltage-dependent Ca2+ channel currents at postsynaptic dorsal horn neurons." | 2.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| "Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
| "Gabapentin is an amino acid, with a mechanism that differs from those of other anticonvulsant drugs such as phenytoin, carbamazepine or valproate." | 2.40 | A summary of mechanistic hypotheses of gabapentin pharmacology. ( Boden, P; Brown, JP; Dooley, DJ; Gee, NS; Kocsis, JD; Singh, L; Su, TZ; Taylor, CP; Welty, DF, 1998) |
| "Gabapentin exposure in treatment-seeking persons with OUD appears to be quite common, and use, both medically and nonmedically, frequently occurs alongside OAMs." | 1.91 | Understanding motivations and use typologies of gabapentin with opioid agonist medications. ( Buttram, ME; Ellis, MS; Qureshi, R, 2023) |
| " However, studies of real-world gabapentinoid dosing demonstrate that the recommended dose targets are frequently not met and do not consider renal insufficiency." | 1.91 | Characterization of Outpatient Gabapentinoid Prescribing for Pain. ( A Bowman, L; Banks, C; Merrey, J; Waldfogel, JM, 2023) |
| "Comorbid diagnosis of headache predicted use of topiramate and VPA, bipolar disease predicted use of LMT and VPA, pain predicted gabapentin, and schizophrenia was associated with VPAs use." | 1.91 | Prescribing Trends of Antiseizure Drugs in Women Veterans With Epilepsy. ( Amuan, ME; Henion, A; Lopez, MR; Panahi, S; Pugh, MJ; VanCott, AC, 2023) |
| "Epicrania fugax (EF) is a primary headache consisting of brief paroxysms of pain, lasting 1-10 s, that move through different nerve territories of one hemicranium with a linear or zigzag trajectory, although there are some clinical variants." | 1.91 | Drug-resistant epicrania fugax: Responding to onabotulinumtoxinA. ( Alberola-Amores, FJ; Moral-Rubio, J, 2023) |
| " Pharmacokinetic parameters were estimated using noncompartmental analysis." | 1.72 | Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses. ( Cox, S; Gold, JR; Grubb, TL; Malavasi, L; Villarino, NL, 2022) |
| "Gabapentin treatment was initiated after baseline evaluation, and the RDD and visual analog scale (VAS) score were both evaluated regularly during the 2-week study period." | 1.72 | Rate-Dependent Depression: A Predictor of the Therapeutic Efficacy in Treating Painful Diabetic Peripheral Neuropathy. ( Calcutt, NA; Guan, Y; Lin, Z; Wang, Z; Xie, C; Zhou, X; Zhu, D; Zhu, Y, 2022) |
| "Gabapentin has emerged as a common therapy for a diverse group of pain syndromes and neurologic conditions in adults." | 1.62 | Gabapentin in Infants: Critical Evaluation of a Novel Sedative/Analgesic Medication. ( McPherson, C, 2021) |
| "Pain is a hallmark of this condition and can be extremely difficult to control." | 1.56 | Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians. ( Chinnadurai, R; Lowney, AC; Miller, M; Sinha, S, 2020) |
| "Gabapentin was a prominent drug of abuse in two cohorts of the primarily opioid-using individuals." | 1.48 | A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. ( Boland, EM; Havens, JR; Lofwall, MR; Quiroz, A; Staton, M; Vickers Smith, R; Young, AM, 2018) |
| " In the dose-response analysis, moderate-dose (OR 2." | 1.46 | Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. ( Antoniou, T; Gomes, T; Juurlink, DN; Mamdani, MM; Paterson, JM; van den Brink, W, 2017) |
| "Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population." | 1.46 | sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. ( Bialer, M; Brennan, KC; Devor, M; Kaufmann, D; Smith, MD; West, PJ; White, HS; Yagen, B, 2017) |
| "Diclofenac treatment produced dose-related reversal of CRANE at 0." | 1.42 | Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats. ( Bannon, AW; Joshi, SK; Zhu, CZ, 2015) |
| "Gabapentin was found to reversibly decrease, but not suppress the flinching frequency of the second response peak only." | 1.40 | Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain. ( Danhof, M; Della Pasqua, O; Taneja, A; Troconiz, IF, 2014) |
| "Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury." | 1.40 | Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy. ( Becerra, L; Borsook, D; Navratilova, E; Ossipov, MH; Patwardhan, A; Porreca, F; Qu, C; Xie, JY, 2014) |
| "6 h, oral bioavailability of 37% and 90%) with anti-inflammatory activity (ED 50 = 37 micromol/kg, mouse) and efficacy in pain models (thermal hyperalgesia, ED 50 = 72 micromol/kg, rat)." | 1.35 | Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. ( Adair, RM; Altenbach, RJ; Bettencourt, BM; Brioni, JD; Cowart, MD; Drizin, I; Esbenshade, TA; Fix-Stenzel, SR; Honore, P; Hsieh, GC; Liu, H; Marsh, KC; McPherson, MJ; Milicic, I; Miller, TR; Sullivan, JP; Wetter, JM; Wishart, N; Witte, DG, 2008) |
| "Gabapentin and R-PIA were administered to obtain the dose-response curve and the 50% effective dose (ED(50))." | 1.35 | The interaction of gabapentin and N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on mechanical allodynia in rats with a spinal nerve ligation. ( Jun, IG; Park, JY, 2008) |
| "Here, we tested the effect of FK1706 on painful diabetic neuropathy in rat model of diabetes induced by streptozotocin (STZ)." | 1.35 | FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. ( Matsuoka, N; Murai, N; Mutoh, S; Price, RD; Yamaji, T; Yamamoto, H; Yamazaki, S, 2008) |
| "Pain is the result of an emotional and sensory experience and preclinical models of OA can thus be useful to better understand the underlying mechanisms of the disease and test new therapeutic options." | 1.35 | Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. ( Dickenson, AH; Ghandehari, J; Vonsy, JL, 2009) |
| " Here we determined the antinociceptive effect of chronic administration of neramexane and compared its effect with that of memantine and gabapentin in a rat model of diabetic neuropathic pain." | 1.35 | Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. ( Chen, SR; Pan, HL; Samoriski, G, 2009) |
| "Primary erythermalgia (erythromelalgia) is a rare autosomal dominant condition characterized by intermittent attacks of erythema, increased skin temperature and severe burning pain in the extremities, in a bilateral symmetrical distribution." | 1.35 | Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. ( Atherton, D; Elmslie, F; Mansour, S; Mortimer, P; Natkunarajah, J, 2009) |
| "Both indomethacin and morphine were able to block or reverse thermal hyperalgesia and normalize gait in the CARR model." | 1.35 | Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. ( Cummons, TA; Harrison, JE; Leventhal, L; Lu, P; Piesla, MJ; Strassle, BW; Whiteside, GT, 2009) |
| "Cilnidipine is a 1,4-dihydropyridine-derived voltage-dependent calcium channel (VDCC) blocker and suppresses N-type VDCC currents in addition to L-type VDCC currents." | 1.35 | Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker. ( Iwata, S; Koganei, H; Shoji, M, 2009) |
| "Gabapentin has established efficacy in the reduction of burn-induced hyperalgesia and allodynia in animal and human experimental burn models." | 1.35 | Successful use of gabapentin in acute pain management following burn injury: a case series. ( Cramond, T; Gray, P; Williams, B, 2008) |
| "Chronic muscle pain is a problem with high prevalence in clinical practice and its pharmacological treatment is difficult." | 1.34 | Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. ( Beyreuther, BK; Geis, C; Sommer, C; Stöhr, T, 2007) |
| "GBP increases the risk of myoclonus in ESRD." | 1.33 | Gabapentin-induced myoclonus in end-stage renal disease. ( Bell, WL; Glenn, DG; O'Donovan, CA; Zhang, C, 2005) |
| "In contrast, analgesia, sedation and catalepsy were not observed in this dose range, but were apparent at 100 mg/kg." | 1.33 | Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. ( Boulet, JM; Chaffer, SM; Elsemore, DA; Gottshall, SL; Harrison, JE; Koetzner, L; Lee, G; Mark, L; Miller, W; Pearson, MS; Rabadi, L; Rotshteyn, Y; Shan, S; Tafesse, L; Toth, M; Turchin, PI; Valenzano, KJ; Whiteside, GT, 2005) |
| "Neuropathic pain is a clinical manifestation characterized by the presence of spontaneous pain, allodynia and hyperalgesia." | 1.33 | Development and expression of neuropathic pain in CB1 knockout mice. ( Castañé, A; Célérier, E; Ledent, C; Maldonado, R; Martín, M; Parmentier, M; Valverde, O, 2006) |
| "Ambroxol's effects were compared with those of gabapentin." | 1.33 | Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. ( Arndt, K; Gaida, W; Klinder, K; Weiser, T, 2005) |
| "Pinacidil activity was not blocked by L-NAME, D-NAME, 7-nitroindazole, ODQ, KT-5823 or okadaic acid." | 1.33 | The nitric oxide-cyclic GMP-protein kinase G-K+ channel pathway participates in the antiallodynic effect of spinal gabapentin. ( Flores-Murrieta, FJ; Granados-Soto, V; Mixcoatl-Zecuatl, T, 2006) |
| "The severe burning pain, deep pressure-like pain, and deep mechanical allodynia, which presented over the contralateral side to the TBI, were successfully relieved with motor cortex stimulation (MCS)." | 1.33 | Motor cortex stimulation for central pain following a traumatic brain injury. ( Choi, ES; Hong, JT; Lee, SW; Son, BC; Sung, JH, 2006) |
| "Paclitaxel (Taxol) is a widely used chemotherapeutic agent in the treatment of several tumors." | 1.33 | Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. ( Hald, A; Inoue, M; Matsumoto, M; Ueda, H; Xie, W, 2006) |
| " This dosage produced a substantial but non-significant decrease in the incidence of postherpetic pain-related responses." | 1.32 | Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. ( Kuraishi, Y; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2004) |
| "Gabapentin (GBP) is a new antiepileptic agent with an original spectrum of activity." | 1.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "The initial hyperalgesia induced by 0." | 1.31 | Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia. ( Assié, MB; Bardin, L; Carilla-Durand, E; Colpaert, FC; Cosi, C; Koek, W; Pauwels, PJ; Tarayre, JP; Vacher, B; Wiesenfeld-Hallin, Z; Xu, XJ, 2002) |
| "Allodynia and hyperalgesia appeared on day 5 post-inoculation." | 1.31 | Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain. ( Andoh, T; Kuraishi, Y; Nemoto, H; Nitta, M; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2000) |
| "Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)." | 1.31 | Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000) |
| "SCI gabapentin-treated rats did not display differences in total rearing time until PSD 28 and a significant difference in total activity of all measured parameters was not seen until PSD 60." | 1.31 | Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury. ( Grady, JJ; Hulsebosch, CE; Mills, CD, 2001) |
| "Acyclovir treatment healed all skin lesions by day 15 after inoculation." | 1.31 | Effects of analgesics on delayed postherpetic pain in mice. ( Andoh, T; Kuraishi, Y; Nojima, H; Sasaki, A; Shiraki, K; Takasaki, I, 2002) |
| "Gabapentin (GBP) is a gamma-aminobutyric acid analog originally synthesized for its anticonvulsant actions." | 1.30 | Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug. ( Gillin, S; Sorkin, LS, 1998) |
| "Gabapentin is an anticonvulsant that may represent a novel class of drugs, which has novel spinal antihyperalgesic activity." | 1.30 | The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. ( Jun, JH; Yaksh, TL, 1998) |
| "Gabapentin (GP) has been shown to have antihyperalgesic properties and the site of drug action is reported to be the central nervous system." | 1.30 | Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin. ( Carlton, SM; Zhou, S, 1998) |
| "A variety of treatments for the pain were ineffective." | 1.30 | Gabapentin for treatment of neuropathic pain in a 12-year-old girl. ( McGraw, T; Stacey, BR, 1998) |
Research
Studies (418)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 36 (8.61) | 18.2507 |
| 2000's | 232 (55.50) | 29.6817 |
| 2010's | 111 (26.56) | 24.3611 |
| 2020's | 39 (9.33) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Hong-Ju, Y | 1 |
| He, L | 1 |
| Wei-Guo, S | 1 |
| Nan, Z | 1 |
| Wei-Xiu, Y | 1 |
| Zhong-Wei, J | 1 |
| Jun-Wei, W | 1 |
| Zheng-Hua, G | 1 |
| Bo-Hua, Z | 1 |
| Zhi-Pu, L | 1 |
| Zhe-Hui, G | 1 |
| Mortell, KH | 1 |
| Anderson, DJ | 1 |
| Lynch, JJ | 1 |
| Nelson, SL | 1 |
| Sarris, K | 1 |
| McDonald, H | 1 |
| Sabet, R | 1 |
| Baker, S | 1 |
| Honore, P | 3 |
| Lee, CH | 1 |
| Jarvis, MF | 2 |
| Gopalakrishnan, M | 1 |
| Yogeeswari, P | 1 |
| Ragavendran, JV | 1 |
| Sriram, D | 1 |
| Nageswari, Y | 1 |
| Kavya, R | 1 |
| Sreevatsan, N | 1 |
| Vanitha, K | 1 |
| Stables, J | 1 |
| Shieh, CC | 1 |
| Chapman, M | 1 |
| Joshi, S | 1 |
| Zhang, XF | 1 |
| Kort, M | 1 |
| Carroll, W | 1 |
| Marron, B | 1 |
| Atkinson, R | 1 |
| Thomas, J | 1 |
| Liu, D | 1 |
| Krambis, M | 1 |
| Liu, Y | 2 |
| McGaraughty, S | 1 |
| Chu, K | 1 |
| Roeloffs, R | 1 |
| Zhong, C | 1 |
| Mikusa, JP | 1 |
| Hernandez, G | 2 |
| Gauvin, D | 1 |
| Wade, C | 1 |
| Zhu, C | 1 |
| Pai, M | 1 |
| Scanio, M | 1 |
| Shi, L | 1 |
| Drizin, I | 2 |
| Gregg, R | 1 |
| Matulenko, M | 1 |
| Hakeem, A | 1 |
| Gross, M | 1 |
| Johnson, M | 1 |
| Marsh, K | 1 |
| Wagoner, PK | 1 |
| Sullivan, JP | 2 |
| Faltynek, CR | 1 |
| Krafte, DS | 1 |
| Field, MJ | 3 |
| Li, Z | 1 |
| Schwarz, JB | 1 |
| Cowart, MD | 1 |
| Altenbach, RJ | 1 |
| Liu, H | 2 |
| Hsieh, GC | 1 |
| Milicic, I | 1 |
| Miller, TR | 1 |
| Witte, DG | 1 |
| Wishart, N | 1 |
| Fix-Stenzel, SR | 1 |
| McPherson, MJ | 1 |
| Adair, RM | 1 |
| Wetter, JM | 1 |
| Bettencourt, BM | 1 |
| Marsh, KC | 1 |
| Esbenshade, TA | 1 |
| Brioni, JD | 1 |
| Rephaeli, A | 1 |
| Gil-Ad, I | 1 |
| Aharoni, A | 1 |
| Tarasenko, I | 1 |
| Tarasenko, N | 1 |
| Geffen, Y | 1 |
| Halbfinger, E | 1 |
| Nisemblat, Y | 1 |
| Weizman, A | 1 |
| Nudelman, A | 1 |
| Payne, JE | 1 |
| Bonnefous, C | 1 |
| Symons, KT | 1 |
| Nguyen, PM | 1 |
| Sablad, M | 1 |
| Rozenkrants, N | 1 |
| Zhang, Y | 1 |
| Wang, L | 1 |
| Yazdani, N | 1 |
| Shiau, AK | 1 |
| Noble, SA | 1 |
| Rix, P | 1 |
| Rao, TS | 1 |
| Hassig, CA | 1 |
| Smith, ND | 1 |
| Rawson, DJ | 1 |
| Brugier, D | 1 |
| Harrison, A | 1 |
| Hough, J | 1 |
| Newman, J | 1 |
| Otterburn, J | 1 |
| Maw, GN | 1 |
| Price, J | 1 |
| Thompson, LR | 1 |
| Turnpenny, P | 1 |
| Warren, AN | 1 |
| Valhondo, M | 1 |
| Marco, I | 1 |
| Martín-Fontecha, M | 1 |
| Vázquez-Villa, H | 1 |
| Ramos, JA | 1 |
| Berkels, R | 1 |
| Lauterbach, T | 1 |
| Benhamú, B | 1 |
| López-Rodríguez, ML | 1 |
| Lebedyeva, IO | 1 |
| Ostrov, DA | 1 |
| Neubert, J | 1 |
| Steel, PJ | 1 |
| Patel, K | 1 |
| Sileno, SM | 1 |
| Goncalves, K | 1 |
| Ibrahim, MA | 1 |
| Alamry, KA | 1 |
| Katritzky, AR | 1 |
| Li, Y | 1 |
| Liu, YB | 1 |
| Zhang, JJ | 1 |
| Ma, SG | 1 |
| Qu, J | 1 |
| Lv, HN | 1 |
| Yu, SS | 1 |
| Healy, MP | 1 |
| Allan, AC | 1 |
| Bailey, K | 1 |
| Billinton, A | 1 |
| Chessell, IP | 1 |
| Clayton, NM | 1 |
| Giblin, GMP | 1 |
| Kay, MA | 1 |
| Khaznadar, T | 1 |
| Michel, AD | 1 |
| Naylor, A | 1 |
| Price, H | 1 |
| Spalding, DJ | 1 |
| Stevens, DA | 1 |
| Swarbrick, ME | 1 |
| Wilson, AW | 1 |
| Cook, A | 1 |
| Modh, A | 1 |
| Ali, H | 1 |
| Sheqwara, J | 1 |
| Chang, S | 1 |
| Ghanem, T | 1 |
| Momin, S | 1 |
| Wu, V | 1 |
| Tam, S | 1 |
| Money, S | 1 |
| Han, X | 1 |
| Fakhoury, L | 1 |
| Movsas, B | 1 |
| Siddiqui, F | 1 |
| Oliveira, ADP | 1 |
| Silva-Néto, RP | 1 |
| Gold, JR | 1 |
| Grubb, TL | 1 |
| Cox, S | 1 |
| Malavasi, L | 1 |
| Villarino, NL | 1 |
| McDowell, L | 1 |
| Bossi, P | 1 |
| Zhou, X | 1 |
| Zhu, Y | 1 |
| Wang, Z | 1 |
| Lin, Z | 1 |
| Zhu, D | 1 |
| Xie, C | 1 |
| Calcutt, NA | 2 |
| Guan, Y | 1 |
| Welch, EK | 1 |
| Dengler, KL | 1 |
| DiCarlo-Meacham, AM | 1 |
| Wheat, JE | 1 |
| Stone, GW | 1 |
| Olsen, C | 1 |
| Von Pechmann, W | 1 |
| Zhang, XY | 1 |
| Barakat, A | 1 |
| Diaz-delCastillo, M | 1 |
| Vollert, J | 1 |
| Sena, ES | 1 |
| Heegaard, AM | 1 |
| Rice, ASC | 1 |
| Soliman, N | 1 |
| Ma, SJ | 2 |
| Wang, K | 2 |
| Iovoli, AJ | 3 |
| Attwood, K | 3 |
| Hermann, G | 2 |
| Farrugia, M | 2 |
| Singh, AK | 3 |
| Kim, TW | 1 |
| Samet, JH | 1 |
| Lodi, S | 1 |
| Kimmel, SD | 1 |
| Forman, LS | 1 |
| Lira, MC | 1 |
| Liebschutz, JM | 1 |
| Williams, EC | 1 |
| Walley, AY | 1 |
| Asgardoon, MH | 1 |
| Jazayeri, SB | 1 |
| Behkar, A | 1 |
| Dabbagh Ohadi, MA | 1 |
| Yarmohammadi, H | 1 |
| Ghodsi, Z | 1 |
| Pomerani, TI | 1 |
| Mojtahedzadeh, M | 1 |
| Rahimi-Movaghar, V | 1 |
| Pan, Y | 1 |
| Davis, PB | 1 |
| Kaebler, DC | 1 |
| Blankfield, RP | 1 |
| Xu, R | 1 |
| Toma, W | 1 |
| Paris, JJ | 1 |
| Warncke, UO | 1 |
| Nass, SR | 1 |
| Caillaud, M | 1 |
| McKiver, B | 1 |
| Ondo, O | 1 |
| Bagdas, D | 1 |
| Bigbee, J | 1 |
| Knapp, PE | 1 |
| Hauser, KF | 1 |
| Damaj, MI | 1 |
| Brant, AR | 1 |
| Reeves, MF | 1 |
| Ye, PP | 1 |
| Scott, RK | 1 |
| Floyd, S | 1 |
| Tefera, E | 1 |
| Lotke, PS | 1 |
| Candon, M | 1 |
| Strominger, J | 1 |
| Gerlach, LB | 1 |
| Maust, DT | 1 |
| Ellis, MS | 4 |
| Qureshi, R | 3 |
| Buttram, ME | 5 |
| Williams, CD | 1 |
| Al-Jammali, Z | 1 |
| Herink, MC | 1 |
| Neimanis, D | 1 |
| Smith, KA | 1 |
| Banks, C | 1 |
| A Bowman, L | 1 |
| Merrey, J | 1 |
| Waldfogel, JM | 1 |
| Yang, HH | 1 |
| Wu, TJ | 1 |
| Suh, JD | 1 |
| Wang, MB | 1 |
| Holliday, M | 1 |
| Beswick, D | 1 |
| Zhang, H | 1 |
| Wells, C | 1 |
| McCormick, J | 1 |
| Maxim, T | 1 |
| Regev, A | 1 |
| Chandy, ZK | 1 |
| Lee, JT | 1 |
| Onal, O | 1 |
| Onal, M | 1 |
| Smith, LE | 1 |
| Murphy, BA | 2 |
| Smith, DK | 2 |
| Lopez, MR | 1 |
| VanCott, AC | 1 |
| Amuan, ME | 1 |
| Panahi, S | 1 |
| Henion, A | 1 |
| Pugh, MJ | 1 |
| Ferron, L | 1 |
| Gandini, MA | 1 |
| Zamponi, GW | 1 |
| Alberola-Amores, FJ | 1 |
| Moral-Rubio, J | 1 |
| Cao, J | 1 |
| An, Q | 1 |
| Han, F | 1 |
| Kurtz, SP | 2 |
| Cicero, TJ | 2 |
| Havens, JR | 2 |
| Goodman, CW | 2 |
| Brett, AS | 2 |
| Hermann, GM | 1 |
| Platek, AJ | 1 |
| Wang, C | 1 |
| Miller, A | 2 |
| Bourgeois, DJ | 1 |
| Ala, S | 1 |
| Zamani, N | 1 |
| Akbari, J | 1 |
| Salehifar, E | 1 |
| Janbabai, G | 1 |
| Koulaeinejad, N | 1 |
| Waddy, SP | 1 |
| Becerra, AZ | 1 |
| Ward, JB | 1 |
| Chan, KE | 1 |
| Fwu, CW | 1 |
| Eggers, PW | 1 |
| Abbott, KC | 1 |
| Kimmel, PL | 1 |
| Gallego, H | 1 |
| Aleshaki, JS | 1 |
| Cmelak, A | 1 |
| Niermann, K | 1 |
| Ghiam, M | 1 |
| Lou, D | 1 |
| Gilbert, J | 1 |
| Gibson, MK | 1 |
| Hawkins, D | 1 |
| Aksan, F | 1 |
| Nelson, EA | 1 |
| Swedish, KA | 1 |
| Chinnadurai, R | 1 |
| Sinha, S | 1 |
| Lowney, AC | 1 |
| Miller, M | 1 |
| Zhou, L | 1 |
| Bhattacharjee, S | 1 |
| Kwoh, CK | 1 |
| Malone, DC | 1 |
| Tighe, PJ | 1 |
| Reisfield, GM | 1 |
| Slack, M | 1 |
| Wilson, DL | 1 |
| Lo-Ciganic, WH | 1 |
| Slovak, JE | 1 |
| Costa, AP | 1 |
| McPherson, C | 1 |
| Tu, TG | 1 |
| Sadeghi, S | 1 |
| Atayee, R | 1 |
| Lee, K | 3 |
| Harvey, A | 1 |
| Waugh, MC | 1 |
| Rice, J | 1 |
| Antolovich, G | 1 |
| Copeland, L | 1 |
| Orsini, F | 1 |
| Scheinberg, A | 1 |
| McKinnon, C | 1 |
| Thorley, M | 1 |
| Baker, F | 1 |
| Chalkiadis, G | 1 |
| Stewart, K | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Antoniou, T | 1 |
| Mamdani, MM | 1 |
| Paterson, JM | 1 |
| van den Brink, W | 1 |
| Vickers Smith, R | 1 |
| Boland, EM | 1 |
| Young, AM | 1 |
| Lofwall, MR | 1 |
| Quiroz, A | 1 |
| Staton, M | 1 |
| Jordan, RI | 1 |
| Mulvey, MR | 1 |
| Bennett, MI | 2 |
| Brown, CS | 1 |
| Bachmann, GA | 1 |
| Wan, J | 1 |
| Foster, DC | 1 |
| Wong, JW | 1 |
| Chin, JM | 1 |
| Schlueter, RJ | 1 |
| Guglielmi, G | 1 |
| Novick, TK | 1 |
| Surapaneni, A | 1 |
| Shin, JI | 1 |
| Ballew, SH | 1 |
| Alexander, GC | 1 |
| Inker, LA | 1 |
| Chang, AR | 1 |
| Grams, ME | 1 |
| Alexander, J | 1 |
| Edwards, RA | 1 |
| Brodsky, M | 1 |
| Manca, L | 1 |
| Grugni, R | 1 |
| Savoldelli, A | 1 |
| Bonfanti, G | 1 |
| Emir, B | 1 |
| Whalen, E | 1 |
| Watt, S | 1 |
| Parsons, B | 1 |
| Monteiro, BP | 1 |
| de Lorimier, LP | 1 |
| Moreau, M | 1 |
| Beauchamp, G | 1 |
| Blair, J | 1 |
| Lussier, B | 1 |
| Pelletier, JP | 1 |
| Troncy, E | 1 |
| Sriperumbuduri, S | 1 |
| Hiremath, S | 1 |
| Gross, JL | 1 |
| Perate, AR | 1 |
| Elkassabany, NM | 1 |
| Wampole, CR | 1 |
| Smith, KE | 1 |
| Polaner, DM | 1 |
| Shafer, SL | 1 |
| Enteshari-Moghaddam, A | 1 |
| Azami, A | 1 |
| Isazadehfar, K | 1 |
| Mohebbi, H | 1 |
| Habibzadeh, A | 1 |
| Jahanpanah, P | 1 |
| Okamoto, M | 1 |
| Takahagi, S | 1 |
| Kamegashira, A | 1 |
| Yanase, Y | 1 |
| Hide, M | 1 |
| Ongun, N | 1 |
| Ongun, GT | 1 |
| Burnsed, JC | 1 |
| Heinan, K | 1 |
| Letzkus, L | 1 |
| Zanelli, S | 1 |
| Kardeş, S | 1 |
| Fraccaro, E | 1 |
| Coetzee, JF | 2 |
| Odore, R | 1 |
| Edwards-Callaway, LN | 1 |
| Kukanich, B | 1 |
| Badino, P | 1 |
| Bertolotti, L | 1 |
| Glynn, H | 1 |
| Dockweiler, J | 1 |
| Allen, K | 1 |
| Bergamasco, L | 1 |
| García-Hernández, L | 1 |
| Navarrete-Vázquez, G | 1 |
| González-Trujano, ME | 1 |
| López-Muñoz, FJ | 2 |
| Déciga-Campos, M | 1 |
| Ramirez-Fort, MK | 1 |
| Doan, HQ | 1 |
| Nguyen, HP | 1 |
| Khan, F | 1 |
| Kauffman, J | 1 |
| Campbell, LS | 1 |
| Taneja, A | 1 |
| Troconiz, IF | 1 |
| Danhof, M | 1 |
| Della Pasqua, O | 1 |
| Liu, J | 2 |
| Wang, LN | 2 |
| McNicol, ED | 2 |
| Yan, PZ | 1 |
| Butler, PM | 1 |
| Kurowski, D | 1 |
| Perloff, MD | 1 |
| Scheinfeld, N | 2 |
| Haviv, Y | 1 |
| Zadik, Y | 1 |
| Sharav, Y | 1 |
| Benoliel, R | 1 |
| Starmer, HM | 1 |
| Yang, W | 1 |
| Raval, R | 1 |
| Gourin, CG | 1 |
| Richardson, M | 1 |
| Kumar, R | 1 |
| Jones, B | 1 |
| McNutt, T | 1 |
| Cheng, Z | 1 |
| Cheng, S | 1 |
| Quon, H | 3 |
| Xie, JY | 1 |
| Qu, C | 1 |
| Patwardhan, A | 1 |
| Ossipov, MH | 1 |
| Navratilova, E | 1 |
| Becerra, L | 2 |
| Borsook, D | 3 |
| Porreca, F | 1 |
| Zhang, MM | 1 |
| Liu, SB | 1 |
| Chen, T | 1 |
| Koga, K | 1 |
| Zhang, T | 1 |
| Li, YQ | 1 |
| Zhuo, M | 1 |
| Işik, B | 1 |
| Yaman, S | 1 |
| Aktuna, S | 1 |
| Turan, A | 2 |
| Suzuki, T | 1 |
| Hashimoto, Y | 1 |
| Anzai, S | 1 |
| Nagasawa, K | 1 |
| Shinde, S | 1 |
| Gordon, P | 1 |
| Sharma, P | 1 |
| Gross, J | 1 |
| Davis, MP | 1 |
| Wodarski, R | 2 |
| Schuh-Hofer, S | 1 |
| Yurek, DA | 1 |
| Wafford, KA | 1 |
| Gilmour, G | 1 |
| Treede, RD | 1 |
| Kennedy, JD | 1 |
| Boyle, Y | 1 |
| Fernando, D | 1 |
| Kurz, H | 1 |
| Miller, SR | 1 |
| Zucchetto, M | 1 |
| Storey, J | 1 |
| Sarıtaş, TB | 1 |
| Korkmaz, M | 1 |
| Sevimli, A | 1 |
| Sarıtaş, ZK | 1 |
| Scholl, JH | 1 |
| van Eekeren, R | 1 |
| van Puijenbroek, EP | 1 |
| Matsumura, S | 1 |
| Taniguchi, W | 1 |
| Nishida, K | 2 |
| Nakatsuka, T | 1 |
| Ito, S | 1 |
| Hauer, JM | 1 |
| Solodiuk, JC | 1 |
| Zhu, CZ | 1 |
| Bannon, AW | 1 |
| Joshi, SK | 1 |
| Inkpen, H | 1 |
| North, JM | 1 |
| Hong, KS | 1 |
| Rauck, RL | 1 |
| Farmakidis, C | 1 |
| Inan, S | 1 |
| Milstein, M | 1 |
| Herskovitz, S | 1 |
| Bassani, AS | 1 |
| Banov, D | 1 |
| Gould, SA | 1 |
| Doods, H | 1 |
| Lamla, T | 1 |
| Pekcec, A | 1 |
| Lee-Kubli, CA | 1 |
| Ingves, M | 1 |
| Henry, KW | 1 |
| Shiao, R | 1 |
| Collyer, E | 1 |
| Tuszynski, MH | 1 |
| Campana, WM | 1 |
| Mimenza Alvarado, A | 1 |
| Aguilar Navarro, S | 1 |
| Alrawashdeh, O | 1 |
| Kataoka, T | 1 |
| Kiyota, N | 1 |
| Shimada, T | 1 |
| Funakoshi, Y | 1 |
| Chayahara, N | 1 |
| Toyoda, M | 1 |
| Fujiwara, Y | 1 |
| Nibu, K | 1 |
| Komori, T | 1 |
| Sasaki, R | 1 |
| Mukohara, T | 1 |
| Minami, H | 1 |
| Hopkins, HL | 1 |
| Duggett, NA | 1 |
| Flatters, SJL | 1 |
| van den Beuken-van Everdingen, MH | 1 |
| de Graeff, A | 1 |
| Jongen, JL | 1 |
| Dijkstra, D | 1 |
| Mostovaya, I | 1 |
| Vissers, KC | 1 |
| Yoshikawa, N | 1 |
| Naito, T | 1 |
| Yagi, T | 1 |
| Kawakami, J | 1 |
| Yin, K | 1 |
| Deuis, JR | 1 |
| Lewis, RJ | 1 |
| Vetter, I | 1 |
| Ehieli, E | 1 |
| Yalamuri, S | 1 |
| Brudney, CS | 1 |
| Pyati, S | 1 |
| Milazzo-Kiedaisch, CA | 1 |
| Itano, J | 1 |
| Dutta, PR | 3 |
| Kaufmann, D | 1 |
| West, PJ | 1 |
| Smith, MD | 1 |
| Yagen, B | 1 |
| Bialer, M | 1 |
| Devor, M | 2 |
| White, HS | 1 |
| Brennan, KC | 1 |
| Ding, W | 1 |
| You, Z | 1 |
| Shen, S | 1 |
| Yang, J | 2 |
| Lim, G | 1 |
| Doheny, JT | 1 |
| Chen, L | 1 |
| Zhu, S | 1 |
| Mao, J | 2 |
| Caraceni, A | 2 |
| Zecca, E | 2 |
| Martini, C | 2 |
| Pigni, A | 1 |
| Bracchi, P | 1 |
| Wood, PL | 1 |
| Mahmood, SA | 1 |
| Moskal, JR | 1 |
| Forde, G | 2 |
| Stanos, S | 1 |
| Price, G | 1 |
| Park, JY | 1 |
| Jun, IG | 1 |
| Boardman, LA | 1 |
| Cooper, AS | 1 |
| Blais, LR | 1 |
| Raker, CA | 1 |
| Yamazaki, S | 1 |
| Yamaji, T | 1 |
| Murai, N | 1 |
| Yamamoto, H | 1 |
| Price, RD | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Hayashida, K | 3 |
| Eisenach, JC | 5 |
| Bannwarth, B | 1 |
| Vonsy, JL | 1 |
| Ghandehari, J | 1 |
| Dickenson, AH | 5 |
| Fürst, Z | 1 |
| Clark, AK | 1 |
| Grist, J | 1 |
| Marchand, F | 1 |
| Malcangio, M | 1 |
| Pigatto, PD | 1 |
| Guzzi, G | 1 |
| Carlsson, KC | 1 |
| van de Schootbrugge, M | 1 |
| Eriksen, HO | 1 |
| Moberg, ER | 1 |
| Karlsson, MO | 1 |
| Hoem, NO | 1 |
| Yalcin, I | 1 |
| Tessier, LH | 1 |
| Petit-Demoulière, N | 1 |
| Doridot, S | 1 |
| Hein, L | 1 |
| Freund-Mercier, MJ | 1 |
| Barrot, M | 1 |
| Dworkin, RH | 1 |
| Barbano, RL | 1 |
| Tyring, SK | 1 |
| Betts, RF | 1 |
| McDermott, MP | 1 |
| Pennella-Vaughan, J | 1 |
| Bennett, GJ | 1 |
| Berber, E | 1 |
| Gnann, JW | 1 |
| Irvine, C | 1 |
| Kamp, C | 1 |
| Kieburtz, K | 1 |
| Max, MB | 2 |
| Schmader, KE | 1 |
| Quilici, S | 1 |
| Chancellor, J | 1 |
| Löthgren, M | 1 |
| Simon, D | 1 |
| Said, G | 1 |
| Le, TK | 1 |
| Garcia-Cebrian, A | 1 |
| Monz, B | 1 |
| Chiechio, S | 1 |
| Zammataro, M | 1 |
| Caraci, F | 1 |
| Rampello, L | 1 |
| Copani, A | 1 |
| Sabato, AF | 2 |
| Nicoletti, F | 1 |
| Lin, CF | 1 |
| Tsaur, ML | 1 |
| Lin, CS | 1 |
| Chen, CC | 1 |
| Huang, YJ | 1 |
| Cheng, JK | 2 |
| Gauchan, P | 1 |
| Andoh, T | 5 |
| Ikeda, K | 1 |
| Fujita, M | 1 |
| Sasaki, A | 3 |
| Kato, A | 1 |
| Kuraishi, Y | 7 |
| Omori, Y | 1 |
| Kagaya, K | 1 |
| Enomoto, R | 1 |
| Nojima, H | 6 |
| Takahata, H | 4 |
| Chen, SR | 3 |
| Samoriski, G | 1 |
| Pan, HL | 3 |
| Gatti, A | 1 |
| Carucci, A | 1 |
| Bertini, L | 1 |
| Mammucari, M | 1 |
| Occhioni, R | 1 |
| De la O-Arciniega, M | 1 |
| Díaz-Reval, MI | 1 |
| Cortés-Arroyo, AR | 1 |
| Domínguez-Ramírez, AM | 1 |
| Marino, F | 1 |
| Takasu, K | 4 |
| Kinoshita, Y | 1 |
| Ono, H | 4 |
| Tanabe, M | 4 |
| Davis, AM | 2 |
| Bruce, AS | 1 |
| Mangiaracina, C | 1 |
| Schulz, T | 1 |
| Hyman, P | 1 |
| Natkunarajah, J | 1 |
| Atherton, D | 1 |
| Elmslie, F | 1 |
| Mansour, S | 1 |
| Mortimer, P | 1 |
| Bar Ad, V | 3 |
| Weinstein, G | 2 |
| Chalian, A | 2 |
| Both, S | 2 |
| Haney, AL | 1 |
| Garner, SS | 1 |
| Cox, TH | 1 |
| Piesla, MJ | 1 |
| Leventhal, L | 1 |
| Strassle, BW | 1 |
| Harrison, JE | 2 |
| Cummons, TA | 1 |
| Lu, P | 1 |
| Whiteside, GT | 3 |
| Fleckenstein, J | 1 |
| Kramer, S | 1 |
| Hoffrogge, P | 1 |
| Thoma, S | 1 |
| Lang, PM | 1 |
| Lehmeyer, L | 1 |
| Schober, GM | 1 |
| Pfab, F | 1 |
| Ring, J | 1 |
| Weisenseel, P | 1 |
| Schotten, KJ | 1 |
| Mansmann, U | 1 |
| Irnich, D | 1 |
| Takatani, J | 1 |
| Takeshima, N | 1 |
| Okuda, K | 1 |
| Miyakawa, H | 1 |
| Noguchi, T | 1 |
| Koganei, H | 1 |
| Shoji, M | 1 |
| Iwata, S | 1 |
| Vedula, SS | 1 |
| Bero, L | 1 |
| Scherer, RW | 1 |
| Dickersin, K | 1 |
| Morris-Stiff, G | 1 |
| Lewis, MH | 1 |
| Takahashi, H | 1 |
| Shimoyama, N | 2 |
| Filler, AG | 1 |
| Bacon, M | 1 |
| Frederickson, M | 1 |
| Howe, FA | 1 |
| Rabinowitz, MD | 1 |
| Sokoloff, AJ | 1 |
| Deacon, TW | 1 |
| Abell, C | 1 |
| Munglani, R | 1 |
| Griffiths, JR | 1 |
| Bell, BA | 1 |
| Lever, AM | 1 |
| Toth, C | 1 |
| Arai, YC | 1 |
| Matsubara, T | 1 |
| Shimo, K | 1 |
| Suetomi, K | 1 |
| Nishihara, M | 1 |
| Ushida, T | 1 |
| Kobayashi, K | 1 |
| Suzuki, C | 1 |
| Kinoshita, A | 1 |
| Kondo, M | 1 |
| Matsubara, S | 1 |
| Hayashi, R | 1 |
| Tohyama, Y | 1 |
| Arakawa, M | 1 |
| Wolfe, KC | 1 |
| Poma, R | 1 |
| Liao, XZ | 1 |
| Zhou, MT | 1 |
| Mao, YF | 1 |
| Xu, H | 2 |
| Chen, H | 1 |
| Sun, JH | 1 |
| Xiong, YC | 1 |
| Tran, DQ | 1 |
| Duong, S | 1 |
| Finlayson, RJ | 1 |
| Kolosov, A | 1 |
| Goodchild, CS | 1 |
| Cooke, I | 1 |
| Tuchman, M | 1 |
| Barrett, JA | 1 |
| Donevan, S | 1 |
| Hedberg, TG | 1 |
| Taylor, CP | 3 |
| Scrivani, S | 1 |
| Wallin, D | 1 |
| Moulton, EA | 1 |
| Cole, S | 1 |
| Wasan, AD | 1 |
| Lockerman, L | 1 |
| Bajwa, Z | 1 |
| Upadhyay, J | 1 |
| Heidelbaugh, JJ | 1 |
| Llanes, M | 1 |
| Weadock, WJ | 1 |
| Munro, G | 3 |
| Dyhr, H | 2 |
| Grunnet, M | 1 |
| Dosoretz, A | 1 |
| Raffa, RB | 1 |
| Pergolizzi, JV | 1 |
| Segarnick, DJ | 1 |
| Tallarida, RJ | 2 |
| Peters, CM | 1 |
| Ewan, EE | 1 |
| Nakajima, K | 1 |
| Obata, H | 2 |
| Xu, Q | 1 |
| Yaksh, TL | 5 |
| Ko, SH | 1 |
| Kwon, HS | 1 |
| Yu, JM | 1 |
| Baik, SH | 1 |
| Park, IB | 1 |
| Lee, JH | 1 |
| Ko, KS | 1 |
| Noh, JH | 1 |
| Kim, DS | 1 |
| Kim, CH | 1 |
| Mok, JO | 1 |
| Park, TS | 1 |
| Son, HS | 1 |
| Cha, BY | 1 |
| Christianson, CA | 1 |
| Corr, M | 1 |
| Firestein, GS | 1 |
| Mobargha, A | 1 |
| Svensson, CI | 2 |
| Tzellos, TG | 1 |
| Toulis, KA | 1 |
| Goulis, DG | 1 |
| Papazisis, G | 1 |
| Zampeli, VA | 1 |
| Vakfari, A | 1 |
| Kouvelas, D | 1 |
| Takasaki, I | 5 |
| Schleich, A | 1 |
| Baumann, H | 1 |
| Touchette, D | 1 |
| Gessler, EM | 1 |
| Ogino, Y | 1 |
| Lantos, PM | 1 |
| Vettorato, E | 1 |
| Corletto, F | 1 |
| Jamshidian, F | 1 |
| Hubbard, AE | 1 |
| Jewell, NP | 1 |
| Oshita, K | 1 |
| Saeki, N | 1 |
| Niinai, H | 1 |
| Hamada, H | 1 |
| Kawamoto, M | 1 |
| Galkin, VV | 1 |
| Nesterova, MV | 1 |
| Emel'ianov, VV | 1 |
| Panah Khahi, M | 1 |
| Yaghooti, AA | 1 |
| Marashi, SH | 1 |
| Nadjafi, A | 1 |
| Udall, M | 1 |
| Harnett, J | 1 |
| Mardekian, J | 1 |
| Storm, A | 1 |
| Hansen, MK | 1 |
| Marcher, L | 1 |
| Erichsen, HK | 2 |
| Sheykhzade, M | 1 |
| Andrews, N | 1 |
| Legg, E | 1 |
| Lisak, D | 1 |
| Issop, Y | 1 |
| Richardson, D | 1 |
| Harper, S | 1 |
| Pheby, T | 2 |
| Huang, W | 1 |
| Burgess, G | 1 |
| Machin, I | 1 |
| Rice, AS | 2 |
| Neelakantan, H | 1 |
| Walker, EA | 1 |
| Yang, JL | 1 |
| Xu, B | 1 |
| Li, SS | 1 |
| Zhang, WS | 1 |
| Deng, XM | 1 |
| Zhang, YQ | 1 |
| Inceoglu, B | 1 |
| Wagner, KM | 1 |
| Bettaieb, A | 1 |
| Schebb, NH | 1 |
| Hwang, SH | 1 |
| Morisseau, C | 1 |
| Haj, FG | 1 |
| Hammock, BD | 1 |
| Kawasaki, M | 1 |
| Hatashima, S | 1 |
| Matsuda, T | 1 |
| Kilic, FS | 1 |
| Sirmagul, B | 1 |
| Yildirim, E | 1 |
| Oner, S | 1 |
| Erol, K | 1 |
| Hauer, J | 1 |
| Mackey, D | 1 |
| Hansen, RR | 1 |
| Brown, DT | 1 |
| Mirza, NR | 1 |
| Arcos, M | 1 |
| Palanca, JM | 1 |
| Montes, F | 1 |
| Barrios, C | 1 |
| Oya, H | 1 |
| Matoba, M | 1 |
| Murakami, S | 1 |
| Ohshiro, T | 1 |
| Kishino, T | 1 |
| Satoh, Y | 1 |
| Tsukahara, T | 1 |
| Hori, S | 1 |
| Maeda, M | 1 |
| Makino, T | 1 |
| Maeda, T | 1 |
| Clarke, H | 1 |
| Kirkham, KR | 1 |
| Orser, BA | 1 |
| Katznelson, R | 1 |
| Mitsakakis, N | 1 |
| Ko, R | 1 |
| Snyman, A | 1 |
| Ma, M | 1 |
| Katz, J | 1 |
| Abe, M | 1 |
| Kurihara, T | 1 |
| Han, W | 1 |
| Shinomiya, K | 1 |
| Tanabe, T | 1 |
| Pelham, A | 1 |
| Lee, MA | 1 |
| Regnard, CB | 1 |
| Wallin, J | 1 |
| Cui, JG | 1 |
| Yakhnitsa, V | 1 |
| Schechtmann, G | 1 |
| Meyerson, BA | 1 |
| Linderoth, B | 1 |
| Hunt, CH | 1 |
| Dodick, DW | 1 |
| Bosch, EP | 1 |
| Chen, B | 1 |
| Stitik, TP | 1 |
| Foye, PM | 1 |
| Nadler, SF | 1 |
| DeLisa, JA | 1 |
| Laughlin, TM | 1 |
| Tram, KV | 1 |
| Wilcox, GL | 1 |
| Birnbaum, AK | 1 |
| Gilron, I | 5 |
| Backonja, MM | 1 |
| Gonzalez, MI | 2 |
| Singh, L | 3 |
| Bortalanza, LB | 1 |
| Ferreira, J | 1 |
| Hess, SC | 1 |
| Delle Monache, F | 1 |
| Yunes, RA | 1 |
| Calixto, JB | 3 |
| Serpell, MG | 1 |
| Vitek, L | 1 |
| Tettenborn, B | 1 |
| Colpaert, FC | 2 |
| Tarayre, JP | 2 |
| Koek, W | 2 |
| Pauwels, PJ | 1 |
| Bardin, L | 1 |
| Xu, XJ | 3 |
| Wiesenfeld-Hallin, Z | 3 |
| Cosi, C | 1 |
| Carilla-Durand, E | 1 |
| Assié, MB | 1 |
| Vacher, B | 1 |
| Luo, ZD | 2 |
| Higuera, ES | 2 |
| Valder, CR | 1 |
| Song, YH | 1 |
| Myers, RR | 1 |
| Garcia-Borreguero, D | 1 |
| Larrosa, O | 1 |
| de la Llave, Y | 1 |
| Verger, K | 1 |
| Masramon, X | 1 |
| Pandey, CK | 2 |
| Bose, N | 1 |
| Garg, G | 1 |
| Singh, N | 1 |
| Baronia, A | 1 |
| Agarwal, A | 1 |
| Singh, PK | 1 |
| Singh, U | 1 |
| Eisenberg, E | 1 |
| Brecker, C | 1 |
| Feng, Y | 2 |
| Cui, M | 2 |
| Willis, WD | 2 |
| Nicolas, X | 1 |
| Vaillant, PY | 1 |
| Bellard, S | 1 |
| Backonja, M | 2 |
| Glanzman, RL | 1 |
| Iida, Y | 1 |
| Zhang, HW | 1 |
| Uehara, S | 1 |
| Murata, J | 1 |
| Saiki, I | 1 |
| Ouchi, H | 1 |
| Neumeier, S | 1 |
| Brinkschmidt, T | 1 |
| Jensen, U | 1 |
| Boyce, JR | 1 |
| Peters, GE | 1 |
| Biederman, J | 1 |
| Jhamandas, K | 1 |
| Hong, M | 1 |
| Yen, HL | 1 |
| Chan, W | 1 |
| Sarantopoulos, C | 2 |
| McCallum, B | 1 |
| Sapunar, D | 1 |
| Kwok, WM | 1 |
| Hogan, Q | 2 |
| Maneuf, YP | 3 |
| Sutton, KS | 1 |
| Chung, FZ | 1 |
| Pinnock, RD | 1 |
| Twaddle, ML | 1 |
| Scheschonka, A | 1 |
| Beuche, W | 1 |
| Kassuya, CA | 1 |
| Silvestre, AA | 1 |
| Rehder, VL | 1 |
| Paradowski, B | 1 |
| Bilinska, M | 1 |
| Oneschuk, D | 1 |
| al-Shahri, MZ | 1 |
| Kumar, P | 1 |
| Jain, MK | 1 |
| Sloan, PA | 1 |
| Kancharla, A | 1 |
| Chesler, EJ | 1 |
| Ritchie, J | 1 |
| Kokayeff, A | 1 |
| Lariviere, WR | 1 |
| Wilson, SG | 1 |
| Mogil, JS | 1 |
| Lockwood, PA | 1 |
| Cook, JA | 1 |
| Ewy, WE | 1 |
| Mandema, JW | 1 |
| Wu, WP | 1 |
| Hao, JX | 2 |
| Ongini, E | 1 |
| Impagnatiello, F | 1 |
| Presotto, C | 1 |
| von Orelli, F | 1 |
| Scullin, P | 1 |
| Sheahan, P | 1 |
| Sheila, K | 1 |
| Reyes-García, G | 2 |
| Medina-Santillán, R | 2 |
| Rocha-González, HI | 2 |
| Granados-Soto, V | 4 |
| Blake, R | 1 |
| Andrews, NA | 1 |
| McKnight, AT | 1 |
| White, WT | 1 |
| Patel, N | 1 |
| Drass, M | 1 |
| Nalamachu, S | 1 |
| Simpson, KH | 1 |
| Kanai, A | 1 |
| McCallum, JB | 1 |
| Shiraki, K | 4 |
| Baron, R | 1 |
| Lotery, HE | 1 |
| McClure, N | 1 |
| Galask, RP | 1 |
| Villarejo, A | 1 |
| Porta-Etessam, J | 3 |
| Camacho, A | 1 |
| González De La Aleja, J | 1 |
| Martínez-Salio, A | 3 |
| Penas, M | 1 |
| Keskinbora, K | 1 |
| Pekel, AF | 1 |
| Aydinli, I | 1 |
| Stahl, SM | 1 |
| Hobgood, C | 1 |
| Hevia, A | 1 |
| Hinchey, P | 1 |
| Bonezzi, C | 1 |
| Arcuri, E | 1 |
| Yaya Tur, R | 1 |
| Maltoni, M | 1 |
| Visentin, M | 1 |
| Gorni, G | 1 |
| Tirelli, W | 1 |
| Barbieri, M | 1 |
| De Conno, F | 1 |
| Iyengar, S | 1 |
| Webster, AA | 1 |
| Hemrick-Luecke, SK | 1 |
| Xu, JY | 1 |
| Simmons, RM | 1 |
| Ilag, VL | 1 |
| Decosterd, I | 1 |
| Allchorne, A | 1 |
| Woolf, CJ | 1 |
| Rasmussen, PV | 1 |
| Sindrup, SH | 1 |
| Jensen, TS | 2 |
| Bach, FW | 1 |
| Lim, LS | 1 |
| Takahashi, PY | 1 |
| Zamiri, M | 1 |
| Bilsland, D | 1 |
| Smiley, MM | 1 |
| Lu, Y | 1 |
| Vera-Portocarrero, LP | 1 |
| Zidan, A | 1 |
| Westlund, KN | 2 |
| van de Vusse, AC | 1 |
| Stomp-van den Berg, SG | 1 |
| Kessels, AH | 1 |
| Weber, WE | 1 |
| Jones, CK | 1 |
| Peters, SC | 1 |
| Shannon, HE | 1 |
| Lossignol, DA | 1 |
| Plehiers, B | 1 |
| Body, JJ | 1 |
| Donovan-Rodriguez, T | 1 |
| Urch, CE | 1 |
| Yoon, MH | 2 |
| Choi, JI | 1 |
| Park, HC | 1 |
| Bae, HB | 1 |
| Jeong, SW | 1 |
| Jeong, CY | 1 |
| Derbyshire, E | 1 |
| Martin, D | 1 |
| Morales-Franco, G | 1 |
| Espinoza-Raya, J | 1 |
| Braune, S | 1 |
| Zhang, C | 1 |
| Glenn, DG | 1 |
| Bell, WL | 1 |
| O'Donovan, CA | 1 |
| Urban, MO | 1 |
| Ren, K | 1 |
| Park, KT | 1 |
| Campbell, B | 1 |
| Anker, N | 1 |
| Stearns, B | 1 |
| Aiyar, J | 1 |
| Belley, M | 1 |
| Cohen, C | 1 |
| Bristow, L | 1 |
| Criscuolo, S | 1 |
| Auletta, C | 1 |
| Lippi, S | 1 |
| Brogi, F | 1 |
| Brogi, A | 1 |
| Valenzano, KJ | 1 |
| Tafesse, L | 1 |
| Lee, G | 1 |
| Boulet, JM | 1 |
| Gottshall, SL | 1 |
| Mark, L | 1 |
| Pearson, MS | 1 |
| Miller, W | 1 |
| Shan, S | 1 |
| Rabadi, L | 1 |
| Rotshteyn, Y | 1 |
| Chaffer, SM | 1 |
| Turchin, PI | 1 |
| Elsemore, DA | 1 |
| Toth, M | 1 |
| Koetzner, L | 1 |
| Hong, HB | 1 |
| Xu, RJ | 1 |
| Hama, AT | 1 |
| Raza, M | 1 |
| Tripathi, M | 1 |
| Navkar, DV | 1 |
| Kumar, A | 1 |
| Singh, UK | 1 |
| Nordmann, GR | 1 |
| Lauder, GR | 1 |
| Grier, DJ | 1 |
| Wiffen, P | 1 |
| Collins, S | 1 |
| McQuay, H | 1 |
| Carroll, D | 1 |
| Jadad, A | 1 |
| Moore, A | 1 |
| Wiffen, PJ | 1 |
| McQuay, HJ | 1 |
| Edwards, JE | 1 |
| Moore, RA | 1 |
| Kroin, JS | 1 |
| Buvanendran, A | 1 |
| Cochran, E | 1 |
| Tuman, KJ | 1 |
| Bassani, F | 1 |
| Bergamaschi, M | 1 |
| Tonino Bolzoni, P | 1 |
| Villetti, G | 1 |
| Pedersen, LH | 1 |
| Nielsen, AN | 1 |
| Blackburn-Munro, G | 2 |
| Suzuki, R | 1 |
| Rahman, W | 1 |
| Rygh, LJ | 1 |
| Webber, M | 1 |
| Hunt, SP | 1 |
| Castañé, A | 1 |
| Célérier, E | 1 |
| Martín, M | 1 |
| Ledent, C | 1 |
| Parmentier, M | 1 |
| Maldonado, R | 1 |
| Valverde, O | 1 |
| Gaida, W | 1 |
| Klinder, K | 1 |
| Arndt, K | 1 |
| Weiser, T | 1 |
| Quintão, NLM | 1 |
| Medeiros, R | 1 |
| Santos, ARS | 1 |
| Campos, MM | 1 |
| Iannetti, GD | 2 |
| Zambreanu, L | 1 |
| Wise, RG | 2 |
| Buchanan, TJ | 1 |
| Huggins, JP | 1 |
| Smart, TS | 2 |
| Vennart, W | 1 |
| Tracey, I | 2 |
| Ross, JR | 1 |
| Goller, K | 1 |
| Hardy, J | 1 |
| Riley, J | 1 |
| Broadley, K | 1 |
| A'hern, R | 1 |
| Williams, J | 1 |
| Baillie, JK | 1 |
| Power, I | 1 |
| Mixcoatl-Zecuatl, T | 1 |
| Flores-Murrieta, FJ | 1 |
| Chiou, LC | 1 |
| Ebell, M | 1 |
| Kripke, C | 1 |
| Guay, DR | 1 |
| Son, BC | 1 |
| Lee, SW | 1 |
| Choi, ES | 1 |
| Sung, JH | 1 |
| Hong, JT | 1 |
| Matsumoto, M | 1 |
| Inoue, M | 1 |
| Hald, A | 1 |
| Xie, W | 1 |
| Ueda, H | 1 |
| Bekkelund, SI | 1 |
| Lilleng, H | 1 |
| Tønseth, S | 1 |
| Rode, F | 1 |
| Broløs, T | 1 |
| Bjerrum, OJ | 1 |
| Mathiesen, O | 1 |
| Imbimbo, BP | 1 |
| Hilsted, KL | 1 |
| Fabbri, L | 1 |
| Dahl, JB | 1 |
| Moulin, D | 1 |
| Meymandi, MS | 2 |
| Sepehri, G | 2 |
| Mobasher, M | 1 |
| Nikolajsen, L | 1 |
| Finnerup, NB | 1 |
| Kramp, S | 1 |
| Vimtrup, AS | 1 |
| Keller, J | 1 |
| Cuignet, O | 1 |
| Pirson, J | 1 |
| Soudon, O | 1 |
| Zizi, M | 1 |
| Felicio, AC | 1 |
| Godeiro, Cde O | 1 |
| Borges, V | 1 |
| Silva, SM | 1 |
| Ferraz, HB | 1 |
| Takeuchi, Y | 1 |
| Honda, M | 1 |
| White, PF | 1 |
| Karamanlioglu, B | 1 |
| Pamukçu, Z | 1 |
| Rashid, RM | 1 |
| Ibrahim, S | 1 |
| Patel, V | 1 |
| Barsukov, IN | 1 |
| Kashin, AV | 1 |
| Kostiuk, GP | 1 |
| Coderre, TJ | 1 |
| Kumar, N | 1 |
| Lefebvre, CD | 1 |
| Yu, JS | 1 |
| Norman, P | 1 |
| Beyreuther, BK | 1 |
| Geis, C | 1 |
| Stöhr, T | 1 |
| Sommer, C | 1 |
| Ortega-Varela, LF | 1 |
| Herrera, JE | 1 |
| Caram-Salas, NL | 1 |
| Arnold, LM | 1 |
| Goldenberg, DL | 2 |
| Stanford, SB | 1 |
| Lalonde, JK | 1 |
| Sandhu, HS | 1 |
| Keck, PE | 1 |
| Welge, JA | 1 |
| Bishop, F | 1 |
| Stanford, KE | 1 |
| Hess, EV | 1 |
| Hudson, JI | 1 |
| Harris, G | 1 |
| Horowitz, B | 1 |
| Borgida, A | 1 |
| Terneus, W | 1 |
| Parker, R | 1 |
| Wallace, VC | 1 |
| Segerdahl, AR | 1 |
| Lambert, DM | 1 |
| Vandevoorde, S | 1 |
| Blackbeard, J | 1 |
| Hasnie, F | 1 |
| Sinclair, AM | 1 |
| Miller, B | 1 |
| Lee, LK | 1 |
| Gil, DW | 1 |
| Cheevers, CV | 1 |
| Donello, JE | 1 |
| Rodríguez, MJ | 1 |
| Díaz, S | 1 |
| Vera-Llonch, M | 1 |
| Dukes, E | 1 |
| Rejas, J | 2 |
| Savica, R | 1 |
| Beghi, E | 1 |
| Mazzaglia, G | 1 |
| Innocenti, F | 1 |
| Brignoli, O | 1 |
| Cricelli, C | 1 |
| Caputi, AP | 1 |
| Musolino, R | 1 |
| Spina, E | 1 |
| Trifirò, G | 1 |
| Spiller, J | 1 |
| Niscola, P | 1 |
| Perrotti, AP | 1 |
| del Poeta, G | 1 |
| Romani, C | 1 |
| Palombi, M | 1 |
| Piccioni, D | 1 |
| Scaramucci, L | 1 |
| Tolu, B | 1 |
| Tendas, A | 1 |
| Cupelli, L | 1 |
| Abruzzese, E | 1 |
| D'Elia, GM | 1 |
| Brunetti, GA | 1 |
| Maurillo, L | 1 |
| Giovannini, M | 1 |
| Cartoni, C | 1 |
| de Fabritiis, P | 1 |
| Christie, J | 1 |
| Rintala, DH | 1 |
| Holmes, SA | 1 |
| Courtade, D | 1 |
| Fiess, RN | 1 |
| Tastard, LV | 1 |
| Loubser, PG | 1 |
| Aizawa, H | 1 |
| Mitsis, GD | 1 |
| Governo, RJ | 1 |
| Morris, PG | 1 |
| Marsden, CA | 1 |
| Chapman, V | 1 |
| Celebi, N | 1 |
| Canbay, O | 1 |
| Aycan, IO | 1 |
| Sahin, A | 1 |
| Aypar, U | 1 |
| Pardo, A | 1 |
| Ruiz, MA | 1 |
| Gray, P | 1 |
| Williams, B | 1 |
| Cramond, T | 1 |
| Kavalieratos, CS | 1 |
| Dimou, T | 1 |
| Bras, M | 1 |
| Haugen, RN | 1 |
| Tharp, MD | 1 |
| Haslam, C | 1 |
| Nurmikko, T | 1 |
| Iyer, R | 1 |
| Egloff, L | 1 |
| Fraas, J | 1 |
| Harris, JD | 1 |
| Coste, O | 1 |
| Pierre, S | 1 |
| Marian, C | 1 |
| Brenneis, C | 1 |
| Angioni, C | 1 |
| Schmidt, H | 1 |
| Popp, L | 1 |
| Geisslinger, G | 1 |
| Scholich, K | 1 |
| Stepanovic-Petrovic, RM | 1 |
| Tomic, MA | 1 |
| Vuckovic, SM | 1 |
| Paranos, S | 1 |
| Ugresic, ND | 1 |
| Prostran, MS | 1 |
| Milovanovic, S | 1 |
| Boskovic, B | 1 |
| Zapp, JJ | 1 |
| McGraw, T | 2 |
| Kosek, P | 1 |
| Shimoyama, M | 1 |
| Inturrisi, CE | 1 |
| Elliott, KJ | 1 |
| Hunter, JC | 2 |
| Gogas, KR | 1 |
| Hedley, LR | 2 |
| Jacobson, LO | 1 |
| Kassotakis, L | 1 |
| Thompson, J | 1 |
| Fontana, DJ | 1 |
| Sist, T | 1 |
| Filadora, V | 1 |
| Miner, M | 1 |
| Lema, M | 1 |
| Samkoff, LM | 1 |
| Daras, M | 1 |
| Tuchman, AJ | 1 |
| Koppel, BS | 1 |
| Wetzel, CH | 1 |
| Connelly, JF | 1 |
| Rosenberg, JM | 1 |
| Harrell, C | 1 |
| Ristic, H | 1 |
| Werner, RA | 1 |
| de Rosayro, AM | 1 |
| Khatri, A | 1 |
| Pearlstein, L | 1 |
| Houtchens, MK | 1 |
| Richert, JR | 1 |
| Sami, A | 1 |
| Rose, JW | 1 |
| Gillin, S | 1 |
| Sorkin, LS | 1 |
| Jun, JH | 1 |
| Gould, HJ | 1 |
| Gee, NS | 1 |
| Su, TZ | 1 |
| Kocsis, JD | 1 |
| Welty, DF | 1 |
| Brown, JP | 1 |
| Dooley, DJ | 1 |
| Boden, P | 1 |
| McCaffery, M | 1 |
| Carlton, SM | 1 |
| Zhou, S | 1 |
| Merren, MD | 1 |
| Ness, TJ | 1 |
| San Pedro, EC | 1 |
| Richards, SJ | 1 |
| Kezar, L | 1 |
| Liu, HG | 1 |
| Mountz, JM | 1 |
| Beydoun, A | 2 |
| Edwards, KR | 1 |
| Schwartz, SL | 1 |
| Fonseca, V | 1 |
| Hes, M | 1 |
| LaMoreaux, L | 1 |
| Garofalo, E | 1 |
| Low, PA | 1 |
| Dotson, RM | 1 |
| Stacey, BR | 1 |
| Gorson, KC | 1 |
| Schott, C | 1 |
| Herman, R | 1 |
| Ropper, AH | 1 |
| Rand, WM | 1 |
| Seidl, JJ | 1 |
| Slawson, JG | 1 |
| McCleary, S | 1 |
| Hughes, J | 1 |
| Schiebel, NE | 1 |
| Ebbert, J | 1 |
| Margolis, K | 1 |
| Hansen, HC | 2 |
| Jett, MF | 1 |
| Dillon, MP | 1 |
| Eglen, RM | 1 |
| van Deventer, H | 1 |
| Bernard, S | 1 |
| Chizh, BA | 1 |
| Wnendt, S | 1 |
| Morello, CM | 1 |
| Leckband, SG | 1 |
| Stoner, CP | 1 |
| Moorhouse, DF | 1 |
| Sahagian, GA | 1 |
| Maurer, I | 1 |
| Volz, HP | 1 |
| Sauer, H | 1 |
| Urban, L | 1 |
| McCaslin, PP | 1 |
| Holtom, N | 1 |
| Solaro, C | 1 |
| Uccelli, MM | 1 |
| Guglieri, P | 1 |
| Uccelli, A | 1 |
| Mancardi, GL | 1 |
| Nicholson, B | 1 |
| García-Morales, I | 1 |
| Berbel, A | 2 |
| Benito-León, J | 2 |
| Pérez, HE | 1 |
| Sánchez, GF | 1 |
| Chen, LL | 1 |
| Nitta, M | 1 |
| Nemoto, H | 1 |
| Zylicz, Z | 1 |
| Dallocchio, C | 1 |
| Buffa, C | 1 |
| Mazzarello, P | 1 |
| Chiroli, S | 1 |
| Kapadia, NP | 1 |
| Harden, N | 1 |
| Chandler, A | 1 |
| Williams, JE | 1 |
| Kayser, V | 1 |
| Christensen, D | 1 |
| Derk, CT | 1 |
| Cynwyd, B | 1 |
| Hulsebosch, CE | 2 |
| Xu, GY | 1 |
| Perez-Polo, JR | 1 |
| McAdoo, DJ | 1 |
| Block, F | 1 |
| Sasaki, K | 1 |
| Smith, CP | 1 |
| Chuang, YC | 1 |
| Lee, JY | 1 |
| Kim, JC | 1 |
| Chancellor, MB | 1 |
| Rovetta, G | 1 |
| Baratto, L | 1 |
| Farinelli, G | 1 |
| Monteforte, P | 1 |
| Mercadante, S | 1 |
| Villari, P | 1 |
| Fulfaro, F | 1 |
| Nozaki-Taguchi, N | 1 |
| Chaplan, SR | 1 |
| Ajakwe, RC | 1 |
| Behm, MO | 1 |
| Kearns, GL | 1 |
| La Spina, I | 1 |
| Porazzi, D | 1 |
| Maggiolo, F | 1 |
| Bottura, P | 1 |
| Suter, F | 1 |
| Devulder, J | 1 |
| Lambert, J | 1 |
| Naeyaert, JM | 1 |
| Mills, CD | 1 |
| Grady, JJ | 1 |
| Brooks-Rock, K | 1 |
| Azulay, JP | 1 |
| Pouget, J | 1 |
| Alam, M | 1 |
| Rabinowitz, AD | 1 |
| Engler, DE | 1 |
| Matthews, EA | 1 |
| Schapiro, RT | 1 |
| Heughan, CE | 1 |
| Sawynok, J | 1 |
| Rose, MA | 1 |
| Kam, PC | 1 |
| Gu, Y | 1 |
| Huang, LY | 1 |
| Bosnjak, S | 1 |
| Jelic, S | 1 |
| Susnjar, S | 1 |
| Luki, V | 1 |
| Sussman, N | 1 |
| To, TP | 1 |
| Lim, TC | 1 |
| Hill, ST | 1 |
| Frauman, AG | 1 |
| Cooper, N | 1 |
| Kirsa, SW | 1 |
| Brown, DJ | 1 |
| Wheeler, G | 1 |
| Bruins Slot, LA | 1 |
| Ribet, JP | 1 |
Clinical Trials (42)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma[NCT03269344] | Phase 3 | 65 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Gabapentin as an Adjunct for Pain Management During Dilation and Evacuation: A Double-blind Randomized Controlled Trial[NCT03635905] | Phase 4 | 130 participants (Actual) | Interventional | 2017-05-26 | Completed | ||
| A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response[NCT01301001] | 230 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
| A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy[NCT00159679] | Phase 4 | 167 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy[NCT00143156] | Phase 3 | 450 participants | Interventional | 2005-03-31 | Completed | ||
| A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).[NCT00156078] | Phase 4 | 450 participants | Interventional | 2005-01-31 | Completed | ||
| Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy[NCT00553475] | Phase 3 | 314 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial[NCT03080493] | Phase 4 | 121 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain[NCT02339662] | Phase 4 | 50 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| A Randomized, Double Blind, Placebo Controlled Study to Investigate the Effect of Donepezil and Gabapentin Combination on an Experimental Pain Model in Healthy Subjects[NCT01485185] | Phase 1 | 48 participants (Actual) | Interventional | 2011-10-11 | Completed | ||
| Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain[NCT01364298] | Phase 4 | 353 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058] | 36 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used[NCT02693821] | Phase 4 | 122 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia[NCT03120962] | 140 participants (Anticipated) | Interventional | 2017-05-31 | Not yet recruiting | |||
| Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain[NCT05311774] | 400 participants (Anticipated) | Interventional | 2022-04-30 | Not yet recruiting | |||
| Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia[NCT00885586] | Phase 4 | 68 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| The Efficacy and Safety of Intradermal Acupuncture for Acute Herpes Zoster: Study Protocol for a Randomized Controlled Trial[NCT05348382] | 72 participants (Anticipated) | Interventional | 2022-07-04 | Recruiting | |||
| Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-05-03 | Recruiting | ||
| Self-Management to Improve Walking Ability in Degenerative Lumbar Spinal Stenosis: the Evaluation of Four Novel Strategies.[NCT02592642] | 104 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI[NCT00243152] | 6 participants (Actual) | Interventional | 2005-10-31 | Completed | |||
| Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients[NCT02160301] | Phase 4 | 0 participants (Actual) | Interventional | 2017-11-30 | Withdrawn (stopped due to Insufficient infrastructure/funding for enrollment) | ||
| The Effect of Preoperative Anxiety Level to Postoperative Pain and Analgesic Consumption in Patients Who Had Laparoscopic Sleeve Gastrectomy[NCT04432558] | 42 participants (Actual) | Observational [Patient Registry] | 2017-04-12 | Completed | |||
| Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures[NCT02957097] | Phase 4 | 0 participants (Actual) | Interventional | 2019-09-30 | Withdrawn (stopped due to Original PI left institution and the PI who took over was not able to initiate the study so it was never started.) | ||
| Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain[NCT00637975] | Phase 2 | 80 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study[NCT00403780] | Phase 4 | 18 participants (Actual) | Interventional | 2006-06-30 | Terminated (stopped due to low inclusion rate) | ||
| Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)[NCT01623271] | 5 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to Due to limited population of research participants.) | |||
| Randomized Controlled Pilot Trial of Adjunct Group Acupuncture vs Usual Care Among Patients With Painful Diabetic Neuropathy[NCT02104466] | 40 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| Effect of Two Different Doses of Oral Pregabalin Premedication for Postoperative Pain Relief After Gynecological Surgeries[NCT04708353] | 90 participants (Anticipated) | Interventional | 2020-08-20 | Recruiting | |||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949] | 0 participants | Expanded Access | Available | ||||
| The Effect of Neurontin on Pain Management in the Acutely Burned Patient[NCT01265056] | 53 participants (Actual) | Interventional | 2010-02-28 | Completed | |||
| Open Labeled, Non-randomized, Study of Efficacy and Safety of Gralise in Fibromyalgia Patients.[NCT02052414] | 34 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Phase III Study of the Use of Gabapentin and Osteopathic Manipulative Medicine to Treat Fibromyalgia[NCT01107574] | Phase 3 | 41 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Evaluation of the Efficiency of a Therapeutic Education Program in Standardized Thermal Cure for Fibromyalgia Patients[NCT02406313] | 152 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| Fibromyalgia of Less Than One Year Duration in Primary Care: Treatment Response in a Double Blind, Placebo Controlled Study of Pregabalin[NCT01397006] | Phase 4 | 0 participants (Actual) | Interventional | 2011-09-30 | Withdrawn | ||
| Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy[NCT01466101] | 0 participants (Actual) | Interventional | 2011-01-31 | Withdrawn (stopped due to PI left the institution. No subjects screened or enrolled.) | |||
| Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859] | Phase 4 | 50 participants (Anticipated) | Interventional | 2010-04-30 | Completed | ||
| Perioperative Administration of Pregabalin in Laparoscopic Living Donor Nephrectomy (L-LDN) - an Adjuvance to Peroral Analgetic Treatment - a Randomized Controlled Study[NCT01059331] | Phase 4 | 80 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase III, Double Blind, Randomized, Placebo-controlled Study to Assess the Efficacy of Adjunct Monochromatic Near-infrared Photoenergy (MIRE) in Patients With Painful Axonal Peripheral Neuropathy[NCT00125268] | Phase 3 | 30 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Unable to enroll enough patients) | ||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Average Opioid Use, Measured in Morphine Equivalents Per Day.
(NCT03269344)
Timeframe: Over the entire study period from baseline to follow-up, approximately 13 weeks
| Intervention | Daily morphine equivalents (Median) |
|---|---|
| Control Arm | 15.6 |
| Experimental Arm | 22.2 |
Change in PRO-CTCAE Scores From Baseline to Follow-up
Scale: Patient-reported outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE), 5-point Likert scale, higher scores indicate worse outcomes. Range of scores 0-40 (min-max). (NCT03269344)
Timeframe: Evaluated change in scores from baseline to 6 weeks post-treatment, approximately 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Control Arm | 1.0 |
| Experimental Arm | 6.5 |
Change in Quality of Life From Mucositis-related Pain Measured by the Patient-Reported Oral Mucositis Symptoms (PROMS) Scale From Baseline to Follow-up
Scale tile: Patient Reported Oral Mucositis Symptoms scale, range 0-1000, higher scores indicate worse outcomes (NCT03269344)
Timeframe: Evaluated change in scores from baseline to 6 weeks post-treatment, approximately 13 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Control Arm | 20.1 |
| Experimental Arm | 29.1 |
Change in Total FACT-HN Scores From Baseline to Follow-up
Scale: Functional Assessment of Cancer Therapy-Trial Outcome (FACT-HN), range 0-148, higher scores indicate better outcomes (NCT03269344)
Timeframe: Administered at baseline and at 6-week follow-up endpoint, approximately 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Control Arm | -15.0 |
| Experimental Arm | -20.0 |
Feeding Tube Placement
Measure of number of patients who required feeding tube placement at any time during the study period (NCT03269344)
Timeframe: Evaluated placement of feeding tube from baseline (start of radiation) to 6 weeks post-treatment, approximately 13 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Arm | 6 |
| Experimental Arm | 18 |
Percent Weight Lost
Percent weight lost from baseline to week 7 of treatment (end of treatment) (NCT03269344)
Timeframe: Percent change from baseline to week 7 of treatment
| Intervention | Percent change (Median) |
|---|---|
| Control Arm | -10.7 |
| Experimental Arm | -11.4 |
Coital Pain
Coital pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever), assessed after each sexual intercourse event. The number of sexual intercourse events was averaged during final week of each treatment arm. (NCT01301001)
Timeframe: Week 6 of each treatment arm
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 3.97 |
| Gabapentin | 3.85 |
Tampon Test Pain Intensity
Tampon pain on a 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). One tampon was inserted each week. Tampon pain was assessed during last week of maintenance phase (7 days). (NCT01301001)
Timeframe: Week 6 for each treatment arm
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 4.29 |
| Gabapentin | 3.96 |
Vulvodynia Pain
Overall vulvodynia pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). Pain was assessed daily during the last week of treatment. Daily scores were averaged. (NCT01301001)
Timeframe: Week 6 for each treatment arm
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 2.88 |
| Gabapentin | 2.71 |
Change From Baseline at Week 1 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1.~Change from baseline: Score at Week 1 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 1
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.39 |
| Pregabalin 300 mg/Day | -0.82 |
| Pregabalin 600 mg/Day | -1.14 |
Change From Baseline at Week 10 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10.~Change from baseline: Score at Week 10 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 10
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.23 |
| Pregabalin 300 mg/Day | -1.93 |
| Pregabalin 600 mg/Day | -2.10 |
Change From Baseline at Week 11 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11.~Change from baseline: Score at Week 11 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 11
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.32 |
| Pregabalin 300 mg/Day | -1.95 |
| Pregabalin 600 mg/Day | -2.09 |
Change From Baseline at Week 12 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12.~Change from baseline: Score at Week 12 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 12
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.36 |
| Pregabalin 300 mg/Day | -2.01 |
| Pregabalin 600 mg/Day | -2.13 |
Change From Baseline at Week 13 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13.~Change from baseline: Score at Week 13 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 13
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.38 |
| Pregabalin 300 mg/Day | -2.04 |
| Pregabalin 600 mg/Day | -2.12 |
Change From Baseline at Week 2 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2.~Change from baseline: Score at Week 2 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 2
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.57 |
| Pregabalin 300 mg/Day | -1.17 |
| Pregabalin 600 mg/Day | -1.80 |
Change From Baseline at Week 3 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3.~Change from baseline: Score at Week 3 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 3
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.80 |
| Pregabalin 300 mg/Day | -1.40 |
| Pregabalin 600 mg/Day | -1.93 |
Change From Baseline at Week 4 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4.~Change from baseline: Score at Week 4 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 4
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.89 |
| Pregabalin 300 mg/Day | -1.53 |
| Pregabalin 600 mg/Day | -2.00 |
Change From Baseline at Week 5 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5.~Change from baseline: Score at Week 5 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 5
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.91 |
| Pregabalin 300 mg/Day | -1.57 |
| Pregabalin 600 mg/Day | -2.07 |
Change From Baseline at Week 6 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6.~Change from baseline: Score at Week 6 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 6
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.94 |
| Pregabalin 300 mg/Day | -1.72 |
| Pregabalin 600 mg/Day | -2.06 |
Change From Baseline at Week 7 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7.~Change from baseline: Score at Week 7 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 7
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.04 |
| Pregabalin 300 mg/Day | -1.76 |
| Pregabalin 600 mg/Day | -2.13 |
Change From Baseline at Week 8 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8.~Change from baseline: Score at Week 8 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.18 |
| Pregabalin 300 mg/Day | -1.85 |
| Pregabalin 600 mg/Day | -2.12 |
Change From Baseline at Week 9 in Mean Weekly Pain Scores
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9.~Change from baseline: Score at Week 9 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 9
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.20 |
| Pregabalin 300 mg/Day | -1.93 |
| Pregabalin 600 mg/Day | -2.06 |
Change From Baseline in Mean Sleep Interference Scores
The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.74 |
| Pregabalin 300 mg/Day | -1.59 |
| Pregabalin 600 mg/Day | -1.36 |
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -7.91 |
| Pregabalin 300 mg/Day | -11.45 |
| Pregabalin 600 mg/Day | -9.73 |
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 0.37 |
| Pregabalin 300 mg/Day | 0.69 |
| Pregabalin 600 mg/Day | 0.54 |
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 12.08 |
| Pregabalin 300 mg/Day | 17.69 |
| Pregabalin 600 mg/Day | 21.73 |
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -9.03 |
| Pregabalin 300 mg/Day | -15.40 |
| Pregabalin 600 mg/Day | -12.81 |
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.63 |
| Pregabalin 300 mg/Day | -3.02 |
| Pregabalin 600 mg/Day | -4.47 |
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -6.00 |
| Pregabalin 300 mg/Day | -5.96 |
| Pregabalin 600 mg/Day | -1.56 |
Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -2.96 |
| Pregabalin 300 mg/Day | 0.83 |
| Pregabalin 600 mg/Day | 4.83 |
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 10.34 |
| Pregabalin 300 mg/Day | 11.84 |
| Pregabalin 600 mg/Day | 12.89 |
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 2.31 |
| Pregabalin 300 mg/Day | 3.29 |
| Pregabalin 600 mg/Day | 4.40 |
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 3.84 |
| Pregabalin 300 mg/Day | 5.33 |
| Pregabalin 600 mg/Day | 7.81 |
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 2.70 |
| Pregabalin 300 mg/Day | 2.43 |
| Pregabalin 600 mg/Day | 3.86 |
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 4.13 |
| Pregabalin 300 mg/Day | 5.05 |
| Pregabalin 600 mg/Day | 6.35 |
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 4.38 |
| Pregabalin 300 mg/Day | 2.28 |
| Pregabalin 600 mg/Day | 3.97 |
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 3.00 |
| Pregabalin 300 mg/Day | 8.06 |
| Pregabalin 600 mg/Day | 11.16 |
Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 5.28 |
| Pregabalin 300 mg/Day | 4.20 |
| Pregabalin 600 mg/Day | 12.87 |
Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.83 |
| Pregabalin 300 mg/Day | -1.43 |
| Pregabalin 600 mg/Day | -1.39 |
Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.59 |
| Pregabalin 300 mg/Day | -0.80 |
| Pregabalin 600 mg/Day | -0.96 |
Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -2.82 |
| Pregabalin 300 mg/Day | -4.60 |
| Pregabalin 600 mg/Day | -4.95 |
Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -3.68 |
| Pregabalin 300 mg/Day | -6.03 |
| Pregabalin 600 mg/Day | -6.36 |
Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -16.92 |
| Pregabalin 300 mg/Day | -24.19 |
| Pregabalin 600 mg/Day | -24.41 |
Change From Baseline to Study Endpoint in Mean Weekly Pain Scores
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.20 |
| Pregabalin 300 mg/Day | -1.82 |
| Pregabalin 600 mg/Day | -1.94 |
Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr). (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.27 |
| Expected Exposure Pregabalin 300 mg/Day | -1.93 |
| Expected Exposure Pregabalin 600 mg/Day | -1.90 |
Clinical Global Impression of Change
Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation
| Intervention | score on scale (Mean) |
|---|---|
| Placebo | 3.3 |
| Pregabalin 300 mg/Day | 2.9 |
| Pregabalin 600 mg/Day | 2.7 |
Number of Responders
A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | participants (Number) |
|---|---|
| Placebo | 29 |
| Pregabalin 300 mg/Day | 39 |
| Pregabalin 600 mg/Day | 16 |
Patient Global Impression of Change
The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation
| Intervention | score on scale (Mean) |
|---|---|
| Placebo | 3.4 |
| Pregabalin 300 mg/Day | 3.2 |
| Pregabalin 600 mg/Day | 2.8 |
Mean Change From Baseline in NRS Pain Score at 2 Hours After Dilator Insertion
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 2 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 3.5 |
| Placebo Oral Capsule | 4 |
Mean Change From Baseline in NRS Pain Score at 4 Hours After Dilator Insertion
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 4 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Mean) |
|---|---|
| Gabapentin | 3 |
| Placebo Oral Capsule | 3.5 |
Mean Change From Baseline in NRS Pain Score at 5 Minutes After Last Dilator Insertion
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person before subject leaves clinic appointment. (NCT03080493)
Timeframe: 5 minutes after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 1 |
| Placebo Oral Capsule | 2 |
Mean Change From Baseline in NRS Pain Score at 8 Hours After Dilator Insertion
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 8 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 2 |
| Placebo Oral Capsule | 2.5 |
Mean Change From Baseline in NRS Pain Score at Time of Presentation for D&E Procedure (Day Following Dilator Insertion)
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person upon presentation for D&E procedure. (NCT03080493)
Timeframe: Time of presentation for D&E (day after dilator insertion)
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 0.5 |
| Placebo Oral Capsule | 1 |
Number of Participants Using Narcotic Pain Medication (Acetaminophen/Codeine)
Subject account of how many used acetaminophen/codeine (standard medications given for supplement NSAID as needed after dilator insertion) (NCT03080493)
Timeframe: Collected between each subject contact (2 hours, 4 hours, 8 hours after dilator insertion and at time of presentation for D&E procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 35 |
| Placebo Oral Capsule | 40 |
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered. (NCT01364298)
Timeframe: Day 7 up to Day 84 (+7 days)
| Intervention | participants (Number) |
|---|---|
| Gabapentin/B-complex | 80 |
| Pregabalin | 93 |
Profile of Mood States (POMS) Score
"POMS is a rating scale, which comprises of 65 items that are evaluated in a 0-4 scale, where 0 means not at all and 4 extremely. The scores for the 65 items are added in various combinations to throw six validated factors which are used to calculate total POMS score: (tension-anxiety) + (depression-dejection) + (anger-hostility)+ (fatigue-Inertia) + (confusion-bewilderment) - (vigor-activity). Score range (-40 to 192). Score -40 denotes the best score and score 192 denotes the worst score." (NCT01364298)
Timeframe: Day 84 (Week 12)
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin/B-complex | 1.3 |
| Pregabalin | 3.4 |
Change From Baseline in Average Numeric Pain Intensity Scale (NPIS) Score at Day 84
An average NPIS pain score (daily average records of the past seven days) was evaluated. Numeric pain intensity scale (NPIS) is a 11-point scale, with 0 representing no pain and 10 representing the worst possible pain. The participants were asked to mark the number that best represents the current level of pain they have experienced during the previous 24 hours. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=147, 123) | Change at Day 84 (n=146, 122) | |
| Gabapentin/B-complex | 6.7 | 3.905 |
| Pregabalin | 6.8 | 4.260 |
Change From Baseline in Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Scale Score at Day 84
The LANSS scale score is 7-item pain scale that consists of grouped sensory description and sensory examination with simple scoring system. Evaluations in two main areas: pain and sensorial exploration. The first 5 questions asks for presence of unpleasant skin sensations (pricking, tingling, pins and needles), appearance of skin (mottled, red, or pink), increased sensitivity of skin to touch, sudden bursts of electric shock sensations, and hot or burning skin sensations. Last 2 questions involve sensory testing for the presence of allodynia and altered pinprick threshold. Different numbers of points, relative to their significance to neuropathic pain, are given to positive answers for maximum of 24 points. A score less than 12 makes unlikely that participant's symptoms are neuropathic in nature, whereas score more than 12 make neuropathic mechanisms likely to be contributing to participant's pain. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=147, 123) | Change at Day 84 (n=146, 122) | |
| Gabapentin/B-complex | 16.2 | 8.082 |
| Pregabalin | 15.8 | 6.967 |
Change From Baseline in Visual Analogue Scale (VAS) Score at Day 84
VAS is used to rate the pain as per 10 centimeter (cm) line. The pain intensity score ranges from '0=no pain' to '10=worst possible pain'. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | centimeter (Mean) | |
|---|---|---|
| Baseline (n=147, 123) | Change at Day 84 (n=146, 122) | |
| Gabapentin/B-complex | 7.0 | 4.182 |
| Pregabalin | 7.1 | 4.529 |
Number of Participants With Various Health Conditions Based on Clinical Global Impression of Change (CGIC) Scale
CGIC is an assessment that the physician performs to assess the participant's global change in health condition from start of the study on a 7-point scale (1 = extremely improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse 6 = much worse, 7 = extremely worse). (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Health: extremely improved | Health: much improved | Health: minimally improved | |
| Gabapentin/B-complex | 55 | 79 | 11 |
| Pregabalin | 47 | 69 | 6 |
Number of Participants With Various Health Conditions Based on Global Impression of Patient Change (GIPC) Scale
GIPC is an assessment that the participant's global change in health condition from start of the study on a 7-point scale (1 = extremely improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse 6 = much worse, 7 = extremely worse). (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Health: extremely improved | Health: much improved | Health: minimally improved | |
| Gabapentin/B-complex | 62 | 73 | 10 |
| Pregabalin | 47 | 65 | 10 |
Percentage of Participants With at Least 30 and 50 Percent (%) Improvement in Numeric Pain Intensity Scale (NPIS) From Baseline at Day 84 (Week 12)
NPIS is a 11-point scale, with 0 representing no pain and 10 representing the worst possible pain. The participants were asked to mark the number that best represents the current level of pain they have experienced during the previous 24 hours. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| At least 30% improvement | At least 50% improvement | |
| Gabapentin/B-complex | 76.9 | 66.0 |
| Pregabalin | 85.4 | 72.4 |
Sleep Evaluation: Number of Participants Who Fell Asleep in Pre-specified Time Duration
Sleep evaluation was performed by assessing number of participants who fell asleep in a particular pre-specified range of time duration, that is, 0-15 minutes, 16-30 minutes, 31-45 minutes, 46-60 minutes and greater than 60 minutes at Day 84 (Week 12). (NCT01364298)
Timeframe: Day 84 (Week 12)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| 0 to 15 minutes | 16 to 30 minutes | 31 to 45 minutes | 46 to 60 minutes | Greater than 60 minutes | |
| Gabapentin/B-complex | 85 | 33 | 13 | 8 | 8 |
| Pregabalin | 72 | 33 | 12 | 4 | 2 |
Blood Oxygenation Level-dependent (BOLD) Changes in Neural Pain Circuitry Following Treatment With Lamotrigine During Experimentally Induced Pain States
fMRI scans acquired Stimuli Type: Brush Stimulation Regions: Face (V2) Right and Left Sides Rating: Pain/ unpleasantness fMRI scans acquired Stimuli Type: Cold, threshold -1°C Stimulation Regions: Face (V2) Right and Left Sides Rating: Pain/ unpleasantness **Extra time allotted for probe repositioning** fMRI scans acquired Stimuli Type: Heat, threshold +1°C Stimulation Regions: Face (V2) Right and Left Sides Rating: Pain/ unpleasantness **Extra time allotted for probe repositioning** Cortical, subcortical, and brain stem sensory regions Z-scores Increase or decrease in activation as affected by the drug (NCT00243152)
Timeframe: Week 10 during scanning session
| Intervention | Z-statistic (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Heat Affected Thalamus (10,-14,8) | Heat Affected Post-Central (-56,-12,28) | Cold Affected Post-Central (68, -8, 32) | Cold Affected Thalamus (-4, -8, 0) | Brush Affected Post-Central (66,-16,14) | Brush Affected Thalamus (-14,-22, 4) | Brush Affected Spinal Trigeminal Nucles(2,-48,-68) | |
| Lamotrigine vs Placebo | -2.9294 | -2.7323 | -2.5114 | -3.033 | 3.905 | -3.791 | 2.9058 |
Subjective Ratings of Pain During Magnetic Resonance Scanning
"Quantitative Sensory Testing (QST)~Stimuli Type: Heat, Cold, Brush Stimulation Regions: Face Affected and contralateral Unaffected mirror area Rating: Pain/ unpleasantness Stimuli Type: Cold, threshold -1°C Stimulation Regions: Face Affected and contralateral Unaffected mirror area Rating: Pain/ unpleasantness Stimuli Type: Heat, threshold +1°C Stimulation Regions: Face Affected and contralateral Unaffected mirror area Rating: Pain/ unpleasantness~Ratings on a likert scale of 0-10 with 0 being defined as no pain and 10 being defined as worst possible pain" (NCT00243152)
Timeframe: week 10 (during the scan)
| Intervention | scores on a pain scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Heat Affected | Heat Unaffected | Cold Affected | Cold Unaffected | Brush Affected | Brush Unaffected | |
| Lamotrigine | 3.2 | 3 | 2.1 | 2.2 | 2.8 | 1.2 |
| Placebo | 5.5 | 4 | 2.5 | 1.1 | 3.9 | .4 |
Visual Analog Scale (VAS) at Visit 3
Subjects rated their pain using the VAS at visit 3, which was the last day of their maintenance phase. After this visit, subjects begin to taper the gralise. The VAS is subject reported on a scale of 0-10 with 0 being no pain and 10 being the worst pain they can imagine. Results reported are an average of the 3 subjects who completed visit 3. (NCT01623271)
Timeframe: At visit 3
| Intervention | units on the VAS (Mean) |
|---|---|
| CRPS I Pain Subjects | 3.67 |
Difference in Psychological Outcomes on the Sickness Inventory Profile (SIP)
The sickness inventory profile (SIP) is a behaviorally based measure of health status. Scores range from 0-68 with higher numbers indicating worse outcomes. The study report total SIP score. The higher the score the worse the function. (NCT01265056)
Timeframe: First Clinic Follow Up After Discharge
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 34.9 |
| Gabapentin | 36.0 |
Opioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents)
(NCT01265056)
Timeframe: From time of enrollment to 2 weeks after being discharged
| Intervention | morphine equivalents (Mean) |
|---|---|
| Placebo | 7.0 |
| Gabapentin | 6.7 |
Psychological Functioning as Evaluated by the Brief Symptom Inventory (BSI) Between Treatment and Placebo Groups
The Brief Symptom Inventory 18 (BSI 18) is designed with reliability in mind. The BSI 18 assessment gathers patient-reported data to help measure psychological distress and psychiatric disorders in medical and community populations. As the latest in an integrated series of test instruments that include the SCL-90-R®, BSI® (53 questions), and DPRS® instruments, the BSI 18 test offers a more effective, easy-to-administer tool to help support clinical decision-making and monitor progress throughout treatment. BSI-18 measures three dimensions with 6 questions a piece (somatization , depression , anxiety) and overall psychological distress scores (Global severity index, GSI). Each of the 18 items range from a score of 0-4; total score ranges from 0-72 with higher scores indicating worse function. The GSI score is calculated as the mean of the three subscales. The study reported the GSI score. Higher score is worse. (NCT01265056)
Timeframe: First Clinic Follow Up After Discharge
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 9 |
| Gabapentin | 7.3 |
Fibromyalgia Impact Questionnaire (FIQ)
The Fibromyalgia Impact Questionnaire (FIQ) is an instrument designed to quantitate the overall impact of fibromyalgia over many dimensions (e.g. function, pain level, fatigue, sleep disturbance, psychological distress etc.). It is scored from 0 to 100 with the latter number being the worst case. The average score for patients seen in tertiary care settings is about 50. The FIQ is widely used to assess change in fibromyalgia status. (NCT02052414)
Timeframe: 15 weeks.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| FIQ Baseline | FIQ Week 4 | FIQ Week 8 | FIQ Week 12 | FIQ Week 15 | |
| Gralise (Gabapentin ER) | 71.04 | 41.82 | 40.79 | 39.27 | 61.86 |
Medical Outcome Study (MOS) Sleep Questionnaires
"Medical Outcomes Study (MOS) sleep questionnaires to assess how Fibromyalgia impacts patients' sleep in various areas.~Specifically, Data reported below measured number of hours subjects spent per night sleeping. MOS sleep questionnaires were assessed at each follow up visits. (visits 1, 2, 3, 4, and 5)." (NCT02052414)
Timeframe: 15 weeks
| Intervention | Hours (Mean) | ||||
|---|---|---|---|---|---|
| Sleep Quantity Baseline | Sleep Quantity week 4 | Sleep quantity week 8 | Sleep quantity week 12 | Sleep quantity week 15 | |
| Gralise (Gabapentin ER) | 5.86 | 7.17 | 6.81 | 7.04 | 6.23 |
Numeric Pain Rating System (NPRS)
Fibromyalgia pain experienced by study subjects will be captured using NPRS at baseline visit, at each follow visits that are scheduled to occur every 4 weeks over 12 weeks of treatment period, and at the end of treatment visit that will occur 3 weeks after treatment period (12 weeks treatment period + 3 weeks = 15 weeks). Any difference in NPRS scores between baseline and any subsequent visits will indicate the magnitude of pain relief as reflected in digital scale of 0-10 (0=no pain, 10=worst pain imaginable). (NCT02052414)
Timeframe: 15 weeks
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| NPRS Baseline (Visit 1) | NPRS on Week 4 (Visit 2) | NPRS on week 8 (Visit 3) | NPRS on Week 12 (Visit 4) | NPRS on week 15 (Visit 5) | |
| Gralise (Gabapentin ER) | 7.29 | 4.72 | 3.95 | 3.83 | 6.94 |
Patient Global Impression of Change (PGIC)
Patient Global impression of Change (PGIC) is an outcome commonly used measure of the efficacy of treatments. PGIC is a 7 point scale that requires the subjects to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT02052414)
Timeframe: 15 Weeks.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| PGIC After 4 weeks | PGIC After 8 weeks | PGIC After 12 weeks | PGIC After 15 weeks | |
| Gralise (Gabapentin ER) | 4.96 | 5.40 | 5.37 | 4.44 |
Self Reported Side Effects.
Side / adverse effects were assessed at each follow up visits and resulted are as follows. (NCT02052414)
Timeframe: 15 Weeks
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Extremity Swelling | Weight Gain | Drowsy | Dizzy | Irritability | Dry Eyes | Pain | Mood Changes | Difficulty Concentrating | Dry Mouth | Suspected Drug interaction | Acute Delerium | Adhesion | None | |
| Gralise (Gabapentin ER) | 2 | 2 | 8 | 3 | 3 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 12 |
Prefrontal GABA+ Concentrations
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Prefrontal Glx Concentrations
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Reviews
69 reviews available for gabapentin and Ache
| Article | Year |
|---|---|
Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Calcium Channels; Carboxylic Acids; Cyclohexanecarboxy | 2007 |
Systematic review and meta-analysis of studies in which burrowing behaviour was assessed in rodent models of disease-associated persistent pain.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Disease M | 2022 |
Pharmacologic therapies of pain in patients with spinal cord injury: a systematic review.
Topics: Amitriptyline; Anticonvulsants; Gabapentin; Humans; Ketamine; Pain; Pregabalin; Spinal Cord Injuries | 2022 |
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval.
Topics: Analgesics; Gabapentin; Humans; Pain; Pregabalin; United States; United States Food and Drug Adminis | 2023 |
Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis.
Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric | 2023 |
A critical appraisal of gabapentinoids for pain in cancer patients.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Drug Therapy, Combination; Gabapentin; Humans; Pain; Pa | 2018 |
The case for cautious consumption: NSAIDs in chronic kidney disease.
Topics: Acute Kidney Injury; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Cost-Ben | 2019 |
Pain Management in Trauma in the Age of the Opioid Crisis.
Topics: Acetaminophen; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Gabapentin; Humans | 2019 |
A Clinical Overview of Off-label Use of Gabapentinoid Drugs.
Topics: Analgesics; Diabetic Neuropathies; Drug Approval; Fibromyalgia; Gabapentin; Humans; Low Back Pain; M | 2019 |
A review of analgesic compounds used in food animals in the United States.
Topics: Adrenergic alpha-Agonists; Amines; Analgesia; Analgesics; Analgesics, Opioid; Anesthetics, Local; An | 2013 |
Pharmacological treatment for pain in Guillain-Barré syndrome.
Topics: Amines; Analgesics; Carbamazepine; Constipation; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amin | 2013 |
Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neopla | 2014 |
Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine.
Topics: Acetaminophen; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclohexaneca | 2013 |
[A case of Guillain-Barré syndrome with severe pain successfully controlled with acetaminophen, gabapentin, and parenterally infused fentanyl].
Topics: Acetaminophen; Amines; Child; Cyclohexanecarboxylic Acids; Drug Combinations; Fentanyl; Gabapentin; | 2014 |
Pharmacological treatment for pain in Guillain-Barré syndrome.
Topics: Amines; Analgesics; Carbamazepine; Constipation; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amin | 2015 |
Headache and Pain in Guillain-Barré Syndrome.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Guillain-Barre Sy | 2015 |
Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics.
Topics: Amines; Analgesics, Opioid; Animals; Antidepressive Agents; Antineoplastic Agents; Cisplatin; Cycloh | 2016 |
Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review.
Topics: Amines; Analgesics; Anticonvulsants; Antidepressive Agents; Chemotherapy, Adjuvant; Cyclohexanecarbo | 2017 |
Analgesia in the surgical intensive care unit.
Topics: Acetaminophen; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Conduction; Anesthetics, Local; C | 2017 |
Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2016 |
Practical management strategies for the chronic pain patient.
Topics: Administration, Cutaneous; Amines; Analgesics; Antidepressive Agents, Tricyclic; Carbamazepine; Chro | 2007 |
[Central and peripheral mechanisms in antinociception: current and future perspectives].
Topics: Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Bridged Bicyclo Compounds, Heterocycl | 2008 |
Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.
Topics: Amines; Analgesics; Analysis of Variance; Bayes Theorem; Cyclohexanecarboxylic Acids; Diabetic Neuro | 2009 |
Pregabalin in the treatment of chronic pain: an overview.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic | 2009 |
[Pain relief by gabapentin via supraspinal mechanisms in neuropathic conditions].
Topics: Amines; Analgesics; Animals; Brain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid | 2009 |
Lumbar spinal stenosis: a brief review of the nonsurgical management.
Topics: Administration, Intranasal; Alprostadil; Amines; Analgesics, Non-Narcotic; Anesthetics, Local; Anti- | 2010 |
Central sensitization and Ca(V)α₂δ ligands in chronic pain syndromes: pathologic processes and pharmacologic effect.
Topics: Amines; Analgesics; Animals; Calcium Channels; Complex Regional Pain Syndromes; Cyclohexanecarboxyli | 2010 |
Gabapentin for the treatment of cancer-related pain syndromes.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2010 |
An algorithm for the treatment of chronic testicular pain.
Topics: Algorithms; Amines; Analgesics; Anesthetics; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive | 2010 |
Oxycodone combinations for pain relief.
Topics: Acetaminophen; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Aspi | 2010 |
Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis.
Topics: Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Fem | 2010 |
[Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia].
Topics: Amines; Analgesics; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Cyclooxygenase Inhibitors | 2011 |
[Molecular mechanisms and clinical pharmacology of chronic pain].
Topics: Amines; Animals; Anterior Horn Cells; Antidepressive Agents; Brain; Chronic Disease; Cyclohexanecarb | 2010 |
Use of anticonvulsants for treatment of neuropathic pain.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; | 2002 |
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvu | 2003 |
Cellular and molecular action of the putative GABA-mimetic, gabapentin.
Topics: Acetates; Amines; Analgesics; Animals; Anticonvulsants; Anxiety; Brain; Cyclohexanecarboxylic Acids; | 2003 |
The role of gabapentin in treating diseases with cutaneous manifestations and pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2003 |
Gabapentin: a viewpoint by Ian Gilron.
Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2003 |
[Nonorganic pain -- only psychogenic?].
Topics: Acetates; Adult; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Back Pain; Chronic Dise | 2003 |
Gabapentin in the treatment of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2004 |
Post-herpetic neuralgia case study: optimizing pain control.
Topics: Acetates; Aged; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2004 |
80-year-old man with fever and ear pain.
Topics: Acetates; Acyclovir; Age Factors; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyc | 2004 |
[Evidence-based pharmacotherapy of neuropathic pain syndromes].
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Antioxidants; Cyclohexanec | 2004 |
[Progress on painful diabetic peripheral neuropathy treated by integrative medicine].
Topics: Amines; Amitriptyline; Analgesics; Animals; Antidepressive Agents, Tricyclic; Blood Glucose; Cyclohe | 2005 |
Anticonvulsant drugs for acute and chronic pain.
Topics: Acute Disease; Amines; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topic; Cycloh | 2005 |
Gabapentin for acute and chronic pain.
Topics: Acute Disease; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Ga | 2005 |
Combination pharmacotherapy for neuropathic pain: current evidence and future directions.
Topics: Amines; Analgesics; Animals; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Synergism; | 2005 |
The mechanism of action of gabapentin in neuropathic pain.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Binding Sites; Calcium Channels; Cyclohexanecarboxylic Ac | 2006 |
Mechanisms of the antinociceptive action of gabapentin.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Calcium Channels, N-Type; Cyclohexanecarboxylic Acids; | 2006 |
Gabapentin for pain: balancing benefit and harm.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Gabapentin; gamma | 2006 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
alpha2delta and the mechanism of action of gabapentin in the treatment of pain.
Topics: Amines; Analgesics; Animals; Brain; Calcium Channels; Cyclohexanecarboxylic Acids; GABA Modulators; | 2006 |
Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles.
Topics: Administration, Cutaneous; Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents; Arthritis; | 2007 |
Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain.
Topics: Adrenergic Uptake Inhibitors; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tr | 2007 |
Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention, Gabapentin GR.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Diabetic Neuropathies; | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
[Psychopharmacotherapy in psychiatric comorbidities among patients with chronic pain].
Topics: Amines; Analgesics; Anticonvulsants; Bupropion; Chronic Disease; Cyclohexanecarboxylic Acids; Dopami | 2007 |
Use of gabapentin in pain management.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic | 1997 |
A summary of mechanistic hypotheses of gabapentin pharmacology.
Topics: Acetates; Amines; Analgesics; Animals; Anti-Anxiety Agents; Anticonvulsants; Brain; Calcium Channels | 1998 |
Treatment of chronic pain with antiepileptic drugs: a new era.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapen | 1999 |
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu | 1999 |
Interstitial cystitis and the potential role of gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Cystitis, Interstitial; Female; Ga | 2000 |
Gabapentin use in neuropathic pain syndromes.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2000 |
Gabapentin in pain management.
Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric A | 2000 |
[Gabapentin therapy for pain].
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Diabetic Neurop | 2001 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Background and rationale for use of anticonvulsants in psychiatry.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cycloh | 1998 |
Gabapentin. Pfizer.
Topics: Acetates; Amines; Analgesics; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase II | 2002 |
Trials
59 trials available for gabapentin and Ache
| Article | Year |
|---|---|
Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.
Topics: Double-Blind Method; Gabapentin; Head and Neck Neoplasms; Humans; Pain; Quality of Life; Squamous Ce | 2022 |
Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial.
Topics: Dilatation; Double-Blind Method; Female; Fentanyl; Gabapentin; Humans; Midazolam; Nausea; Pain; Pain | 2023 |
Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial.
Topics: Analgesics, Opioid; Gabapentin; Head and Neck Neoplasms; Humans; Mucositis; Pain; Quality of Life; S | 2023 |
A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer.
Topics: Adult; Aged; Analgesics; Chemoradiotherapy; Dose-Response Relationship, Drug; Female; Gabapentin; Hu | 2020 |
Efficacy of gabapentin mouthwash in managing oral mucositis pain in patients undergoing chemotherapy: a prospective, randomised, double-blind, controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Double-Blind Method; Female; Gaba | 2020 |
Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation.
Topics: Chemoradiotherapy; Gabapentin; Head and Neck Neoplasms; Humans; Pain; Prospective Studies | 2020 |
Gabapentin for the Treatment of Vulvodynia: A Randomized Controlled Trial.
Topics: Adult; Analgesics; Cross-Over Studies; Delayed-Action Preparations; Diagnostic Techniques, Obstetric | 2018 |
Pain characterization and response to palliative care in dogs with naturally-occurring appendicular osteosarcoma: An open label clinical trial.
Topics: Amitriptyline; Analgesics; Animals; Bone Neoplasms; Central Nervous System Sensitization; Dog Diseas | 2018 |
Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis.
Topics: Acetaminophen; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Dulox | 2019 |
Is gabapentin effective in dry eye disease and neuropathic ocular pain?
Topics: Adult; Analgesics; Dry Eye Syndromes; Eye Pain; Female; Gabapentin; Humans; Male; Middle Aged; Pain; | 2021 |
Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2014 |
The effect of a combination of gabapentin and donepezil in an experimental pain model in healthy volunteers: Results of a randomized controlled trial.
Topics: Adolescent; Adult; Amines; Analgesics, Non-Narcotic; Cross-Over Studies; Cyclohexanecarboxylic Acids | 2014 |
Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy.
Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Drug Combinatio | 2016 |
Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
Topics: Acetaminophen; Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Carcinoma | 2016 |
A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain.
Topics: Amines; Analgesics; Chromatography, High Pressure Liquid; Cyclohexanecarboxylic Acids; Data Accuracy | 2016 |
Topical gabapentin in the treatment of localized and generalized vulvodynia.
Topics: Administration, Topical; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2008 |
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster.
Topics: Acute Disease; Aged; Amines; Analgesics, Opioid; Clinical Trials as Topic; Cyclohexanecarboxylic Aci | 2009 |
Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Female; Gabapentin | 2010 |
Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; | 2010 |
A fMRI evaluation of lamotrigine for the treatment of trigeminal neuropathic pain: pilot study.
Topics: Adult; Amines; Anticonvulsants; Brain; Cold Temperature; Cross-Over Studies; Cyclohexanecarboxylic A | 2010 |
Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy.
Topics: Acetaminophen; Adult; Aged; Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Diabetes Mellit | 2010 |
[Biological age and the pain syndrome at diabetic polyneuropathy].
Topics: Adult; Aging; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; | 2011 |
Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia.
Topics: Adult; Amines; Anesthesia, Spinal; Anesthesiology; Cyclohexanecarboxylic Acids; Double-Blind Method; | 2011 |
Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial.
Topics: Adult; Amines; Analysis of Variance; Anti-Anxiety Agents; Anxiety; Catastrophization; Cyclohexanecar | 2013 |
Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analysis of Variance; Chi-Square Distribution; Cyc | 2002 |
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.
Topics: Acetates; Adult; Aged; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Method; | 2002 |
Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study.
Topics: Acetates; Adult; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind M | 2002 |
Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Anxiety Agents; Clonidine; Cyclohexanecarboxy | 2003 |
Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
Topics: Acetates; Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Anesthetics, Loca | 2003 |
Gabapentin for painful legs and moving toes syndrome.
Topics: Acetates; Aged; Amines; Cyclohexanecarboxylic Acids; Electromyography; Excitatory Amino Acid Antagon | 2004 |
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me | 2004 |
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me | 2004 |
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me | 2004 |
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me | 2004 |
Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion.
Topics: Acetates; Adult; Aged; Amines; Chi-Square Distribution; Cyclohexanecarboxylic Acids; Depression; Dos | 2004 |
Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379].
Topics: Adult; Aged; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2004 |
Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. preliminary results.
Topics: Activities of Daily Living; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropat | 2004 |
Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin.
Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; | 2005 |
The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit.
Topics: Adult; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Carbamazepine; Conscious Sedation; Crit | 2005 |
Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans.
Topics: Adult; Amines; Analgesics; Analysis of Variance; Capsaicin; Central Nervous System; Cross-Over Studi | 2005 |
Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study.
Topics: Aged; Amines; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Dose-Response Relations | 2005 |
CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.
Topics: Adult; Amines; Analgesics; Capsaicin; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind | 2006 |
A randomized study of the effects of gabapentin on postamputation pain.
Topics: Aged; Amines; Amputation Stumps; Amputation, Surgical; Analgesics; Cyclohexanecarboxylic Acids; Fema | 2006 |
Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia.
Topics: Adult; Amines; Analgesics; Anesthesia, Conduction; Anesthesia, Intravenous; Cyclohexanecarboxylic Ac | 2007 |
[The tebantin use in the complex therapy of pain syndrome during the mixed forms of alcoholic polyneuropathy].
Topics: Alcoholic Neuropathy; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fe | 2006 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
Topics: Amines; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Double-Blind Meth | 2007 |
Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury.
Topics: Adult; Aged; Amines; Amitriptyline; Analgesics; Analysis of Variance; Antidepressive Agents, Tricycl | 2007 |
The effect of gabapentin on neuropathic pain.
Topics: Acetates; Adolescent; Adult; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Gabapentin; gam | 1997 |
Open label gabapentin treatment for pain in multiple sclerosis.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gab | 1997 |
Gabapentin for treatment of pain and tremor: a large case series.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Arachnoiditis; Cerebellar Neoplasms; Cyc | 1998 |
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; D | 1998 |
Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Diabetic Neuropathies | 1999 |
Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain.
Topics: Acetates; Adrenergic Uptake Inhibitors; Aged; Amines; Amitriptyline; Analgesics; Cross-Over Studies; | 1999 |
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu | 1999 |
Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.
Topics: Acetates; Amines; Anticonvulsants; Circadian Rhythm; Cyclohexanecarboxylic Acids; Gabapentin; gamma- | 2000 |
Gabapentin therapy for diabetic neuropathic pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Double-Blind Metho | 2000 |
Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Ataxia; Cyclohexanecarboxylic | 2000 |
Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain.
Topics: Acetates; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Cystitis, Interstit | 2001 |
Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study.
Topics: Acetates; Adolescent; Amines; Analgesics; Antineoplastic Agents; Cyclohexanecarboxylic Acids; Female | 2002 |
Other Studies
291 other studies available for gabapentin and Ache
| Article | Year |
|---|---|
Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury.
Topics: Amines; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal | 2004 |
Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels.
Topics: Amino Acids; Animals; Benzene; Calcium Channel Blockers; Calcium Channels; Ligands; Molecular Struct | 2006 |
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; gamma-Aminobutyric Acid; Hyperalgesia; | 2007 |
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Topics: Action Potentials; Analgesics; Aniline Compounds; Animals; Capsaicin; Evoked Potentials; Furans; Gan | 2007 |
Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
Topics: Amines; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Histamine Antagonists; Ligands; M | 2008 |
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
Topics: Analgesics; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Fluoxetine; Formaldehyde; gam | 2009 |
Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective
Topics: Administration, Oral; Analgesics; Animals; Cell Line; Drug Tolerance; Fluoroquinolones; Humans; In V | 2010 |
Part 3: Design and synthesis of proline-derived α2δ ligands.
Topics: Animals; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Molecular Structure; Pain; Proli | 2011 |
New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo.
Topics: Analgesics; Animals; Binding, Competitive; Cyclic AMP; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP | 2013 |
Gabapentin hybrid peptides and bioconjugates.
Topics: Acylation; Amines; Analgesics; Animals; Behavior, Animal; Crystallography, X-Ray; Cyclization; Cyclo | 2014 |
Antinociceptive Grayanoids from the Roots of Rhododendron molle.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Diterpenes; Drugs, | 2015 |
Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP
Topics: Animals; Anti-Inflammatory Agents; Blood Cells; Dinoprostone; Drug Evaluation, Preclinical; Half-Lif | 2018 |
Circadian rhythmicity on red ear syndrome in a patient with migraine: A case report.
Topics: Adult; Circadian Rhythm; Ear; Erythema; Female; Gabapentin; Humans; Migraine Disorders; Pain; Parest | 2021 |
Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses.
Topics: Administration, Oral; Animals; Area Under Curve; Female; Gabapentin; Horses; Pain | 2022 |
The Burning Question: Prophylactic Gabapentin for Mucositis-Related Pain in Patients Undergoing Chemoradiation Therapy for Head and Neck Cancer?
Topics: Chemoradiotherapy; Gabapentin; Head and Neck Neoplasms; Humans; Mucositis; Pain | 2022 |
Rate-Dependent Depression: A Predictor of the Therapeutic Efficacy in Treating Painful Diabetic Peripheral Neuropathy.
Topics: Depression; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Gabapentin; Humans; Pain | 2022 |
Effects of Preoperative Gabapentin on Clinical Outcomes After Outpatient Midurethral Sling Placement.
Topics: Female; Gabapentin; Humans; Male; Outpatients; Pain; Retrospective Studies; Suburethral Slings; Urin | 2022 |
Association of Gabapentin Use With Pain Control and Feeding Tube Placement Among Patients With Head and Neck Cancer Receiving Chemoradiotherapy.
Topics: Chemoradiotherapy; Gabapentin; Head and Neck Neoplasms; Humans; Intubation, Gastrointestinal; Pain | 2022 |
Functional Impairment and Cognitive Symptoms Among People with HIV Infection on Chronic Opioid Therapy for Pain: The Impact of Gabapentin and Other Sedating Medications.
Topics: Analgesics, Opioid; Chronic Pain; Cognition; Cross-Sectional Studies; Gabapentin; HIV Infections; Hu | 2022 |
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy.
Topics: Amines; Analgesics; Cardiovascular Diseases; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gab | 2022 |
Persistent sensory changes and sex differences in transgenic mice conditionally expressing HIV-1 Tat regulatory protein.
Topics: Animals; Cryopyrin-Associated Periodic Syndromes; Doxycycline; Female; Gabapentin; Gene Products, ta | 2022 |
Antiepileptic prescribing to persons living with dementia residing in nursing homes: A tale of two indications.
Topics: Aged; Alzheimer Disease; Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Gabapentin; Huma | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Characterization of Outpatient Gabapentinoid Prescribing for Pain.
Topics: Adult; Amines; Analgesics; Gabapentin; Humans; Outpatients; Pain; Pregabalin; Retrospective Studies | 2023 |
In Response to Regarding: Postoperative Gabapentin's Effect on Opioid Consumption and Pain Control Following Sinonasal Surgery.
Topics: Amines; Analgesics, Opioid; Gabapentin; Humans; Pain; Pain Management | 2023 |
Postoperative Gabapentin's Effect on Opioid Consumption and Pain Control Following Sinonasal Surgery.
Topics: Amines; Analgesics, Opioid; Gabapentin; Humans; Pain; Pain Management; Pain, Postoperative | 2023 |
Prescribing Trends of Antiseizure Drugs in Women Veterans With Epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Gabapentin; Humans; Lamotrigine; Levetiracetam | 2023 |
Fighting pain: the structure of gabapentin and its binding site in the Ca
Topics: Binding Sites; Calcium Channels; Gabapentin; Humans; Pain; Protein Domains | 2023 |
Drug-resistant epicrania fugax: Responding to onabotulinumtoxinA.
Topics: Botulinum Toxins, Type A; Gabapentin; Headache; Headache Disorders; Humans; Pain | 2023 |
[Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway].
Topics: Animals; Gabapentin; Interleukin-6; Male; MAP Kinase Signaling System; Metformin; Mice; Mice, Inbred | 2023 |
Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers.
Topics: Analgesics; Florida; Gabapentin; Health Personnel; Humans; Interviews as Topic; Off-Label Use; Pain; | 2019 |
An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user.
Topics: Adult; Anthropology, Cultural; Decision Theory; Drug Users; Female; Gabapentin; Humans; Male; Opioid | 2019 |
Gabapentinoids for Pain: Potential Unintended Consequences.
Topics: Analgesics; Chronic Pain; Drug Misuse; Gabapentin; Humans; Pain; Practice Guidelines as Topic; Prega | 2019 |
Concomitant Use of Gabapentinoids with Opioids Is Associated with Increased Mortality and Morbidity among Dialysis Patients.
Topics: Adult; Aged; Analgesics, Opioid; Cause of Death; Drug Prescriptions; Female; Gabapentin; Hospitaliza | 2020 |
Raynaud phenomenon of the nipple successfully treated with nifedipine and gabapentin.
Topics: Adult; Breast Diseases; Breast Feeding; Female; Gabapentin; Humans; Nifedipine; Nipples; Pain; Rayna | 2020 |
A COVID-19 patient with intense burning pain.
Topics: Acetaminophen; Analgesics; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome; Back Pain; | 2020 |
Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians.
Topics: Acetaminophen; Advance Care Planning; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Analgesic | 2020 |
Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries.
Topics: Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Cross-Sectional Studies; Drug Utilization; | 2021 |
A pilot study of transdermal gabapentin in cats.
Topics: Administration, Cutaneous; Animals; Cats; Gabapentin; Pain; Pilot Projects | 2021 |
Gabapentin in Infants: Critical Evaluation of a Novel Sedative/Analgesic Medication.
Topics: Adult; Analgesics; Gabapentin; Humans; Hypnotics and Sedatives; Infant; Infant, Newborn; Intensive C | 2021 |
Gabapentinoid Dosing and Associated Toxicities in Patients With or Without Concomitant Opioids During Hospitalization.
Topics: Adult; Analgesics; Analgesics, Opioid; Gabapentin; Hospitalization; Humans; Pain; Pregabalin | 2022 |
A pilot feasibility study of gabapentin for managing pain in children with dystonic cerebral palsy.
Topics: Adolescent; Australia; Cerebral Palsy; Child; Child, Preschool; Feasibility Studies; Female; Gabapen | 2021 |
Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.
Topics: Adult; Aged; Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studi | 2017 |
A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.
Topics: Adult; Analgesics; Drug Users; Female; Gabapentin; Humans; Kentucky; Longitudinal Studies; Male; Off | 2018 |
Shingles in Pregnancy: An Elusive Case of Left Upper Quadrant Abdominal Pain.
Topics: Abdominal Pain; Analgesics; Antiviral Agents; Female; Gabapentin; Gynecological Examination; Hawaii; | 2018 |
Peer-reviewed homeopathy study sparks uproar in Italy.
Topics: Animals; Dissent and Disputes; Gabapentin; Homeopathy; Humans; Inflammation; Italy; Pain; Peer Revie | 2018 |
Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD.
Topics: Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Drug Utilization; Female; G | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Beyond Opioids for Pain Management in Adult Critically Ill Patients.
Topics: Acetaminophen; Adrenergic alpha-2 Receptor Agonists; Adult; Analgesia; Analgesics; Analgesics, Non-N | 2019 |
Falling Dominoes.
Topics: Accidental Falls; Adolescent; Child; Gabapentin; Humans; Pain; Pregabalin | 2019 |
Successful treatment of refractory dermal pain with etizolam and clonazepam in a patient with acquired idiopathic generalized anhidrosis.
Topics: Adult; Biopsy; Clonazepam; Diazepam; Drug Resistance; Drug Therapy, Combination; Gabapentin; Glucoco | 2019 |
Gabapentin for pain, movement disorders, and irritability in neonates and infants.
Topics: Analgesics; Female; Gabapentin; Humans; Infant; Infant, Newborn; Intensive Care Units, Neonatal; Mal | 2020 |
Comment on "Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis".
Topics: Analgesics; Duloxetine Hydrochloride; Gabapentin; Humans; Osteoarthritis, Knee; Pain | 2019 |
A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning.
Topics: Amines; Analgesics; Animals; Area Under Curve; Cattle; Clonixin; Cyclohexanecarboxylic Acids; Dinopr | 2013 |
Antihyperalgesic activity of a novel synthesized analogue of lidocaine in diabetic rats.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Diabetes Complications; | 2013 |
Chronic unilateral eruption of painful, erythematous papules and nodules. Piloleiomyoma.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2013 |
Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain.
Topics: Amines; Analgesics; Animals; Computer Simulation; Cyclohexanecarboxylic Acids; Dose-Response Relatio | 2014 |
Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment.
Topics: Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Baclofen; Carbamazepine; Clinical Proto | 2014 |
Effect of gabapentin on swallowing during and after chemoradiation for oropharyngeal squamous cell cancer.
Topics: Amines; Analgesics; Carcinoma, Squamous Cell; Chemoradiotherapy; Cyclohexanecarboxylic Acids; Deglut | 2014 |
Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy.
Topics: Amines; Analgesics; Animals; Biomarkers; Cyclohexanecarboxylic Acids; Dopamine; Gabapentin; gamma-Am | 2014 |
Effects of NB001 and gabapentin on irritable bowel syndrome-induced behavioral anxiety and spontaneous pain.
Topics: Adenosine Triphosphate; Amines; Animals; Anxiety; Behavior, Animal; Cyclohexanecarboxylic Acids; Gab | 2014 |
Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?
Topics: Aged; Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chemotherapy, Adjuvant; C | 2015 |
Development and pharmacological characterization of a model of sleep disruption-induced hypersensitivity in the rat.
Topics: Amines; Animals; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapenti | 2015 |
Comparison of the effects of gabapentin and pregabalin on wound healing in rats.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Human | 2016 |
Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non-diabetic patients.
Topics: Amines; Analgesics; Blood Glucose; Cyclohexanecarboxylic Acids; Diabetes Mellitus; Gabapentin; gamma | 2015 |
In vivo two-photon imaging of structural dynamics in the spinal dorsal horn in an inflammatory pain model.
Topics: Acute Disease; Amines; Animals; Calcium Channel Blockers; Calcium Channels; Cyclohexanecarboxylic Ac | 2015 |
Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis.
Topics: Adolescent; Adult; Amines; Analgesics; Central Nervous System Diseases; Child; Child, Preschool; Cyc | 2015 |
Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats.
Topics: Adjuvants, Immunologic; Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxy | 2015 |
Chronic progressive polyarthritis in a domestic shorthair cat.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Buprenorphine; Cat Diseases; Cats; | 2015 |
The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Prep | 2016 |
Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model.
Topics: Administration, Cutaneous; Aged; Amines; Baclofen; Clonidine; Cyclohexanecarboxylic Acids; Drug Comp | 2016 |
Pharmacological characterization of intraplantar Complete Freund's Adjuvant-induced burrowing deficits.
Topics: Amines; Analgesics; Animals; Antibodies; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; D | 2016 |
Analysis of the behavioral, cellular and molecular characteristics of pain in severe rodent spinal cord injury.
Topics: Amines; Animals; Calcitonin Gene-Related Peptide; Calcium-Binding Proteins; Carbenoxolone; Connexin | 2016 |
Painless legs and moving toes syndrome associated with a sacral Tarlov cyst: a case report.
Topics: Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Dyskinesias; Female; Gabapentin; gamma-Am | 2016 |
Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target.
Topics: Amines; Amitriptyline; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; Gai | 2016 |
sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.
Topics: Amides; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin | 2017 |
An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Functional Lateral | 2017 |
Gabapentin for breakthrough pain due to bone metastases.
Topics: Amines; Analgesics; Bone Neoplasms; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid | 2008 |
Antinociceptive action of GLYX-13: an N-methyl-D-aspartate receptor glycine site partial agonist.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2008 |
Gabapentin toxicity in renal failure: the importance of dose adjustment.
Topics: Acute Kidney Injury; Aged; Amines; Animals; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A | 2009 |
The interaction of gabapentin and N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on mechanical allodynia in rats with a spinal nerve ligation.
Topics: Adenosine; Amines; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Syne | 2008 |
FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Diabetic | 2008 |
Multiplicative interactions to enhance gabapentin to treat neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Donepezil; Dose-Response Relationship, Dru | 2008 |
Is there a role for anticonvulsants in the management of rheumatic pain?
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Am | 2008 |
Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats.
Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Cold Temperature; Cyclohexanecarb | 2009 |
Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats.
Topics: Amines; Analgesics; Animals; Astrocytes; Cell Count; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2009 |
Neuropathic pain in children after exposure to mercury.
Topics: Amines; Analgesics, Non-Narcotic; Burning Mouth Syndrome; Child; Cyclohexanecarboxylic Acids; Gabape | 2008 |
A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling.
Topics: Adult; Aged; Algorithms; Amines; Area Under Curve; Bayes Theorem; Biological Availability; Cyclohexa | 2009 |
Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; | 2009 |
Intrathecal gabapentin does not act as a hyperpolarization-activated cyclic nucleotide-gated channel activator in the rat formalin test.
Topics: Amines; Analgesics; Animals; Cardiotonic Agents; Cyclic Nucleotide-Gated Cation Channels; Cyclohexan | 2009 |
Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit.
Topics: Administration, Oral; Amines; Analgesics, Non-Narcotic; Animals; Antineoplastic Agents; Antineoplast | 2009 |
A mouse model of sural nerve injury-induced neuropathy: gabapentin inhibits pain-related behaviors and the hyperactivity of wide-dynamic range neurons in the dorsal horn.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Cold Temperature; Cyclohexanecarboxylic | 2009 |
Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Cyclopentanes; Diabetes Mellitus, Experime | 2009 |
Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Drug Synergism; Gabapent | 2009 |
Gabapentin therapy for chronic proctalgia following stapled haemorrhoidopexy.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hemorrhoids; H | 2009 |
Protein kinase A-dependence of the supraspinally mediated analgesic effects of gabapentin on thermal and mechanical hypersensitivity.
Topics: Amines; Analgesics; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclohexanecarboxylic Acids; Dose | 2009 |
How does gabapentin relieve neuropathic pain?
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pain; | 2009 |
Moving from tube to oral feeding in medically fragile nonverbal toddlers.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Appetite Regulation; Appetite Stimulants; Chil | 2009 |
Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.
Topics: Adolescent; Adult; Amines; Calcium Channel Blockers; Carbamazepine; Cyclohexanecarboxylic Acids; Dru | 2009 |
Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Deglutition Disorders; Dose-Response Relationship, | 2010 |
Gabapentin therapy for pain and irritability in a neurologically impaired infant.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Infant | 2009 |
Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models.
Topics: Amines; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Axotomy; Carrageenan; | 2009 |
A case of perineal pain related to interstitial cystitis which was supposed to be relieved with gabapentin.
Topics: Amines; Analgesics; Anesthetics, Local; Cyclohexanecarboxylic Acids; Cystitis, Interstitial; Cystosc | 2009 |
Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker.
Topics: Administration, Oral; Amines; Analgesics; Animals; Calcium Channel Blockers; Calcium Channels, N-Typ | 2009 |
Outcome reporting in industry-sponsored trials of gabapentin for off-label use.
Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu | 2009 |
Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study.
Topics: Aged; Amines; Analgesics; Analgesics, Opioid; Chronic Disease; Cyclohexanecarboxylic Acids; Female; | 2010 |
Tri-partite complex for axonal transport drug delivery achieves pharmacological effect.
Topics: Amines; Analgesics; Animals; Axonal Transport; Cell Line; Cells, Cultured; Cricetinae; Cyclohexaneca | 2010 |
Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy.
Topics: Aged; Amines; Analgesics; Cohort Studies; Cyclohexanecarboxylic Acids; Data Interpretation, Statisti | 2010 |
Syringomyelia in the Cavalier King Charles spaniel (CKCS) dog.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arnold-Chiari Malformation; Breeding; Cyclohe | 2010 |
Analgesic effects of gabapentin on mechanical hypersensitivity in a rat model of chronic pancreatitis.
Topics: Amines; Analgesics; Animals; Calcium Channels; Calcium Channels, L-Type; Cyclohexanecarboxylic Acids | 2010 |
Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
Topics: Amines; Analgesics, Opioid; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ex | 2010 |
Selective potentiation of gabapentin-mediated antinociception in the rat formalin test by the nicotinic acetylcholine receptor agonist ABT-594.
Topics: Amines; Analgesics; Animals; Azetidines; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-R | 2010 |
Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy.
Topics: Amines; Analgesics; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2010 |
Lack of analgesic efficacy of spinal ondansetron on thermal and mechanical hypersensitivity following spinal nerve ligation in the rat.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapen | 2010 |
Characterization of the acute and persistent pain state present in K/BxN serum transfer arthritis.
Topics: Activating Transcription Factor 3; Amines; Analgesics; Analysis of Variance; Animals; Arthritis, Rhe | 2010 |
[Disease with generalized pain. Guillain-Barré syndrome].
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Female; Gabapentin; | 2011 |
Painful traumatic neuroma of the tongue treated with serial alcohol injections.
Topics: Aged; Amines; Analgesics; Anesthetics, Local; Central Nervous System Depressants; Cyclohexanecarboxy | 2011 |
Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Drug Approval; Drug Label | 2011 |
Chronic Lyme disease: the controversies and the science.
Topics: Amines; Analgesics; Anti-Bacterial Agents; Arthritis, Rheumatoid; Borrelia burgdorferi; Chronic Dise | 2011 |
Gabapentin as part of multi-modal analgesia in two cats suffering multiple injuries.
Topics: Amines; Analgesia; Analgesics; Animals; Buprenorphine; Cat Diseases; Cats; Cyclohexanecarboxylic Aci | 2011 |
Accounting for perception, placebo and unmasking effects in estimating treatment effects in randomised clinical trials.
Topics: Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Pain | 2014 |
Successful treatment of tabetic lightning pain and visceral crisis with gabapentin.
Topics: Amines; Cyclohexanecarboxylic Acids; Extremities; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; | 2011 |
Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Databases, Factual; Diabetic Nephropathies; F | 2012 |
The combined predictive capacity of rat models of algogen-induced and neuropathic hypersensitivity to clinically used analgesics varies with nociceptive endpoint and consideration of locomotor function.
Topics: Amines; Analgesics; Animals; Capsaicin; Cyclohexanecarboxylic Acids; Disease Models, Animal; Duloxet | 2012 |
Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Cyclohexanec | 2012 |
Temperature-dependent enhancement of the antinociceptive effects of opioids in combination with gabapentin in mice.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gam | 2012 |
Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats.
Topics: Amines; Animals; Arthritis; Calcium Channels, L-Type; Chemokine CX3CL1; CX3C Chemokine Receptor 1; C | 2012 |
Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes.
Topics: Amines; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Dia | 2012 |
Non-surgical therapy for bilateral glossopharyngeal neuralgia caused by Eagle's syndrome, diagnosed by three-dimensional computed tomography: a case report.
Topics: Aged; Amines; Analgesics; Anesthetics, Local; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu | 2012 |
Antinociceptive effects of gabapentin & its mechanism of action in experimental animal studies.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dinoprostone; Gabapentin; gamma-Aminobutyr | 2012 |
Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment.
Topics: Amines; Analgesics; Apnea; Central Nervous System; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2013 |
Positive allosteric modulation of GABA-A receptors reduces capsaicin-induced primary and secondary hypersensitivity in rats.
Topics: Amines; Analgesics, Opioid; Animals; Behavior, Animal; Benzimidazoles; Capsaicin; Cyclohexanecarboxy | 2012 |
Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model.
Topics: Amines; Animals; Antioxidants; Calcium Channels; Catalase; Cyclohexanecarboxylic Acids; Drug Combina | 2013 |
Mandatory palliative care education for surgical residents: initial focus on teaching pain management.
Topics: Adult; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Curriculum; | 2013 |
Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Calcium Channels; Cyclohexanecarboxylic Aci | 2002 |
Gabapentin for coeliac plexus pain.
Topics: Acetates; Aged; Amines; Analgesics; Celiac Plexus; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2002 |
Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy.
Topics: Acetates; Amines; Analgesics; Animals; Anticonvulsants; Calcium Channel Blockers; Cyclohexanecarboxy | 2002 |
SUNCT responsive to gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Conjunctiva; Cyclohexanecarboxylic Acids; Female; Gabapentin; g | 2002 |
Central post-stroke pain syndrome: yet another use for gabapentin?
Topics: Acetates; Activities of Daily Living; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxyli | 2002 |
Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception.
Topics: Acetates; Acute Disease; Adrenergic alpha-Agonists; Amines; Analgesics, Non-Narcotic; Analgesics, Op | 2002 |
Is gabapentin a "Broad-spectrum" analgesic?
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2002 |
Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain.
Topics: Acetates; Amines; Animals; Benzofurans; Carbamates; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2002 |
Anti-allodynic action of the tormentic acid, a triterpene isolated from plant, against neuropathic and inflammatory persistent pain in mice.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Freund' | 2002 |
Cavernous angioma in the brachium pontis presenting with trigeminal neuralgia: a case report.
Topics: Acetates; Amines; Analgesics; Central Nervous System Vascular Malformations; Cyclohexanecarboxylic A | 2002 |
Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia.
Topics: Acetates; Adrenergic Uptake Inhibitors; Amines; Aminopyridines; Analgesia; Analgesics; Animals; Cell | 2002 |
Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin.
Topics: Acetates; Amines; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Dis | 2002 |
Lumbar spinal cord stimulation for cervical-originated central pain: a case report.
Topics: Acetates; Amines; Antidepressive Agents, Tricyclic; Cervical Vertebrae; Cyclohexanecarboxylic Acids; | 2002 |
Gabapentin markedly reduces acetic acid-induced visceral nociception.
Topics: Acetates; Amines; Analgesics; Animals; Calcium; Cyclohexanecarboxylic Acids; Excitatory Amino Acids; | 2003 |
[Recognizing the "neck-tongue" syndrome].
Topics: Acetates; Amines; Analgesics; Analgesics, Non-Narcotic; Arthritis; Cervical Vertebrae; Cyclohexaneca | 2003 |
Suppression by gabapentin of pain-related mechano-responses in mice given orthotopic tumor inoculation.
Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hyperal | 2003 |
[Case report on a patient with SUNCT-syndrome].
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Functional Laterality; Gabapentin | 2003 |
Complete vasomotor collapse: an unusual manifestation of the carotid sinus reflex.
Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapenti | 2003 |
Gabapentin blocks and reverses antinociceptive morphine tolerance in the rat paw-pressure and tail-flick tests.
Topics: Acetates; Amines; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2003 |
An East-West approach to the management of central post-stroke pain.
Topics: Acetates; Acupuncture; Aged; Amines; Amitriptyline; Analgesics, Opioid; Antidepressive Agents, Secon | 2003 |
ATP-sensitive potassium channels in rat primary afferent neurons: the effect of neuropathic injury and gabapentin.
Topics: Acetates; Amines; Animals; ATP-Binding Cassette Transporters; Basal Ganglia; Cyclohexanecarboxylic A | 2003 |
The trend to move palliative care upstream.
Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H | 2003 |
Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Herpes Z | 2003 |
[Effect of anticonvulsant gabapentin on visceral nociception and its relationship with amino acid neurotransmitters released from spinal cord].
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, | 2003 |
Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain.
Topics: Acetates; Amines; Analgesics; Animals; Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Edema; | 2003 |
[Unclear chronic aches. Often depression plays a part therein].
Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Age | 2003 |
[Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus].
Topics: Acetates; Aged; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ty | 2003 |
The pattern of gabapentin use in a tertiary palliative care unit.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; G | 2003 |
Treatment of neuropathic orbital pain with gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Eye Diseases; Female; Gabapen | 2003 |
Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited.
Topics: Acetates; Amines; Analgesia; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; | 2003 |
The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.
Topics: Acetates; Amines; Analgesics; Chronic Disease; Clinical Trials, Phase II as Topic; Computer Simulati | 2003 |
A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury.
Topics: Acetates; Amines; Animals; Aorta, Thoracic; Behavior, Animal; Cyclic GMP; Cyclohexanecarboxylic Acid | 2004 |
Myoclonic jerks associated with gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut | 2003 |
Synergistic interaction between spinal gabapentin and oral B vitamins in a neuropathic pain model.
Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug | 2003 |
Reduction by gabapentin of K+-evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat.
Topics: Acetates; Amines; Animals; Blood Glucose; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experiment | 2004 |
Painful neuropathy alters the effect of gabapentin on sensory neuron excitability in rats.
Topics: Acetates; Action Potentials; Amines; Analgesics; Analysis of Variance; Animals; Calcium Channels; Cy | 2004 |
Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, A | 2004 |
Vulvodynia.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Biofeedback, Psychology; Chroni | 2004 |
Gabapentin (Neurontin) for chronic pain.
Topics: Acetates; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Costs; Drug Interac | 2004 |
The use of gabapentin in a 12-year-old boy with cancer pain.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Child; Cyclohexanecarboxylic Acids; Dose-Response | 2004 |
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.
Topics: Acetates; Amines; Anticonvulsants; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic Acids; G | 2004 |
Profiles in patient safety: when an error occurs.
Topics: Acetates; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropath | 2004 |
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cycl | 2004 |
Future Pain Drugs - Europe 2003. 15-16 September 2003, London, UK.
Topics: Acetaminophen; Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, A | 2003 |
Differential analgesic sensitivity of two distinct neuropathic pain models.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Animals; Cold Temperature; Cyclohexanecarboxylic A | 2004 |
Treatment of bath PUVA-induced skin pain with gabapentin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; | 2004 |
Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model.
Topics: Acetates; Acute Disease; Amines; Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Bradykin | 2004 |
Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents.
Topics: Adrenergic Uptake Inhibitors; Amines; Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Age | 2005 |
[Gabapentin (Neurontin) and cancer pain: a pilot study].
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2004 |
Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Bone Neoplasms; Cell Line, Tumor; Cyclohexanecarboxyl | 2005 |
Analysis of interactions between serotonin and gabapentin or adenosine in the spinal cord of rats.
Topics: Adenosine; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dru | 2005 |
Neutropenia occurring after starting gabapentin for neuropathic pain.
Topics: Adenocarcinoma; Amines; Analgesics; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Gab | 2004 |
Gabapentin-induced myoclonus in end-stage renal disease.
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2005 |
Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action.
Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Benzylamines; Chronic Disease; Cyclohexanecarb | 2005 |
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anxiety; Ataxia; Behavior, Ani | 2005 |
The effect of antinociceptive drugs tested at different times after nerve injury in rats.
Topics: Amines; Analgesics; Animals; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Dose-Res | 2005 |
Computed tomography guided lumbar sympathetic block for complex regional pain syndrome in a child: a case report and review.
Topics: Amines; Amitriptyline; Analgesics; Anesthetics, Local; Antidepressive Agents, Tricyclic; Autonomic N | 2006 |
Characterization of pain and pharmacologic responses in an animal model of lumbar adhesive arachnoiditis.
Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Arachnoiditis; Behavior, Animal; Cauda Equina; Cycl | 2005 |
CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats.
Topics: Administration, Oral; Amines; Analgesics; Animals; Behavior, Animal; Capsaicin; Cyclohexanecarboxyli | 2005 |
Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.
Topics: Amines; Analgesics; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Bupropio | 2005 |
Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin.
Topics: Action Potentials; Amines; Analgesics; Analysis of Variance; Animals; Behavior, Animal; Cell Count; | 2005 |
Development and expression of neuropathic pain in CB1 knockout mice.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2006 |
Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain.
Topics: Ambroxol; Amines; Analgesics; Animals; Behavior, Animal; Constriction, Pathologic; Cyclohexanecarbox | 2005 |
The effects of diacerhein on mechanical allodynia in inflammatory and neuropathic models of nociception in mice.
Topics: Amines; Animals; Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; Cyclohexanecarboxylic Acid | 2005 |
The nitric oxide-cyclic GMP-protein kinase G-K+ channel pathway participates in the antiallodynic effect of spinal gabapentin.
Topics: Amines; Analgesics; Animals; Apamin; Carbazoles; Charybdotoxin; Cyclic GMP; Cyclic GMP-Dependent Pro | 2006 |
Motor cortex stimulation for central pain following a traumatic brain injury.
Topics: Accidental Falls; Adult; Amines; Amitriptyline; Analgesics, Non-Narcotic; Aphasia, Broca; Brain Inju | 2006 |
Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin.
Topics: Amines; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Blotting, Western; Calcium Cha | 2006 |
Gabapentin may cause reversible visual field constriction.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans | 2006 |
Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Cyclohexanols; Dose-Response Relationship, | 2006 |
Does acute pain associated with herpes zoster respond to treatment with gabapentin?
Topics: Acute Disease; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Met | 2006 |
Gabapentin enhances the analgesic response to morphine in acute model of pain in male rats.
Topics: Amines; Analgesics, Opioid; Animals; Area Under Curve; Cyclohexanecarboxylic Acids; Disease Models, | 2006 |
Effects of gabapentin on morphine consumption and pain in severely burned patients.
Topics: Administration, Oral; Amines; Analgesics; Burns; Case-Control Studies; Cyclohexanecarboxylic Acids; | 2007 |
Bilateral hemifacial spasm and trigeminal neuralgia: a unique form of painful tic convulsif.
Topics: Aged; Amines; Amitriptyline; Analgesics; Arachnoid Cysts; Botulinum Toxins, Type A; Cyclohexanecarbo | 2007 |
Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury.
Topics: Amines; Analgesics; Animals; Chromatography, High Pressure Liquid; Cyclohexanecarboxylic Acids; Gaba | 2007 |
Painful pemphigus vulgaris.
Topics: Administration, Cutaneous; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Fentanyl; Gabapen | 2007 |
A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Cold Temperature; Cyclohexanecarboxylic Acids; Disease | 2007 |
Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UK.
Topics: Amidohydrolases; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2007 |
Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF.
Topics: Acetamides; Amines; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Excitatory Amino Acid An | 2007 |
Isobolographic analyses of the gabapentin-metamizol combination after local peripheral, intrathecal and oral administration in the rat.
Topics: Administration, Cutaneous; Administration, Oral; Amines; Analgesics; Animals; Cyclohexanecarboxylic | 2007 |
Evaluation of gabapentin in the treatment of generalized vulvodynia, unprovoked.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Ad | 2007 |
Pregabalin and duloxetine for the treatment of neuropathic pain disorders.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Duloxetine Hydrochloride; Ga | 2007 |
Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil.
Topics: Administration, Oral; Amines; Analgesics; Animals; Cholinesterase Inhibitors; Cyclohexanecarboxylic | 2007 |
The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy.
Topics: Amides; Amines; Animals; Behavior, Animal; Camphanes; Cyclohexanecarboxylic Acids; Dose-Response Rel | 2007 |
Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Calcium Channel Blockers; Chronic Disease; Cycloh | 2007 |
Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice.
Topics: Acetic Acid; Amines; Analgesics; Analgesics, Opioid; Analysis of Variance; Animals; Cyclohexanecarbo | 2008 |
Transient allodynia pain models in mice for early assessment of analgesic activity.
Topics: Adrenergic alpha-Antagonists; Amines; Amitriptyline; Analgesics; Animals; Clonidine; Cyclohexanecarb | 2008 |
Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005.
Topics: Adolescent; Adult; Age Distribution; Aged; Amines; Anticonvulsants; Carbamazepine; Catchment Area, H | 2007 |
Acupuncture, ketamine and piriformis syndrome--a case report from palliative care.
Topics: Acupuncture Therapy; Amines; Analgesics; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Gab | 2007 |
Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures.
Topics: Acute Disease; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic | 2007 |
Gestational trophoblastic disease with painful skin metastases.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Fatal Outcome; Female; Gabapentin; gamma-Ami | 2008 |
Gabapentin for painful legs and moving toes syndrome.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2007 |
Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice.
Topics: Amines; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclohexanecarboxylic Acids; Efferent Pathway | 2008 |
Regions of interest analysis in pharmacological fMRI: how do the definition criteria influence the inferred result?
Topics: Adult; Amines; Analgesics; Brain; Capsaicin; Cyclohexanecarboxylic Acids; Echo-Planar Imaging; Gabap | 2008 |
Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study.
Topics: Administration, Oral; Amines; Analgesics; Animals; Blood Pressure; Brain; Brain Mapping; Cyclohexane | 2008 |
Mercury intoxication and neuropathic pain.
Topics: Adolescent; Amines; Analgesics, Opioid; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Female | 2008 |
Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patient-reported outcomes measures.
Topics: Amines; Analgesics; Cohort Studies; Cyclohexanecarboxylic Acids; Data Interpretation, Statistical; G | 2008 |
Successful use of gabapentin in acute pain management following burn injury: a case series.
Topics: Adult; Amines; Analgesics; Burns; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyri | 2008 |
Gabapentin therapy for painful, blind glaucomatous eye: case report.
Topics: Aged; Amines; Analgesics; Blindness; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2008 |
The use of gabapentin for recurrent painful attacks with multiple piloleiomyomas.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Leiomy | 2008 |
Pharmacological treatment of neuropathic pain in older persons.
Topics: Aged; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Chronic Disease | 2008 |
Urinary and rectal incontinence during gabapentin therapy.
Topics: Aged; Amines; Anticonvulsants; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Fecal In | 2008 |
Antinociceptive activity of the S1P-receptor agonist FTY720.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Fingolim | 2008 |
The antinociceptive effects of anticonvulsants in a mouse visceral pain model.
Topics: Acetic Acid; Amines; Analgesics; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Cyclohex | 2008 |
Postpoliomyelitis pain treated with gabapentin.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Ac | 1996 |
Erythromelalgia pain managed with gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Erythromelalgia; Female; Ga | 1997 |
Spinal gabapentin is antinociceptive in the rat formalin test.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, | 1997 |
The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain.
Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Anticonvulsants; Chronic Disease; Cyclohexanec | 1997 |
Gabapentin for idiopathic trigeminal neuralgia: report of two cases.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapent | 1997 |
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut | 1997 |
Pain in Guillain-Barré syndrome.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 1997 |
Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug.
Topics: Acetates; Amines; Analgesics; Animals; Antibodies, Monoclonal; Blood Pressure; Cyclohexanecarboxylic | 1998 |
The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat.
Topics: Acetates; Amines; Animals; Anticonvulsants; Burns; Cyclohexanecarboxylic Acids; Dose-Response Relati | 1998 |
Gabapentin induced polyneuropathy.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 1998 |
Gabapentin for lancinating neuropathic pain.
Topics: Acetates; Acquired Immunodeficiency Syndrome; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabap | 1998 |
Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Dose-Response | 1998 |
A case of spinal cord injury-related pain with baseline rCBF brain SPECT imaging and beneficial response to gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Brain; Cerebrovascular Circulation; Cyclohexanecarboxylic Acids | 1998 |
Symptomatic treatment of painful neuropathy.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; G | 1998 |
Gabapentin for treatment of neuropathic pain in a 12-year-old girl.
Topics: Acetates; Amines; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H | 1998 |
Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats.
Topics: Acetates; Afferent Pathways; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease | 1999 |
Gabapentin for painful diabetic neuropathy.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Double-Blind Metho | 1999 |
Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus | 1999 |
Gabapentin for painful diabetic neuropathy.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gabapentin; gamma- | 1999 |
Gabapentin for painful diabetic neuropathy.
Topics: Acetates; Amines; Analgesics; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Diabeti | 1999 |
Behavioral effects of RS-45041-190, a selective I2 imidazoline ligand, in rats.
Topics: Acetates; Amines; Analgesics; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 1999 |
The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat.
Topics: Acetates; Amines; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Dose-Response Relationship | 1999 |
Use of gabapentin to treat taxane-induced myalgias.
Topics: Acetates; Amines; Analgesics; Antineoplastic Agents, Phytogenic; Cyclohexanecarboxylic Acids; Doceta | 1999 |
The race to control pain: more participants, more targets.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapentin; gamma- | 1999 |
Gabapentin leads to remission of somatoform pain disorder with major depression.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Depressive Disorder; Female; Gabapen | 1999 |
Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats.
Topics: Acetates; Amines; Analgesics; Animals; Cold Temperature; Cyclohexanecarboxylic Acids; Drug Administr | 2000 |
Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxy | 2000 |
Gabapentin for treatment of thalamic pain syndrome.
Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric | 2000 |
Gabapentin in acute painful diabetic neuropathy.
Topics: Acetates; Acute Disease; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathie | 2000 |
Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain.
Topics: Acetates; Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; | 2000 |
Painful gynecomastia: an unusual toxicity of gabapentin?
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; | 2000 |
Gabapentin for chronic pain in spinal cord injury: a case report.
Topics: Acetates; Adult; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Gabapenti | 2000 |
Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital.
Topics: Acetates; Amines; Analgesics; Cancer Care Facilities; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 2000 |
Antinociceptive effect of systemic gabapentin in mononeuropathic rats, depends on stimulus characteristics and level of test integration.
Topics: Acetates; Amines; Analgesics; Animals; Cold Temperature; Cyclohexanecarboxylic Acids; Gabapentin; ga | 2000 |
Malignant appearing cachexia in an older patient with Bruns-Garland syndrome.
Topics: Acetates; Aged; Amines; Analgesics; Cachexia; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2 | 2000 |
Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Drug Tolerance | 2001 |
Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Chronic Disease; Contusions; Cyclohexanecar | 2000 |
Three-month follow-up of shoulder-hand syndrome induced by phenobarbital and treated with gabapentin.
Topics: Acetaminophen; Acetates; Amines; Analgesics; Anticonvulsants; Arthralgia; Cyclohexanecarboxylic Acid | 2001 |
Gabapentin for opiod-related myoclonus in cancer patients.
Topics: Acetates; Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 2001 |
Vincristine-induced allodynia in the rat.
Topics: Acetates; Amines; Analgesics; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Cyclohexaneca | 2001 |
Treatment of pain with gabapentin in a neonate.
Topics: Acetates; Amines; Analgesics; Arthrogryposis; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu | 2001 |
Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 2001 |
Gabapentin for pain control in cancer patients' wound dressing care.
Topics: Acetates; Amines; Analgesics; Bandages; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric | 2001 |
Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Exploratory Beh | 2001 |
Treating painful diabetic neuropathy with gabapentin.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Dose-Response Rela | 2001 |
[Diabetic neuropathies].
Topics: Acetates; Amines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbamazepine; Controlled Clinic | 2001 |
Gabapentin treatment of multiple piloleiomyoma-related pain.
Topics: Acetates; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2002 |
A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Electrophysi | 2002 |
The interaction between gabapentin and amitriptyline in the rat formalin test after systemic administration.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Cy | 2002 |
Effects of analgesics on delayed postherpetic pain in mice.
Topics: Acetates; Acute Disease; Acyclovir; Amines; Analgesics; Analgesics, Opioid; Animals; Antiviral Agent | 2002 |
Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons.
Topics: Acetates; Afferent Pathways; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Fluorescent D | 2002 |
Gabapentin for neuropathic pain following spinal cord injury.
Topics: Acetates; Acute Disease; Adolescent; Adult; Aged; Amines; Chronic Disease; Cyclohexanecarboxylic Aci | 2002 |
Gabapentin (neuronetin) in the treatment of SUNCT syndrome.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Ac | 2002 |
Experimental conditions for the continuous subcutaneous infusion of four central analgesics in rats.
Topics: Acetates; Amines; Analgesics; Anesthetics, Dissociative; Animals; Anticonvulsants; Antidepressive Ag | 2002 |